McKesson Corporation58155Q103US58155Q103107/21/2023Election of eleven directors for a one-year term: Richard H. Carmona, M.D.DIRECTOR ELECTIONSISSUER100476.0000000FOR100476.000000FORS000002088McKesson Corporation58155Q103US58155Q103107/21/2023Election of eleven directors for a one-year term: Dominic J. CarusoDIRECTOR ELECTIONSISSUER100476.0000000FOR100476.000000FORS000002088McKesson Corporation58155Q103US58155Q103107/21/2023Election of eleven directors for a one-year term: W. Roy DunbarDIRECTOR ELECTIONSISSUER100476.0000000FOR100476.000000FORS000002088McKesson Corporation58155Q103US58155Q103107/21/2023Election of eleven directors for a one-year term: James H. HintonDIRECTOR ELECTIONSISSUER100476.0000000FOR100476.000000FORS000002088McKesson Corporation58155Q103US58155Q103107/21/2023Election of eleven directors for a one-year term: Donald R. KnaussDIRECTOR ELECTIONSISSUER100476.0000000FOR100476.000000FORS000002088McKesson Corporation58155Q103US58155Q103107/21/2023Election of eleven directors for a one-year term: Bradley E. LermanDIRECTOR ELECTIONSISSUER100476.0000000FOR100476.000000FORS000002088McKesson Corporation58155Q103US58155Q103107/21/2023Election of eleven directors for a one-year term: Linda P. MantiaDIRECTOR ELECTIONSISSUER100476.0000000FOR100476.000000FORS000002088McKesson Corporation58155Q103US58155Q103107/21/2023Election of eleven directors for a one-year term: Maria MartinezDIRECTOR ELECTIONSISSUER100476.0000000FOR100476.000000FORS000002088McKesson Corporation58155Q103US58155Q103107/21/2023Election of eleven directors for a one-year term: Susan R. SalkaDIRECTOR ELECTIONSISSUER100476.0000000FOR100476.000000FORS000002088McKesson Corporation58155Q103US58155Q103107/21/2023Election of eleven directors for a one-year term: Brian S. TylerDIRECTOR ELECTIONSISSUER100476.0000000FOR100476.000000FORS000002088McKesson Corporation58155Q103US58155Q103107/21/2023Election of eleven directors for a one-year term: Kathleen Wilson-ThompsonDIRECTOR ELECTIONSISSUER100476.0000000AGAINST100476.000000AGAINSTS000002088McKesson Corporation58155Q103US58155Q103107/21/2023Ratification of Appointment of Deloitte & Touche LLP as the Company's Independent Registered Public Accounting Firm for Fiscal Year 2024.AUDIT-RELATEDISSUER100476.0000000FOR100476.000000FORS000002088McKesson Corporation58155Q103US58155Q103107/21/2023Advisory vote on executive compensation.SECTION 14A SAY-ON-PAY VOTESISSUER100476.0000000FOR100476.000000FORS000002088McKesson Corporation58155Q103US58155Q103107/21/2023Advisory vote on the frequency of the advisory vote on executive compensation.SECTION 14A SAY-ON-PAY VOTESISSUER100476.0000000ONE YEAR100476.000000FORS000002088McKesson Corporation58155Q103US58155Q103107/21/2023Shareholder proposal requesting shareholder ratification of termination pay.COMPENSATIONSECURITY HOLDER100476.0000000AGAINST100476.000000FORS000002088ICON plcG4705A100IE000571120907/25/2023Election of Directors: Mr. Ciaran MurrayDIRECTOR ELECTIONSISSUER36963.0000000FOR36963.000000FORS000002088ICON plcG4705A100IE000571120907/25/2023Election of Directors: Dr. Steve CutlerDIRECTOR ELECTIONSISSUER36963.0000000FOR36963.000000FORS000002088ICON plcG4705A100IE000571120907/25/2023Election of Directors: Mr. Ronan MurphyDIRECTOR ELECTIONSISSUER36963.0000000FOR36963.000000FORS000002088ICON plcG4705A100IE000571120907/25/2023Election of Directors: Dr. John ClimaxDIRECTOR ELECTIONSISSUER36963.0000000FOR36963.000000FORS000002088ICON plcG4705A100IE000571120907/25/2023Election of Directors: Mr. Eugene McCagueDIRECTOR ELECTIONSISSUER36963.0000000FOR36963.000000FORS000002088ICON plcG4705A100IE000571120907/25/2023Election of Directors: Ms. Joan GarahyDIRECTOR ELECTIONSISSUER36963.0000000FOR36963.000000FORS000002088ICON plcG4705A100IE000571120907/25/2023Election of Directors: Ms. Julie O'NeillDIRECTOR ELECTIONSISSUER36963.0000000FOR36963.000000FORS000002088ICON plcG4705A100IE000571120907/25/2023Election of Directors: Dr. Linda GraisDIRECTOR ELECTIONSISSUER36963.0000000FOR36963.000000FORS000002088ICON plcG4705A100IE000571120907/25/2023To review the Company's affairs and consider the Accounts and ReportsCORPORATE GOVERNANCEISSUER36963.0000000FOR36963.000000FORS000002088ICON plcG4705A100IE000571120907/25/2023To authorize the fixing of the Auditors' RemunerationAUDIT-RELATEDISSUER36963.0000000FOR36963.000000FORS000002088ICON plcG4705A100IE000571120907/25/2023To authorize the Company to allot sharesCAPITAL STRUCTUREISSUER36963.0000000FOR36963.000000FORS000002088ICON plcG4705A100IE000571120907/25/2023To disapply the statutory pre-emption rightsCAPITAL STRUCTUREISSUER36963.0000000FOR36963.000000FORS000002088ICON plcG4705A100IE000571120907/25/2023To authorize the Company to make market purchases of sharesCAPITAL STRUCTUREISSUER36963.0000000FOR36963.000000FORS000002088ICON plcG4705A100IE000571120907/25/2023To authorize the price range at which the Company can reissue shares that it holds as treasury sharesCAPITAL STRUCTUREISSUER36963.0000000FOR36963.000000FORS000002088Doximity, Inc.26622P107US26622P107507/26/2023To elect Class Il Directors to serve until the annual meeting of stockholders to be held in 2026 or until his or her successor has been duly elected and qualified: Kevin SpainDIRECTOR ELECTIONSISSUER1196986.0000000WITHHOLD1196986.000000AGAINSTS000002088Doximity, Inc.26622P107US26622P107507/26/2023To elect Class Il Directors to serve until the annual meeting of stockholders to be held in 2026 or until his or her successor has been duly elected and qualified: Timothy CabralDIRECTOR ELECTIONSISSUER1196986.0000000WITHHOLD1196986.000000AGAINSTS000002088Doximity, Inc.26622P107US26622P107507/26/2023To ratify the appointment of Deloitte & Touche LLP as the independent registered public accounting firm for the year ending March 31, 2024.AUDIT-RELATEDISSUER1196986.0000000FOR1196986.000000FORS000002088Doximity, Inc.26622P107US26622P107507/26/2023To hold a non-binding, advisory vote on the frequency of future advisory votes on executive compensation.SECTION 14A SAY-ON-PAY VOTESISSUER1196986.0000000ONE YEAR1196986.000000FORS000002088STERIS plcG8473T100IE00BFY8C75407/27/2023Re-election of Directors: Dr. Esther M. AlegriaDIRECTOR ELECTIONSISSUER158040.0000000FOR158040.000000FORS000002088STERIS plcG8473T100IE00BFY8C75407/27/2023Re-election of Directors: Richard C. BreedenDIRECTOR ELECTIONSISSUER158040.0000000FOR158040.000000FORS000002088STERIS plcG8473T100IE00BFY8C75407/27/2023Re-election of Directors: Daniel A. CarestioDIRECTOR ELECTIONSISSUER158040.0000000FOR158040.000000FORS000002088STERIS plcG8473T100IE00BFY8C75407/27/2023Re-election of Directors: Cynthia L. FeldmannDIRECTOR ELECTIONSISSUER158040.0000000FOR158040.000000FORS000002088STERIS plcG8473T100IE00BFY8C75407/27/2023Re-election of Directors: Christopher S. HollandDIRECTOR ELECTIONSISSUER158040.0000000FOR158040.000000FORS000002088STERIS plcG8473T100IE00BFY8C75407/27/2023Re-election of Directors: Dr. Jacqueline B. KosecoffDIRECTOR ELECTIONSISSUER158040.0000000FOR158040.000000FORS000002088STERIS plcG8473T100IE00BFY8C75407/27/2023Re-election of Directors: Paul E. MartinDIRECTOR ELECTIONSISSUER158040.0000000FOR158040.000000FORS000002088STERIS plcG8473T100IE00BFY8C75407/27/2023Re-election of Directors: Dr. Nirav R. ShahDIRECTOR ELECTIONSISSUER158040.0000000FOR158040.000000FORS000002088STERIS plcG8473T100IE00BFY8C75407/27/2023Re-election of Directors: Dr. Mohsen M. SohiDIRECTOR ELECTIONSISSUER158040.0000000FOR158040.000000FORS000002088STERIS plcG8473T100IE00BFY8C75407/27/2023Re-election of Directors: Dr. Richard M. SteevesDIRECTOR ELECTIONSISSUER158040.0000000FOR158040.000000FORS000002088STERIS plcG8473T100IE00BFY8C75407/27/2023To ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the year ending March 31, 2024.AUDIT-RELATEDISSUER158040.0000000FOR158040.000000FORS000002088STERIS plcG8473T100IE00BFY8C75407/27/2023To appoint Ernst & Young Chartered Accountants as the Company's statutory auditor under Irish law to hold office until the conclusion of the Company's next annual general meeting.AUDIT-RELATEDISSUER158040.0000000FOR158040.000000FORS000002088STERIS plcG8473T100IE00BFY8C75407/27/2023To authorize the Board of Directors of the Company or the Audit Committee of the Board of Directors to determine the remuneration of Ernst & Young Chartered Accountants as the Company's statutory auditor under Irish law.AUDIT-RELATEDISSUER158040.0000000FOR158040.000000FORS000002088STERIS plcG8473T100IE00BFY8C75407/27/2023To approve, on a non-binding advisory basis, the compensation of the Company's named executive officers as disclosed pursuant to the disclosure rules of the U.S. Securities and Exchange Commission, including the compensation discussion and analysis and the tabular and narrative disclosure contained in the Company's proxy statement dated June 7, 2023.SECTION 14A SAY-ON-PAY VOTESISSUER158040.0000000FOR158040.000000FORS000002088STERIS plcG8473T100IE00BFY8C75407/27/2023To approve, on a non-binding advisory basis, whether the non-binding advisory vote on named executive officer compensation should be held every one, two, or three years.SECTION 14A SAY-ON-PAY VOTESISSUER158040.0000000ONE YEAR158040.000000FORS000002088STERIS plcG8473T100IE00BFY8C75407/27/2023To approve a proposal renewing the Board of Director's authority to issue shares under Irish law.CAPITAL STRUCTUREISSUER158040.0000000FOR158040.000000FORS000002088STERIS plcG8473T100IE00BFY8C75407/27/2023To approve a proposal renewing the Board of Director's authority to opt-out of statutory pre-emption rights under Irish law.CAPITAL STRUCTUREISSUER158040.0000000FOR158040.000000FORS000002088Replimune Group, Inc.76029N106US76029N106309/06/2023Election of Directors: Paolo PucciDIRECTOR ELECTIONSISSUER1540691.0000000FOR1540691.000000FORS000002088Replimune Group, Inc.76029N106US76029N106309/06/2023Election of Directors: Veleka Peeples-DyerDIRECTOR ELECTIONSISSUER1540691.0000000FOR1540691.000000FORS000002088Replimune Group, Inc.76029N106US76029N106309/06/2023To ratify the selection of PricewaterhouseCoopers LLP as the independent registered public accounting firm for Replimune Group, Inc. for the fiscal year ending March 31, 2024.AUDIT-RELATEDISSUER1540691.0000000FOR1540691.000000FORS000002088Legend Biotech Corporation52490G102US52490G102209/21/2023To receive the audited consolidated financial statements of the Company for the fiscal year ended December 31, 2022.CORPORATE GOVERNANCEISSUER1561895.0000000FOR1561895.000000FORS000002088Legend Biotech Corporation52490G102US52490G102209/21/2023To ratify the appointment of Ernst & Young LLP as independent auditor of the Company (the "Independent Auditor") for the fiscal year ending December 31, 2023.AUDIT-RELATEDISSUER1561895.0000000FOR1561895.000000FORS000002088Legend Biotech Corporation52490G102US52490G102209/21/2023To re-elect Dr. Li Zhu, whose term of office will expire pursuant to article 88(b) of the Company's memorandum of association, to serve as a Class III director of the Company for a full term of three (3) years.DIRECTOR ELECTIONSISSUER1561895.0000000FOR1561895.000000FORS000002088Legend Biotech Corporation52490G102US52490G102209/21/2023To re-elect Dr. Corazon D. Sanders, whose term of office will expire pursuant to article 88(b) of the Company's memorandum of association, to serve as a Class III director of the Company for a full term of three (3) years.DIRECTOR ELECTIONSISSUER1561895.0000000FOR1561895.000000FORS000002088Legend Biotech Corporation52490G102US52490G102209/21/2023To re-elect Dr. Li Mao, whose term of office will expire pursuant to article 88(b) of the Company's memorandum of association, to serve as a Class III director of the Company for a full term of three (3) years.DIRECTOR ELECTIONSISSUER1561895.0000000FOR1561895.000000FORS000002088Legend Biotech Corporation52490G102US52490G102209/21/2023To authorize each of the directors and officers of the Company to take any and every action that might be necessary to effect the foregoing resolutions as such director or officer, in his or her absolute discretion, thinks fit.CORPORATE GOVERNANCEISSUER1561895.0000000FOR1561895.000000FORS000002088Pharming Group NVN69603145NL001039102509/25/2023Elect Richard Peters as Non-Executive DirectorDIRECTOR ELECTIONSISSUER4197710.0000000FOR4197710.000000FORS000002088Pharming Group NVN69603145NL001039102509/25/2023Approve Remuneration to the New Chair of the Board of DirectorsCOMPENSATIONISSUER4197710.0000000FOR4197710.000000FORS000002088Ambrx Biopharma, Inc.641871108US641871108010/10/2023To consider and vote upon a proposal to approve by special resolution and adopt the Agreement and Plan of Merger, dated as of September 11, 2023 (as it may be amended from time to time, the "Merger Agreement"), by and among Ambrx, New Ambrx Biopharma Inc., a Delaware corporation and newly-formed direct wholly owned subsidiary of Ambrx ("NewCo"), and Ambrx Merger Sub Inc. ("Merger Sub"), a Cayman Islands exempted company and newly-formed direct wholly owned subsidiary of NewCo, and to authorize by special resolution the plan of merger to be registered with the Registrar of Companies of the Cayman Islands in respect of the merger (the "Cayman Plan of Merger"), by and between Ambrx and Merger Sub. The Merger Agreement and the Cayman Plan of Merger provide for, among other things, the merger of Merger Sub with and into Ambrx (the "Merger"), with Ambrx surviving the Merger as a direct wholly owned subsidiary of NewCo, and in connection therewith changing its name to "Ambrx Biopharma Cayman, Inc.", in each case on the terms of and subject to the conditions of the Merger Agreement and the Cayman Plan of Merger. Your approval of the Merger Proposal will constitute your approval and adoption of the Merger Agreement, the Cayman Plan of Merger, the Merger and the Proposed Organizational Documents (as defined below).EXTRAORDINARY TRANSACTIONSCORPORATE GOVERNANCEISSUER719735.0000000FOR719735.000000FORS000002088Ambrx Biopharma, Inc.641871108US641871108010/10/2023On a non-binding advisory basis, to authorize the difference in authorized share capital between (a) Ambrx, which consists of $105,000 divided into 1,050,000,000 shares comprising (i) 950,000,000 ordinary shares, par value $0.0001 per share ("Ambrx Ordinary Shares"), and (ii) 100,000,000 undesignated shares, par value $0.0001 per share, of such class or classes (however designated) as the board of directors of Ambrx (the "Ambrx Board") may determine in accordance with Articles 8 and 9 of the Ambrx Governing Documents, and (b) NewCo, which consists of 251,000,000 shares of capital stock of NewCo, comprising (i) 250,000,000 shares of common stock, par value $0.0001 per share, of NewCo ("NewCo Common Stock") and (ii) 1,000,000 shares of preferred stock, par value $0.0001 per share, of NewCo;CAPITAL STRUCTUREISSUER719735.0000000FOR719735.000000FORS000002088Ambrx Biopharma, Inc.641871108US641871108010/10/2023On a non-binding advisory basis, to authorize provisions in the Proposed Certificate of Incorporation prohibiting cumulative voting rights for holders of NewCo Common Stock;SHAREHOLDER RIGHTS AND DEFENSESISSUER719735.0000000FOR719735.000000FORS000002088Ambrx Biopharma, Inc.641871108US641871108010/10/2023On a non-binding advisory basis, to authorize provisions in the Proposed Certificate of Incorporation limiting personal liability of NewCo directors and officers for monetary damages for breach of fiduciary duty as a director or as an officer to the extent permissible under the Delaware General Corporate Law ("DGCL");CORPORATE GOVERNANCEISSUER719735.0000000FOR719735.000000FORS000002088Ambrx Biopharma, Inc.641871108US641871108010/10/2023On a non-binding advisory basis, to authorize provisions in the Proposed Bylaws that provide, subject to certain exceptions, that the Court of Chancery of the State of Delaware shall be the sole and exclusive forum for any NewCo stockholder to bring (i) any derivative action or proceeding brought on behalf of NewCo, (ii) any action asserting a claim of breach of a duty (including any fiduciary duty) owed by any current or former director, officer, stockholder, employee or agent of NewCo to NewCo or NewCo stockholders, (iii) any action asserting a claim against NewCo or any current or former director, officer, stockholder, employee or agent of NewCo arising out of or relating to any provision of the DGCL, the Proposed Certificate of Incorporation or the Proposed Bylaws (each, as in effect from time to time), or (iv) any action asserting a claim against NewCo or any current or former director, officer, stockholder, employee or agent of NewCo governed by the internal affairs doctrine of the State of Delaware. This exclusive forum provision would not apply to suits brought to enforce a duty or liability vested in the exclusive jurisdiction of a court or forum other than the Court of Chancery, such as those created by the Securities Exchange Act of 1934, as amended, or any other claim for which the federal courts have exclusive jurisdiction. In addition, the Proposed Bylaws provide that the federal district courts of the U.S. will be the exclusive forum for the resolution of any complaint asserting a cause of action under the Securities Act of 1933, as amended;SHAREHOLDER RIGHTS AND DEFENSESCORPORATE GOVERNANCEISSUER719735.0000000FOR719735.000000FORS000002088Ambrx Biopharma, Inc.641871108US641871108010/10/2023On a non-binding advisory basis, to adopt a staggered term for the board of directors of NewCo ("NewCo Board"). Directors will initially be divided into three classes. Each class will consist of, as equally as possible, one-third the total number of the directors constituting the entire NewCo Board. The term of the initial Class I, II and III directors will terminate on the date of the 2026, 2024 and 2025 Annual Meeting of NewCo stockholders, respectively. At each succeeding annual meeting beginning in 2024, successors to the class of directors whose term expires at the annual meeting shall be elected for a three year term; andSHAREHOLDER RIGHTS AND DEFENSESISSUER719735.0000000AGAINST719735.000000AGAINSTS000002088Ambrx Biopharma, Inc.641871108US641871108010/10/2023On a non-binding advisory basis, to adopt a threshold of holders of at least 80% of the shares of NewCo who are entitled to vote at an election of directors to amend, alter, change or repeal, or to adopt any provision inconsistent with the purpose and intent of (i) Paragraphs (c), (d), (e), or (f) of Article Fifth or any provision of Articles Sixth, Seventh, Eighth, Ninth, Eleventh and Twelfth of the Proposed Certificate of Incorporation and (ii) Sections 3, 4 or 5 of Article II or Sections 1, 2, 4, or 6 of Article III or any of the provisions of Article VIII, Article IX or Article X of the Proposed Bylaws.CORPORATE GOVERNANCEISSUER719735.0000000AGAINST719735.000000AGAINSTS000002088Ambrx Biopharma, Inc.641871108US641871108010/10/2023To consider and vote upon a proposal to approve, by ordinary resolution, the adjournment of the Extraordinary General Meeting to a later date or dates, if necessary, either (i) to permit further solicitation and vote of proxies in the event that there are insufficient votes for, or otherwise in connection with, the approval of one or more proposals at the Extraordinary General Meeting, to be effective as of the date of the Extraordinary General Meeting or (ii) the Ambrx Board determines before the extraordinary General Meeting that it is not necessary or no longer desirable to proceed with the other proposals.CORPORATE GOVERNANCEISSUER719735.0000000AGAINST719735.000000AGAINSTS000002088Stoke Therapeutics, Inc.86150R107US86150R107710/24/2023To approve the one-time approximately value neutral exchange of certain outstanding stock options issued pursuant to our 2014 Equity Incentive Plan or our 2019 Equity Incentive Plan that are held by our eligible employees into restricted stock units.COMPENSATIONISSUER218265.0000000AGAINST218265.000000AGAINSTS000002088Bio-Techne Corporation09073M104US09073M104510/26/2023To set the number of Directors at nine.CORPORATE GOVERNANCEISSUER431139.0000000FOR431139.000000FORS000002088Bio-Techne Corporation09073M104US09073M104510/26/2023Election of Directors: Robert V. BaumgartnerDIRECTOR ELECTIONSISSUER431139.0000000FOR431139.000000FORS000002088Bio-Techne Corporation09073M104US09073M104510/26/2023Election of Directors: Julie L. BushmanDIRECTOR ELECTIONSISSUER431139.0000000FOR431139.000000FORS000002088Bio-Techne Corporation09073M104US09073M104510/26/2023Election of Directors: John L. HigginsDIRECTOR ELECTIONSISSUER431139.0000000FOR431139.000000FORS000002088Bio-Techne Corporation09073M104US09073M104510/26/2023Election of Directors: Joseph D. KeeganDIRECTOR ELECTIONSISSUER431139.0000000FOR431139.000000FORS000002088Bio-Techne Corporation09073M104US09073M104510/26/2023Election of Directors: Charles R. KummethDIRECTOR ELECTIONSISSUER431139.0000000FOR431139.000000FORS000002088Bio-Techne Corporation09073M104US09073M104510/26/2023Election of Directors: Roeland NusseDIRECTOR ELECTIONSISSUER431139.0000000FOR431139.000000FORS000002088Bio-Techne Corporation09073M104US09073M104510/26/2023Election of Directors: Alpna SethDIRECTOR ELECTIONSISSUER431139.0000000FOR431139.000000FORS000002088Bio-Techne Corporation09073M104US09073M104510/26/2023Election of Directors: Randolph SteerDIRECTOR ELECTIONSISSUER431139.0000000FOR431139.000000FORS000002088Bio-Techne Corporation09073M104US09073M104510/26/2023Election of Directors: Rupert VesseyDIRECTOR ELECTIONSISSUER431139.0000000FOR431139.000000FORS000002088Bio-Techne Corporation09073M104US09073M104510/26/2023Approve, on an advisory basis, the compensation of our executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER431139.0000000FOR431139.000000FORS000002088Bio-Techne Corporation09073M104US09073M104510/26/2023Approve, on an advisory bass, the frequency of advisory votes on executive compensation to occur every (1) year.SECTION 14A SAY-ON-PAY VOTESISSUER431139.0000000ONE YEAR431139.000000FORS000002088Bio-Techne Corporation09073M104US09073M104510/26/2023Ratify the appointment of KPMG, LLP as the Company's independent registered public accounting firm for the 2024 fiscal year.AUDIT-RELATEDISSUER431139.0000000FOR431139.000000FORS000002088Revolution Medicines, Inc.76155X100US76155X100011/08/2023To approve the issuance of shares of Revolution Medicines common stock (including securities convertible into or exercisable for shares of Revolution Medicines common stock) to certain equityholders of EQRX, Inc., which is referred to as EQRX, pursuant to the Agreement and Plan of Merger, dated as of July 31, 2023 (as it may be amended from time to time), by and among Revolution Medicines, Equinox Merger Sub I, Inc., Equinox Merger Sub II LLC, and EQRX, which proposal is referred to as the Revolution Medicines share issuance proposal; andEXTRAORDINARY TRANSACTIONSISSUER1559044.0000000FOR1559044.000000FORS000002088Revolution Medicines, Inc.76155X100US76155X100011/08/2023To approve the adjournment of the Revolution Medicines special meeting, to a later date or dates, if necessary or appropriate, to solicit additional proxies if there are not sufficient votes at the time of the Revolution Medicines special meeting to approve the Revolution Medicines share issuance proposal.CORPORATE GOVERNANCEISSUER1559044.0000000AGAINST1559044.000000AGAINSTS000002088Taysha Gene Therapies, Inc.877619106US877619106111/15/2023To approve an amendment to the Company's Amended and Restated Certificate of Incorporation, as amended to date, to increase the number of authorized shares of common stock from 200,000,000 to 400,000,000.CAPITAL STRUCTUREISSUER1010608.0000000FOR1010608.000000FORS000002088Becton, Dickinson and Company075887109US075887109101/23/2024Election of Directors: William M. BrownDIRECTOR ELECTIONSISSUER778179.0000000FOR778179.000000FORS000002088Becton, Dickinson and Company075887109US075887109101/23/2024Election of Directors: Catherine M. BurzikDIRECTOR ELECTIONSISSUER778179.0000000FOR778179.000000FORS000002088Becton, Dickinson and Company075887109US075887109101/23/2024Election of Directors: Carrie L. ByingtonDIRECTOR ELECTIONSISSUER778179.0000000FOR778179.000000FORS000002088Becton, Dickinson and Company075887109US075887109101/23/2024Election of Directors: R. Andrew EckertDIRECTOR ELECTIONSISSUER778179.0000000FOR778179.000000FORS000002088Becton, Dickinson and Company075887109US075887109101/23/2024Election of Directors: Claire M. FraserDIRECTOR ELECTIONSISSUER778179.0000000FOR778179.000000FORS000002088Becton, Dickinson and Company075887109US075887109101/23/2024Election of Directors: Jeffrey W. HendersonDIRECTOR ELECTIONSISSUER778179.0000000FOR778179.000000FORS000002088Becton, Dickinson and Company075887109US075887109101/23/2024Election of Directors: Christopher JonesDIRECTOR ELECTIONSISSUER778179.0000000FOR778179.000000FORS000002088Becton, Dickinson and Company075887109US075887109101/23/2024Election of Directors: Thomas E. PolenDIRECTOR ELECTIONSISSUER778179.0000000FOR778179.000000FORS000002088Becton, Dickinson and Company075887109US075887109101/23/2024Election of Directors: Timothy M. RingDIRECTOR ELECTIONSISSUER778179.0000000FOR778179.000000FORS000002088Becton, Dickinson and Company075887109US075887109101/23/2024Election of Directors: Bertram L. ScottDIRECTOR ELECTIONSISSUER778179.0000000FOR778179.000000FORS000002088Becton, Dickinson and Company075887109US075887109101/23/2024Election of Directors: Joanne WaldstreicherDIRECTOR ELECTIONSISSUER778179.0000000FOR778179.000000FORS000002088Becton, Dickinson and Company075887109US075887109101/23/2024Ratification of the selection of the independent registered public accounting firm.AUDIT-RELATEDISSUER778179.0000000FOR778179.000000FORS000002088Becton, Dickinson and Company075887109US075887109101/23/2024Advisory vote to approve named executive officer compensation.SECTION 14A SAY-ON-PAY VOTESISSUER778179.0000000FOR778179.000000FORS000002088Catalent, Inc.148806102US148806102901/25/2024Election of Twelve Director Nominees: Michael J. BarberDIRECTOR ELECTIONSISSUER1165831.0000000FOR1165831.000000FORS000002088Catalent, Inc.148806102US148806102901/25/2024Election of Twelve Director Nominees: Steven K. BargDIRECTOR ELECTIONSISSUER1165831.0000000FOR1165831.000000FORS000002088Catalent, Inc.148806102US148806102901/25/2024Election of Twelve Director Nominees: J. Martin CarrollDIRECTOR ELECTIONSISSUER1165831.0000000FOR1165831.000000FORS000002088Catalent, Inc.148806102US148806102901/25/2024Election of Twelve Director Nominees: Rolf ClassonDIRECTOR ELECTIONSISSUER1165831.0000000FOR1165831.000000FORS000002088Catalent, Inc.148806102US148806102901/25/2024Election of Twelve Director Nominees: Frank A. D'AmelioDIRECTOR ELECTIONSISSUER1165831.0000000FOR1165831.000000FORS000002088Catalent, Inc.148806102US148806102901/25/2024Election of Twelve Director Nominees: John J. GreischDIRECTOR ELECTIONSISSUER1165831.0000000FOR1165831.000000FORS000002088Catalent, Inc.148806102US148806102901/25/2024Election of Twelve Director Nominees: Gregory T. LucierDIRECTOR ELECTIONSISSUER1165831.0000000FOR1165831.000000FORS000002088Catalent, Inc.148806102US148806102901/25/2024Election of Twelve Director Nominees: Alessandro MaselliDIRECTOR ELECTIONSISSUER1165831.0000000FOR1165831.000000FORS000002088Catalent, Inc.148806102US148806102901/25/2024Election of Twelve Director Nominees: Donald E. Morel, Jr.DIRECTOR ELECTIONSISSUER1165831.0000000FOR1165831.000000FORS000002088Catalent, Inc.148806102US148806102901/25/2024Election of Twelve Director Nominees: Stephanie OkeyDIRECTOR ELECTIONSISSUER1165831.0000000FOR1165831.000000FORS000002088Catalent, Inc.148806102US148806102901/25/2024Election of Twelve Director Nominees: Michelle R. RyanDIRECTOR ELECTIONSISSUER1165831.0000000FOR1165831.000000FORS000002088Catalent, Inc.148806102US148806102901/25/2024Election of Twelve Director Nominees: Jack StahlDIRECTOR ELECTIONSISSUER1165831.0000000FOR1165831.000000FORS000002088Catalent, Inc.148806102US148806102901/25/2024Ratification of Appointment of Ernst & Young LLP as Independent Auditor for Fiscal 2024AUDIT-RELATEDISSUER1165831.0000000FOR1165831.000000FORS000002088Catalent, Inc.148806102US148806102901/25/2024Advisory Vote to Approve Our Executive Compensation. (Say-on-Pay).SECTION 14A SAY-ON-PAY VOTESISSUER1165831.0000000FOR1165831.000000FORS000002088Catalent, Inc.148806102US148806102901/25/2024Approval of Amendment to Catalent, Inc. 2018 Omnibus Incentive Plan.COMPENSATIONISSUER1165831.0000000FOR1165831.000000FORS000002088SAGE Therapeutics, Inc.78667J108US78667J108801/31/2024To approve a one-time stock option exchange program for non-executive officer employees of Sage (the ''Option Exchange Proposal'').COMPENSATIONISSUER306940.0000000FOR306940.000000FORS000002088SAGE Therapeutics, Inc.78667J108US78667J108801/31/2024To approve a proposal to adjourn the Special Meeting to a later date or dates, if necessary or appropriate, to permit further solicitation and vote of proxies in the event that there are insufficient votes for, or otherwise in connection with, the approval of the Option Exchange Proposal.CORPORATE GOVERNANCEISSUER306940.0000000AGAINST306940.000000AGAINSTS000002088Pharvaris NVN69605108NL00150005Y403/06/2024Amend Articles Re: Organization RelatedCORPORATE GOVERNANCEISSUER631660.0000000FOR631660.000000FORS000002088Hologic, Inc.436440101US436440101203/07/2024Election of Directors: Stephen P. MacMillanDIRECTOR ELECTIONSISSUER1430135.0000000FOR1430135.000000FORS000002088Hologic, Inc.436440101US436440101203/07/2024Election of Directors: Sally W. CrawfordDIRECTOR ELECTIONSISSUER1430135.0000000FOR1430135.000000FORS000002088Hologic, Inc.436440101US436440101203/07/2024Election of Directors: Charles J. DockendorffDIRECTOR ELECTIONSISSUER1430135.0000000FOR1430135.000000FORS000002088Hologic, Inc.436440101US436440101203/07/2024Election of Directors: Scott T. GarrettDIRECTOR ELECTIONSISSUER1430135.0000000FOR1430135.000000FORS000002088Hologic, Inc.436440101US436440101203/07/2024Election of Directors: Ludwig N. HantsonDIRECTOR ELECTIONSISSUER1430135.0000000FOR1430135.000000FORS000002088Hologic, Inc.436440101US436440101203/07/2024Election of Directors: Nanaz MohtashamiDIRECTOR ELECTIONSISSUER1430135.0000000FOR1430135.000000FORS000002088Hologic, Inc.436440101US436440101203/07/2024Election of Directors: Christiana StamoulisDIRECTOR ELECTIONSISSUER1430135.0000000FOR1430135.000000FORS000002088Hologic, Inc.436440101US436440101203/07/2024Election of Directors: Stacey D. StewartDIRECTOR ELECTIONSISSUER1430135.0000000FOR1430135.000000FORS000002088Hologic, Inc.436440101US436440101203/07/2024Election of Directors: Amy M. WendellDIRECTOR ELECTIONSISSUER1430135.0000000FOR1430135.000000FORS000002088Hologic, Inc.436440101US436440101203/07/2024A non-binding advisory vote to approve executive compensation.SECTION 14A SAY-ON-PAY VOTESISSUER1430135.0000000FOR1430135.000000FORS000002088Hologic, Inc.436440101US436440101203/07/2024Ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for fiscal 2024.AUDIT-RELATEDISSUER1430135.0000000FOR1430135.000000FORS000002088Cencora, Inc.03073E105US03073E105503/12/2024Election of Eleven Directors: Ornella BarraDIRECTOR ELECTIONSISSUER180563.0000000FOR180563.000000FORS000002088Cencora, Inc.03073E105US03073E105503/12/2024Election of Eleven Directors: Werner BaumannDIRECTOR ELECTIONSISSUER180563.0000000FOR180563.000000FORS000002088Cencora, Inc.03073E105US03073E105503/12/2024Election of Eleven Directors: Steven H. CollisDIRECTOR ELECTIONSISSUER180563.0000000FOR180563.000000FORS000002088Cencora, Inc.03073E105US03073E105503/12/2024Election of Eleven Directors: D. Mark DurcanDIRECTOR ELECTIONSISSUER180563.0000000FOR180563.000000FORS000002088Cencora, Inc.03073E105US03073E105503/12/2024Election of Eleven Directors: Richard W. GochnauerDIRECTOR ELECTIONSISSUER180563.0000000FOR180563.000000FORS000002088Cencora, Inc.03073E105US03073E105503/12/2024Election of Eleven Directors: Lon R. GreenbergDIRECTOR ELECTIONSISSUER180563.0000000FOR180563.000000FORS000002088Cencora, Inc.03073E105US03073E105503/12/2024Election of Eleven Directors: Kathleen W. HyleDIRECTOR ELECTIONSISSUER180563.0000000FOR180563.000000FORS000002088Cencora, Inc.03073E105US03073E105503/12/2024Election of Eleven Directors: Lorence H. Kim, M.D.DIRECTOR ELECTIONSISSUER180563.0000000FOR180563.000000FORS000002088Cencora, Inc.03073E105US03073E105503/12/2024Election of Eleven Directors: Redonda G. Miller, M.D.DIRECTOR ELECTIONSISSUER180563.0000000FOR180563.000000FORS000002088Cencora, Inc.03073E105US03073E105503/12/2024Election of Eleven Directors: Dennis M. NallyDIRECTOR ELECTIONSISSUER180563.0000000FOR180563.000000FORS000002088Cencora, Inc.03073E105US03073E105503/12/2024Election of Eleven Directors: Lauren M. TylerDIRECTOR ELECTIONSISSUER180563.0000000FOR180563.000000FORS000002088Cencora, Inc.03073E105US03073E105503/12/2024Advisory vote to approve the compensation of the Company's names executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER180563.0000000FOR180563.000000FORS000002088Cencora, Inc.03073E105US03073E105503/12/2024Ratification of Ernst & Young LLP as the Company's independent registered public accounting firm for fiscal year 2024AUDIT-RELATEDISSUER180563.0000000FOR180563.000000FORS000002088Cencora, Inc.03073E105US03073E105503/12/2024Approval of an amendment of the certificate of incorporation to provide for the exculpation of officers as permitted by Delaware law.CORPORATE GOVERNANCEISSUER180563.0000000FOR180563.000000FORS000002088Cencora, Inc.03073E105US03073E105503/12/2024Approval of miscellaneous amendments to the certificate of incorporation.CORPORATE GOVERNANCEISSUER180563.0000000FOR180563.000000FORS000002088Cencora, Inc.03073E105US03073E105503/12/2024Shareholder proposal regarding voting standard for election of directors.CORPORATE GOVERNANCESECURITY HOLDER180563.0000000AGAINST180563.000000FORS000002088Agilent Technologies, Inc.00846U101US00846U101603/14/2024Election of Directors: To elect four directors to a three-year term. At the annual meeting, the Board of Directors intends to present the following nominees for election as directors: Mala AnandDIRECTOR ELECTIONSISSUER1129086.0000000AGAINST1129086.000000AGAINSTS000002088Agilent Technologies, Inc.00846U101US00846U101603/14/2024Election of Directors: To elect four directors to a three-year term. At the annual meeting, the Board of Directors intends to present the following nominees for election as directors: Koh Boon HweeDIRECTOR ELECTIONSISSUER1129086.0000000AGAINST1129086.000000AGAINSTS000002088Agilent Technologies, Inc.00846U101US00846U101603/14/2024Election of Directors: To elect four directors to a three-year term. At the annual meeting, the Board of Directors intends to present the following nominees for election as directors: Michael R. McMullenDIRECTOR ELECTIONSISSUER1129086.0000000FOR1129086.000000FORS000002088Agilent Technologies, Inc.00846U101US00846U101603/14/2024Election of Directors: To elect four directors to a three-year term. At the annual meeting, the Board of Directors intends to present the following nominees for election as directors: Daniel K. Podolsky, M.DDIRECTOR ELECTIONSISSUER1129086.0000000AGAINST1129086.000000AGAINSTS000002088Agilent Technologies, Inc.00846U101US00846U101603/14/2024To approve, on a non-binding advisory basis, the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER1129086.0000000FOR1129086.000000FORS000002088Agilent Technologies, Inc.00846U101US00846U101603/14/2024To ratify the Audit and Finance Committee's appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm.AUDIT-RELATEDISSUER1129086.0000000FOR1129086.000000FORS000002088Agilent Technologies, Inc.00846U101US00846U101603/14/2024To vote on a shareholder proposal regarding simple majority vote, if properly presented at the meeting.CORPORATE GOVERNANCESECURITY HOLDER1129086.0000000FOR1129086.000000NONES000002088Arrowhead Pharmaceuticals, Inc.04280A100US04280A100703/14/2024Election of Directors: Douglass GivenDIRECTOR ELECTIONSISSUER288541.0000000FOR288541.000000FORS000002088Arrowhead Pharmaceuticals, Inc.04280A100US04280A100703/14/2024Election of Directors: Michael S. PerryDIRECTOR ELECTIONSISSUER288541.0000000FOR288541.000000FORS000002088Arrowhead Pharmaceuticals, Inc.04280A100US04280A100703/14/2024Election of Directors: Christopher AnzaloneDIRECTOR ELECTIONSISSUER288541.0000000FOR288541.000000FORS000002088Arrowhead Pharmaceuticals, Inc.04280A100US04280A100703/14/2024Election of Directors: Mauro FerrariDIRECTOR ELECTIONSISSUER288541.0000000FOR288541.000000FORS000002088Arrowhead Pharmaceuticals, Inc.04280A100US04280A100703/14/2024Election of Directors: Adeoye OlukotunDIRECTOR ELECTIONSISSUER288541.0000000FOR288541.000000FORS000002088Arrowhead Pharmaceuticals, Inc.04280A100US04280A100703/14/2024Election of Directors: William WaddillDIRECTOR ELECTIONSISSUER288541.0000000FOR288541.000000FORS000002088Arrowhead Pharmaceuticals, Inc.04280A100US04280A100703/14/2024Election of Directors: Victoria VakienerDIRECTOR ELECTIONSISSUER288541.0000000FOR288541.000000FORS000002088Arrowhead Pharmaceuticals, Inc.04280A100US04280A100703/14/2024Advisory Vote to Approve Executive Compensation.SECTION 14A SAY-ON-PAY VOTESISSUER288541.0000000FOR288541.000000FORS000002088Arrowhead Pharmaceuticals, Inc.04280A100US04280A100703/14/2024To ratify the selection of KPMG LLP as independent auditors of the Company for the fiscal year ending September 30, 2024.AUDIT-RELATEDISSUER288541.0000000FOR288541.000000FORS000002088AstraZeneca PLC046353108US046353108904/11/2024Accept Financial Statements and Statutory ReportsCORPORATE GOVERNANCEISSUER4511684.0000000FOR4511684.000000FORS000002088AstraZeneca PLC046353108US046353108904/11/2024Approve DividendsCAPITAL STRUCTUREISSUER4511684.0000000FOR4511684.000000FORS000002088AstraZeneca PLC046353108US046353108904/11/2024Reappoint PricewaterhouseCoopers LLP as AuditorsAUDIT-RELATEDISSUER4511684.0000000FOR4511684.000000FORS000002088AstraZeneca PLC046353108US046353108904/11/2024Authorise Board to Fix Remuneration of AuditorsAUDIT-RELATEDISSUER4511684.0000000FOR4511684.000000FORS000002088AstraZeneca PLC046353108US046353108904/11/2024Re-elect Michel Demare as DirectorDIRECTOR ELECTIONSISSUER4511684.0000000FOR4511684.000000FORS000002088AstraZeneca PLC046353108US046353108904/11/2024Re-elect Pascal Soriot as DirectorDIRECTOR ELECTIONSISSUER4511684.0000000FOR4511684.000000FORS000002088AstraZeneca PLC046353108US046353108904/11/2024Re-elect Aradhana Sarin as DirectorDIRECTOR ELECTIONSISSUER4511684.0000000FOR4511684.000000FORS000002088AstraZeneca PLC046353108US046353108904/11/2024Re-elect Philip Broadley as DirectorDIRECTOR ELECTIONSISSUER4511684.0000000FOR4511684.000000FORS000002088AstraZeneca PLC046353108US046353108904/11/2024Re-elect Euan Ashley as DirectorDIRECTOR ELECTIONSISSUER4511684.0000000FOR4511684.000000FORS000002088AstraZeneca PLC046353108US046353108904/11/2024Re-elect Deborah DiSanzo as DirectorDIRECTOR ELECTIONSISSUER4511684.0000000FOR4511684.000000FORS000002088AstraZeneca PLC046353108US046353108904/11/2024Re-elect Diana Layfield as DirectorDIRECTOR ELECTIONSISSUER4511684.0000000FOR4511684.000000FORS000002088AstraZeneca PLC046353108US046353108904/11/2024Elect Anna Manz as DirectorDIRECTOR ELECTIONSISSUER4511684.0000000FOR4511684.000000FORS000002088AstraZeneca PLC046353108US046353108904/11/2024Re-elect Sheri McCoy as DirectorDIRECTOR ELECTIONSISSUER4511684.0000000FOR4511684.000000FORS000002088AstraZeneca PLC046353108US046353108904/11/2024Re-elect Tony Mok as DirectorDIRECTOR ELECTIONSISSUER4511684.0000000FOR4511684.000000FORS000002088AstraZeneca PLC046353108US046353108904/11/2024Re-elect Nazneen Rahman as DirectorDIRECTOR ELECTIONSISSUER4511684.0000000FOR4511684.000000FORS000002088AstraZeneca PLC046353108US046353108904/11/2024Re-elect Andreas Rummelt as DirectorDIRECTOR ELECTIONSISSUER4511684.0000000FOR4511684.000000FORS000002088AstraZeneca PLC046353108US046353108904/11/2024Re-elect Marcus Wallenberg as DirectorDIRECTOR ELECTIONSISSUER4511684.0000000FOR4511684.000000FORS000002088AstraZeneca PLC046353108US046353108904/11/2024Approve Remuneration ReportCOMPENSATIONISSUER4511684.0000000FOR4511684.000000FORS000002088AstraZeneca PLC046353108US046353108904/11/2024Approve Remuneration PolicyCOMPENSATIONISSUER4511684.0000000FOR4511684.000000FORS000002088AstraZeneca PLC046353108US046353108904/11/2024Amend Performance Share Plan 2020COMPENSATIONISSUER4511684.0000000FOR4511684.000000FORS000002088AstraZeneca PLC046353108US046353108904/11/2024Authorise UK Political Donations and ExpenditureOTHER SOCIAL ISSUESISSUER4511684.0000000FOR4511684.000000FORS000002088AstraZeneca PLC046353108US046353108904/11/2024Authorise Issue of EquityCAPITAL STRUCTUREISSUER4511684.0000000FOR4511684.000000FORS000002088AstraZeneca PLC046353108US046353108904/11/2024Authorise Issue of Equity without Pre-emptive RightsCAPITAL STRUCTUREISSUER4511684.0000000FOR4511684.000000FORS000002088AstraZeneca PLC046353108US046353108904/11/2024Authorise Issue of Equity without Pre-emptive Rights in Connection with an Acquisition or Other Capital InvestmentCAPITAL STRUCTUREISSUER4511684.0000000FOR4511684.000000FORS000002088AstraZeneca PLC046353108US046353108904/11/2024Authorise Market Purchase of Ordinary SharesCAPITAL STRUCTUREISSUER4511684.0000000FOR4511684.000000FORS000002088AstraZeneca PLC046353108US046353108904/11/2024Authorise the Company to Call General Meeting with Two Weeks' NoticeCORPORATE GOVERNANCEISSUER4511684.0000000FOR4511684.000000FORS000002088IQVIA Holdings Inc.46266C105US46266C105304/16/2024The election of six directors: Ari BousbibDIRECTOR ELECTIONSISSUER181836.0000000FOR181836.000000FORS000002088IQVIA Holdings Inc.46266C105US46266C105304/16/2024The election of six directors: Carol J. BurtDIRECTOR ELECTIONSISSUER181836.0000000FOR181836.000000FORS000002088IQVIA Holdings Inc.46266C105US46266C105304/16/2024The election of six directors: Colleen A. GogginsDIRECTOR ELECTIONSISSUER181836.0000000FOR181836.000000FORS000002088IQVIA Holdings Inc.46266C105US46266C105304/16/2024The election of six directors: John M. Leonard, M.D.DIRECTOR ELECTIONSISSUER181836.0000000FOR181836.000000FORS000002088IQVIA Holdings Inc.46266C105US46266C105304/16/2024The election of six directors: Todd B. SisitskyDIRECTOR ELECTIONSISSUER181836.0000000FOR181836.000000FORS000002088IQVIA Holdings Inc.46266C105US46266C105304/16/2024The election of six directors: Sheila A. StampsDIRECTOR ELECTIONSISSUER181836.0000000FOR181836.000000FORS000002088IQVIA Holdings Inc.46266C105US46266C105304/16/2024Approve an advisory (non-binding) resolution to approve IQVIA's executive compensation (say-on-pay).SECTION 14A SAY-ON-PAY VOTESISSUER181836.0000000FOR181836.000000FORS000002088IQVIA Holdings Inc.46266C105US46266C105304/16/2024If properly presented, a stockholder proposal concerning political spending.OTHER SOCIAL ISSUESSECURITY HOLDER181836.0000000AGAINST181836.000000FORS000002088IQVIA Holdings Inc.46266C105US46266C105304/16/2024Ratification of the appointment of PricewaterhouseCoopers LLP as IQVIA's independent registered public accounting firm for 2024.AUDIT-RELATEDISSUER181836.0000000FOR181836.000000FORS000002088Humana Inc.444859102US444859102804/18/2024Election of Directors: Raquel C.Bono, M.D.DIRECTOR ELECTIONSISSUER265006.0000000FOR265006.000000FORS000002088Humana Inc.444859102US444859102804/18/2024Election of Directors: Bruce D. BroussardDIRECTOR ELECTIONSISSUER265006.0000000FOR265006.000000FORS000002088Humana Inc.444859102US444859102804/18/2024Election of Directors: Frank A. D'AmelioDIRECTOR ELECTIONSISSUER265006.0000000FOR265006.000000FORS000002088Humana Inc.444859102US444859102804/18/2024Election of Directors: David T. Feinberg, M.D.DIRECTOR ELECTIONSISSUER265006.0000000FOR265006.000000FORS000002088Humana Inc.444859102US444859102804/18/2024Election of Directors: Wayne A. I. Frederick, M.D.DIRECTOR ELECTIONSISSUER265006.0000000FOR265006.000000FORS000002088Humana Inc.444859102US444859102804/18/2024Election of Directors: John W. GarrattDIRECTOR ELECTIONSISSUER265006.0000000FOR265006.000000FORS000002088Humana Inc.444859102US444859102804/18/2024Election of Directors: Kurt J. HilzingerDIRECTOR ELECTIONSISSUER265006.0000000FOR265006.000000FORS000002088Humana Inc.444859102US444859102804/18/2024Election of Directors: Karen W. KatzDIRECTOR ELECTIONSISSUER265006.0000000FOR265006.000000FORS000002088Humana Inc.444859102US444859102804/18/2024Election of Directors: Marcy S. KlevornDIRECTOR ELECTIONSISSUER265006.0000000FOR265006.000000FORS000002088Humana Inc.444859102US444859102804/18/2024Election of Directors: Jorge S. MesquitaDIRECTOR ELECTIONSISSUER265006.0000000FOR265006.000000FORS000002088Humana Inc.444859102US444859102804/18/2024Election of Directors: Brad D. SmithDIRECTOR ELECTIONSISSUER265006.0000000FOR265006.000000FORS000002088Humana Inc.444859102US444859102804/18/2024The ratification of the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm.AUDIT-RELATEDISSUER265006.0000000FOR265006.000000FORS000002088Humana Inc.444859102US444859102804/18/2024Non-binding advisory vote for the approval of the compensation of the named executive officers as disclosed in the 2024 proxy statement.SECTION 14A SAY-ON-PAY VOTESISSUER265006.0000000FOR265006.000000FORS000002088Humana Inc.444859102US444859102804/18/2024The approval of the amendment to the Company's Restated Certificate of Incorporation to limit the liability of certain officers of the Company as permitted by Delaware law.CORPORATE GOVERNANCEISSUER265006.0000000FOR265006.000000FORS000002088Humana Inc.444859102US444859102804/18/2024The approval of the amendment to the Company's Restated Certificate of Incorporation to eliminate supermajority voting requirement in connection with certain transactions.CORPORATE GOVERNANCEISSUER265006.0000000FOR265006.000000FORS000002088Humana Inc.444859102US444859102804/18/2024The stockholder proposal on simple majority vote, if properly presented at the meeting.CORPORATE GOVERNANCESECURITY HOLDER265006.0000000AGAINST265006.000000FORS000002088Siemens Healthineers AGD6T479107DE000SHL100604/18/2024Approve Allocation of Income and Dividends of EUR 0.95 per ShareCAPITAL STRUCTUREISSUER306511.0000000FOR306511.000000FORS000002088Siemens Healthineers AGD6T479107DE000SHL100604/18/2024Approve Discharge of Management Board Member Bernhard Montag for Fiscal Year 2023CORPORATE GOVERNANCEISSUER306511.0000000FOR306511.000000FORS000002088Siemens Healthineers AGD6T479107DE000SHL100604/18/2024Approve Discharge of Management Board Member Jochen Schmitz for Fiscal Year 2023CORPORATE GOVERNANCEISSUER306511.0000000FOR306511.000000FORS000002088Siemens Healthineers AGD6T479107DE000SHL100604/18/2024Approve Discharge of Management Board Member Darleen Caron for Fiscal Year 2023CORPORATE GOVERNANCEISSUER306511.0000000FOR306511.000000FORS000002088Siemens Healthineers AGD6T479107DE000SHL100604/18/2024Approve Discharge of Management Board Member Elisabeth Staudinger-Leibrecht for Fiscal Year 2023CORPORATE GOVERNANCEISSUER306511.0000000FOR306511.000000FORS000002088Siemens Healthineers AGD6T479107DE000SHL100604/18/2024Approve Discharge of Supervisory Board Member Ralf Thomas for Fiscal Year 2023CORPORATE GOVERNANCEISSUER306511.0000000FOR306511.000000FORS000002088Siemens Healthineers AGD6T479107DE000SHL100604/18/2024Approve Discharge of Supervisory Board Member Karl-Heinz Streibich for Fiscal Year 2023CORPORATE GOVERNANCEISSUER306511.0000000FOR306511.000000FORS000002088Siemens Healthineers AGD6T479107DE000SHL100604/18/2024Approve Discharge of Supervisory Board Member Veronika Bienert (from Feb. 15, 2023) for Fiscal Year 2023CORPORATE GOVERNANCEISSUER306511.0000000FOR306511.000000FORS000002088Siemens Healthineers AGD6T479107DE000SHL100604/18/2024Approve Discharge of Supervisory Board Member Roland Busch for Fiscal Year 2023CORPORATE GOVERNANCEISSUER306511.0000000FOR306511.000000FORS000002088Siemens Healthineers AGD6T479107DE000SHL100604/18/2024Approve Discharge of Supervisory Board Member Norbert Gaus (until Feb. 15, 2023) for Fiscal Year 2023CORPORATE GOVERNANCEISSUER306511.0000000FOR306511.000000FORS000002088Siemens Healthineers AGD6T479107DE000SHL100604/18/2024Approve Discharge of Supervisory Board Member Marion Helmes for Fiscal Year 2023CORPORATE GOVERNANCEISSUER306511.0000000FOR306511.000000FORS000002088Siemens Healthineers AGD6T479107DE000SHL100604/18/2024Approve Discharge of Supervisory Board Member Andreas Hoffmann (until Feb. 15, 2023) for Fiscal Year 2023CORPORATE GOVERNANCEISSUER306511.0000000FOR306511.000000FORS000002088Siemens Healthineers AGD6T479107DE000SHL100604/18/2024Approve Discharge of Supervisory Board Member Peter Koerte (from Feb. 15, 2023) for Fiscal Year 2023CORPORATE GOVERNANCEISSUER306511.0000000FOR306511.000000FORS000002088Siemens Healthineers AGD6T479107DE000SHL100604/18/2024Approve Discharge of Supervisory Board Member Sarena Lin (from Feb. 15, 2023) for Fiscal Year 2023CORPORATE GOVERNANCEISSUER306511.0000000FOR306511.000000FORS000002088Siemens Healthineers AGD6T479107DE000SHL100604/18/2024Approve Discharge of Supervisory Board Member Philipp Roesler (until Feb. 15, 2023) for Fiscal Year 2023CORPORATE GOVERNANCEISSUER306511.0000000FOR306511.000000FORS000002088Siemens Healthineers AGD6T479107DE000SHL100604/18/2024Approve Discharge of Supervisory Board Member Peer Schatz for Fiscal Year 2023CORPORATE GOVERNANCEISSUER306511.0000000FOR306511.000000FORS000002088Siemens Healthineers AGD6T479107DE000SHL100604/18/2024Approve Discharge of Supervisory Board Member Gregory Sorensen (until Feb. 15, 2023) for Fiscal Year 2023CORPORATE GOVERNANCEISSUER306511.0000000FOR306511.000000FORS000002088Siemens Healthineers AGD6T479107DE000SHL100604/18/2024Approve Discharge of Supervisory Board Member Nathalie von Siemens for Fiscal Year 2023CORPORATE GOVERNANCEISSUER306511.0000000FOR306511.000000FORS000002088Siemens Healthineers AGD6T479107DE000SHL100604/18/2024Approve Discharge of Supervisory Board Member Dow Wilson (from Feb. 15, 2023) for Fiscal Year 2023CORPORATE GOVERNANCEISSUER306511.0000000FOR306511.000000FORS000002088Siemens Healthineers AGD6T479107DE000SHL100604/18/2024Ratify PricewaterhouseCoopers GmbH as Auditors for Fiscal Year 2024AUDIT-RELATEDISSUER306511.0000000FOR306511.000000FORS000002088Siemens Healthineers AGD6T479107DE000SHL100604/18/2024Approve Remuneration ReportCOMPENSATIONISSUER306511.0000000FOR306511.000000FORS000002088Siemens Healthineers AGD6T479107DE000SHL100604/18/2024Amend Corporate PurposeCORPORATE GOVERNANCEISSUER306511.0000000FOR306511.000000FORS000002088Siemens Healthineers AGD6T479107DE000SHL100604/18/2024Amend Articles of AssociationCORPORATE GOVERNANCEISSUER306511.0000000FOR306511.000000FORS000002088Siemens Healthineers AGD6T479107DE000SHL100604/18/2024Elect Ralf Thomas to the Supervisory BoardDIRECTOR ELECTIONSISSUER306511.0000000FOR306511.000000FORS000002088Siemens Healthineers AGD6T479107DE000SHL100604/18/2024Elect Karl-Heinz Streibich to the Supervisory BoardDIRECTOR ELECTIONSISSUER306511.0000000FOR306511.000000FORS000002088Siemens Healthineers AGD6T479107DE000SHL100604/18/2024Elect Roland Busch to the Supervisory BoardDIRECTOR ELECTIONSISSUER306511.0000000ABSTAIN306511.000000AGAINSTS000002088Siemens Healthineers AGD6T479107DE000SHL100604/18/2024Elect Marion Helmes to the Supervisory BoardDIRECTOR ELECTIONSISSUER306511.0000000FOR306511.000000FORS000002088Siemens Healthineers AGD6T479107DE000SHL100604/18/2024Elect Sarena Lin to the Supervisory BoardDIRECTOR ELECTIONSISSUER306511.0000000FOR306511.000000FORS000002088Siemens Healthineers AGD6T479107DE000SHL100604/18/2024Elect Peer Schatz to the Supervisory BoardDIRECTOR ELECTIONSISSUER306511.0000000FOR306511.000000FORS000002088Siemens Healthineers AGD6T479107DE000SHL100604/18/2024Elect Nathalie von Siemens to the Supervisory BoardDIRECTOR ELECTIONSISSUER306511.0000000ABSTAIN306511.000000AGAINSTS000002088Siemens Healthineers AGD6T479107DE000SHL100604/18/2024Elect Dow Wilson to the Supervisory BoardDIRECTOR ELECTIONSISSUER306511.0000000FOR306511.000000FORS000002088Siemens Healthineers AGD6T479107DE000SHL100604/18/2024Elect Veronika Bienert to the Supervisory BoardDIRECTOR ELECTIONSISSUER306511.0000000ABSTAIN306511.000000AGAINSTS000002088Siemens Healthineers AGD6T479107DE000SHL100604/18/2024Elect Peter Koerte to the Supervisory BoardDIRECTOR ELECTIONSISSUER306511.0000000ABSTAIN306511.000000AGAINSTS000002088West Pharmaceutical Services, Inc.955306105US955306105504/23/2024Election of Directors: Mark A. ButhmanDIRECTOR ELECTIONSISSUER286627.0000000FOR286627.000000FORS000002088West Pharmaceutical Services, Inc.955306105US955306105504/23/2024Election of Directors: William F. FeeheryDIRECTOR ELECTIONSISSUER286627.0000000FOR286627.000000FORS000002088West Pharmaceutical Services, Inc.955306105US955306105504/23/2024Election of Directors: Robert F. FrielDIRECTOR ELECTIONSISSUER286627.0000000FOR286627.000000FORS000002088West Pharmaceutical Services, Inc.955306105US955306105504/23/2024Election of Directors: Eric M. GreenDIRECTOR ELECTIONSISSUER286627.0000000FOR286627.000000FORS000002088West Pharmaceutical Services, Inc.955306105US955306105504/23/2024Election of Directors: Thomas W. HofmannDIRECTOR ELECTIONSISSUER286627.0000000FOR286627.000000FORS000002088West Pharmaceutical Services, Inc.955306105US955306105504/23/2024Election of Directors: Molly E. JosephDIRECTOR ELECTIONSISSUER286627.0000000FOR286627.000000FORS000002088West Pharmaceutical Services, Inc.955306105US955306105504/23/2024Election of Directors: Deborah L. V. KellerDIRECTOR ELECTIONSISSUER286627.0000000FOR286627.000000FORS000002088West Pharmaceutical Services, Inc.955306105US955306105504/23/2024Election of Directors: Myla P. Lai-GoldmanDIRECTOR ELECTIONSISSUER286627.0000000FOR286627.000000FORS000002088West Pharmaceutical Services, Inc.955306105US955306105504/23/2024Election of Directors: Stephen H. LockhartDIRECTOR ELECTIONSISSUER286627.0000000FOR286627.000000FORS000002088West Pharmaceutical Services, Inc.955306105US955306105504/23/2024Election of Directors: Douglas A. MichelsDIRECTOR ELECTIONSISSUER286627.0000000FOR286627.000000FORS000002088West Pharmaceutical Services, Inc.955306105US955306105504/23/2024Election of Directors: Paolo PucciDIRECTOR ELECTIONSISSUER286627.0000000FOR286627.000000FORS000002088West Pharmaceutical Services, Inc.955306105US955306105504/23/2024Advisory vote to approve named executive officer compensation;SECTION 14A SAY-ON-PAY VOTESISSUER286627.0000000FOR286627.000000FORS000002088West Pharmaceutical Services, Inc.955306105US955306105504/23/2024Amend and Restate Our Amended and Restated Articles of Incorporation to Eliminate Supermajority Transaction Requirement;CORPORATE GOVERNANCEISSUER286627.0000000FOR286627.000000FORS000002088West Pharmaceutical Services, Inc.955306105US955306105504/23/2024Amend and Restate Our Amended and Restated Articles of Incorporation to Eliminate Supermajority Amendment Requirement;CORPORATE GOVERNANCEISSUER286627.0000000FOR286627.000000FORS000002088West Pharmaceutical Services, Inc.955306105US955306105504/23/2024Ratification of the appointment of PricewaterhouseCoopers LLP ("PwC") as our independent registered public accounting firm for 2024; andAUDIT-RELATEDISSUER286627.0000000FOR286627.000000FORS000002088West Pharmaceutical Services, Inc.955306105US955306105504/23/2024Shareholder Proposal Entitled "Simple Majority Vote"CORPORATE GOVERNANCESECURITY HOLDER286627.0000000AGAINST286627.000000FORS000002088The Cigna Group125523100US125523100304/24/2024Election of Directors: David M. CordaniDIRECTOR ELECTIONSISSUER793162.0000000FOR793162.000000FORS000002088The Cigna Group125523100US125523100304/24/2024Election of Directors: William J. DeLaneyDIRECTOR ELECTIONSISSUER793162.0000000FOR793162.000000FORS000002088The Cigna Group125523100US125523100304/24/2024Election of Directors: Eric J. FossDIRECTOR ELECTIONSISSUER793162.0000000FOR793162.000000FORS000002088The Cigna Group125523100US125523100304/24/2024Election of Directors: Retired Maj. Gen. Elder Granger, M.D.DIRECTOR ELECTIONSISSUER793162.0000000FOR793162.000000FORS000002088The Cigna Group125523100US125523100304/24/2024Election of Directors: Neesha HathiDIRECTOR ELECTIONSISSUER793162.0000000FOR793162.000000FORS000002088The Cigna Group125523100US125523100304/24/2024Election of Directors: George KurianDIRECTOR ELECTIONSISSUER793162.0000000FOR793162.000000FORS000002088The Cigna Group125523100US125523100304/24/2024Election of Directors: Kathleen M. MazzarellaDIRECTOR ELECTIONSISSUER793162.0000000FOR793162.000000FORS000002088The Cigna Group125523100US125523100304/24/2024Election of Directors: Mark B. McClellan, M.D., Ph.D.DIRECTOR ELECTIONSISSUER793162.0000000FOR793162.000000FORS000002088The Cigna Group125523100US125523100304/24/2024Election of Directors: Philip O. Ozuah, M.D., Ph.D.DIRECTOR ELECTIONSISSUER793162.0000000FOR793162.000000FORS000002088The Cigna Group125523100US125523100304/24/2024Election of Directors: Kimberly A. RossDIRECTOR ELECTIONSISSUER793162.0000000FOR793162.000000FORS000002088The Cigna Group125523100US125523100304/24/2024Election of Directors: Eric C. WisemanDIRECTOR ELECTIONSISSUER793162.0000000FOR793162.000000FORS000002088The Cigna Group125523100US125523100304/24/2024Election of Directors: Donna F. ZarconeDIRECTOR ELECTIONSISSUER793162.0000000FOR793162.000000FORS000002088The Cigna Group125523100US125523100304/24/2024Advisory approval of The Cigna Group's executive compensation.SECTION 14A SAY-ON-PAY VOTESISSUER793162.0000000FOR793162.000000FORS000002088The Cigna Group125523100US125523100304/24/2024Ratification of the appointment of PricewaterhouseCoopers LLP as The Cigna Group's independent registered public accounting firm for 2024.AUDIT-RELATEDISSUER793162.0000000FOR793162.000000FORS000002088The Cigna Group125523100US125523100304/24/2024Shareholder proposal - improve the shareholder right to call a special shareholder meeting.CORPORATE GOVERNANCESECURITY HOLDER793162.0000000AGAINST793162.000000FORS000002088The Cigna Group125523100US125523100304/24/2024Shareholder proposal - Report to shareholders on risks created by the The Cigna Group's diversity, equity, and inclusion efforts.ENVIRONMENT OR CLIMATEDIVERSITY, EQUITY, AND INCLUSIONOTHER SOCIAL ISSUESSECURITY HOLDER793162.0000000AGAINST793162.000000FORS000002088HCA Healthcare, Inc.40412C101US40412C101804/25/2024Election of Directors: Thomas F. Frist IIIDIRECTOR ELECTIONSISSUER493715.0000000FOR493715.000000FORS000002088HCA Healthcare, Inc.40412C101US40412C101804/25/2024Election of Directors: Samuel N. HazenDIRECTOR ELECTIONSISSUER493715.0000000FOR493715.000000FORS000002088HCA Healthcare, Inc.40412C101US40412C101804/25/2024Election of Directors: Meg G. CroftonDIRECTOR ELECTIONSISSUER493715.0000000FOR493715.000000FORS000002088HCA Healthcare, Inc.40412C101US40412C101804/25/2024Election of Directors: Robert J. DennisDIRECTOR ELECTIONSISSUER493715.0000000FOR493715.000000FORS000002088HCA Healthcare, Inc.40412C101US40412C101804/25/2024Election of Directors: Nancy-Ann DeParleDIRECTOR ELECTIONSISSUER493715.0000000FOR493715.000000FORS000002088HCA Healthcare, Inc.40412C101US40412C101804/25/2024Election of Directors: William R. FristDIRECTOR ELECTIONSISSUER493715.0000000FOR493715.000000FORS000002088HCA Healthcare, Inc.40412C101US40412C101804/25/2024Election of Directors: Hugh F. JohnstonDIRECTOR ELECTIONSISSUER493715.0000000FOR493715.000000FORS000002088HCA Healthcare, Inc.40412C101US40412C101804/25/2024Election of Directors: Michael W. MichelsonDIRECTOR ELECTIONSISSUER493715.0000000FOR493715.000000FORS000002088HCA Healthcare, Inc.40412C101US40412C101804/25/2024Election of Directors: Wayne J. Riley M.D.DIRECTOR ELECTIONSISSUER493715.0000000FOR493715.000000FORS000002088HCA Healthcare, Inc.40412C101US40412C101804/25/2024Election of Directors: Andrea B. SmithDIRECTOR ELECTIONSISSUER493715.0000000FOR493715.000000FORS000002088HCA Healthcare, Inc.40412C101US40412C101804/25/2024To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the year ending December 31, 2024.AUDIT-RELATEDISSUER493715.0000000FOR493715.000000FORS000002088HCA Healthcare, Inc.40412C101US40412C101804/25/2024Advisory vote to approve named executive officer compensation.SECTION 14A SAY-ON-PAY VOTESISSUER493715.0000000FOR493715.000000FORS000002088HCA Healthcare, Inc.40412C101US40412C101804/25/2024Advisory vote to approve the frequency of future advisory votes to approve named executive officer compensation.SECTION 14A SAY-ON-PAY VOTESISSUER493715.0000000ONE YEAR493715.000000FORS000002088HCA Healthcare, Inc.40412C101US40412C101804/25/2024Stockholder proposal, if properly presented at the meeting, regarding report on risk mitigation regarding state restrictions for emergency abortions.OTHER SOCIAL ISSUESSECURITY HOLDER493715.0000000AGAINST493715.000000FORS000002088HCA Healthcare, Inc.40412C101US40412C101804/25/2024Stockholder proposal, if properly presented at the meeting, regarding report on patient feedback regarding quality of care.OTHER SOCIAL ISSUESSECURITY HOLDER493715.0000000AGAINST493715.000000FORS000002088HCA Healthcare, Inc.40412C101US40412C101804/25/2024Stockholder proposal, if property presented at the meeting, regarding report on maternal health outcomes.OTHER SOCIAL ISSUESSECURITY HOLDER493715.0000000AGAINST493715.000000FORS000002088Intuitive Surgical, Inc.46120E602US46120E602304/25/2024Election of Directors: Craig H. Barratt, Ph.D.DIRECTOR ELECTIONSISSUER1620867.0000000FOR1620867.000000FORS000002088Intuitive Surgical, Inc.46120E602US46120E602304/25/2024Election of Directors: Joseph C. BeeryDIRECTOR ELECTIONSISSUER1620867.0000000FOR1620867.000000FORS000002088Intuitive Surgical, Inc.46120E602US46120E602304/25/2024Election of Directors: Lewis ChewDIRECTOR ELECTIONSISSUER1620867.0000000FOR1620867.000000FORS000002088Intuitive Surgical, Inc.46120E602US46120E602304/25/2024Election of Directors: Gary S. Guthart, Ph.D.DIRECTOR ELECTIONSISSUER1620867.0000000FOR1620867.000000FORS000002088Intuitive Surgical, Inc.46120E602US46120E602304/25/2024Election of Directors: Amal M. JohnsonDIRECTOR ELECTIONSISSUER1620867.0000000FOR1620867.000000FORS000002088Intuitive Surgical, Inc.46120E602US46120E602304/25/2024Election of Directors: Sreelakshmi KolliDIRECTOR ELECTIONSISSUER1620867.0000000FOR1620867.000000FORS000002088Intuitive Surgical, Inc.46120E602US46120E602304/25/2024Election of Directors: Amy L. Ladd, M.D.DIRECTOR ELECTIONSISSUER1620867.0000000FOR1620867.000000FORS000002088Intuitive Surgical, Inc.46120E602US46120E602304/25/2024Election of Directors: Keith R. Leonard, Jr.DIRECTOR ELECTIONSISSUER1620867.0000000FOR1620867.000000FORS000002088Intuitive Surgical, Inc.46120E602US46120E602304/25/2024Election of Directors: Jami Dover NachtsheimDIRECTOR ELECTIONSISSUER1620867.0000000FOR1620867.000000FORS000002088Intuitive Surgical, Inc.46120E602US46120E602304/25/2024Election of Directors: Monica P. Reed, M.D.DIRECTOR ELECTIONSISSUER1620867.0000000FOR1620867.000000FORS000002088Intuitive Surgical, Inc.46120E602US46120E602304/25/2024Election of Directors: Mark J. RubashDIRECTOR ELECTIONSISSUER1620867.0000000FOR1620867.000000FORS000002088Intuitive Surgical, Inc.46120E602US46120E602304/25/2024To approve, by advisory vote, the compensation of the Company's Named Executive Officers.SECTION 14A SAY-ON-PAY VOTESISSUER1620867.0000000FOR1620867.000000FORS000002088Intuitive Surgical, Inc.46120E602US46120E602304/25/2024The ratification of appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024.AUDIT-RELATEDISSUER1620867.0000000FOR1620867.000000FORS000002088Intuitive Surgical, Inc.46120E602US46120E602304/25/2024The amendment and restatement of the Amended and Restated 2010 Incentive Award Plan.COMPENSATIONISSUER1620867.0000000FOR1620867.000000FORS000002088Intuitive Surgical, Inc.46120E602US46120E602304/25/2024The amendment and restatement of the Amended and Restated 2000 Employee Stock Purchase Plan.COMPENSATIONISSUER1620867.0000000FOR1620867.000000FORS000002088Intuitive Surgical, Inc.46120E602US46120E602304/25/2024The stockholder proposal requesting a racial and gender pay gap report, if properly presented at the Annual Meeting.DIVERSITY, EQUITY, AND INCLUSIONSECURITY HOLDER1620867.0000000AGAINST1620867.000000FORS000002088Lantheus Holdings, Inc.516544103US516544103204/25/2024The election of three Class III directors to our Board of Directors: Mr. Brian MarkisonDIRECTOR ELECTIONSISSUER495318.0000000FOR495318.000000FORS000002088Lantheus Holdings, Inc.516544103US516544103204/25/2024The election of three Class III directors to our Board of Directors: Mr. Gary PrudenDIRECTOR ELECTIONSISSUER495318.0000000AGAINST495318.000000AGAINSTS000002088Lantheus Holdings, Inc.516544103US516544103204/25/2024The election of three Class III directors to our Board of Directors: Dr. James H. ThrallDIRECTOR ELECTIONSISSUER495318.0000000AGAINST495318.000000AGAINSTS000002088Lantheus Holdings, Inc.516544103US516544103204/25/2024The approval, on an advisory basis, of the compensation paid to our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER495318.0000000FOR495318.000000FORS000002088Lantheus Holdings, Inc.516544103US516544103204/25/2024The approval of an amendment to the Lantheus Holdings, Inc. 2015 Equity Incentive Plan to increase the number of Shares reserved for issuance thereunder.COMPENSATIONISSUER495318.0000000FOR495318.000000FORS000002088Lantheus Holdings, Inc.516544103US516544103204/25/2024The ratification of the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024.AUDIT-RELATEDISSUER495318.0000000FOR495318.000000FORS000002088UCB SAB93562120BE000373953004/25/2024Approve Financial Statements, Allocation of Income, and Dividends of EUR 1.36 per ShareCAPITAL STRUCTURECORPORATE GOVERNANCEISSUER60546.0000000FOR60546.000000FORS000002088UCB SAB93562120BE000373953004/25/2024Approve Remuneration ReportCOMPENSATIONISSUER60546.0000000FOR60546.000000FORS000002088UCB SAB93562120BE000373953004/25/2024Approve Remuneration PolicyCOMPENSATIONISSUER60546.0000000FOR60546.000000FORS000002088UCB SAB93562120BE000373953004/25/2024Approve Discharge of DirectorsCORPORATE GOVERNANCEISSUER60546.0000000FOR60546.000000FORS000002088UCB SAB93562120BE000373953004/25/2024Approve Discharge of AuditorsAUDIT-RELATEDCORPORATE GOVERNANCEISSUER60546.0000000FOR60546.000000FORS000002088UCB SAB93562120BE000373953004/25/2024Elect Pierre Gurdjian as DirectorDIRECTOR ELECTIONSISSUER60546.0000000FOR60546.000000FORS000002088UCB SAB93562120BE000373953004/25/2024Indicate Pierre Gurdjian as Independent DirectorDIRECTOR ELECTIONSCORPORATE GOVERNANCEISSUER60546.0000000FOR60546.000000FORS000002088UCB SAB93562120BE000373953004/25/2024Reelect Ulf Wiinberg as DirectorDIRECTOR ELECTIONSISSUER60546.0000000FOR60546.000000FORS000002088UCB SAB93562120BE000373953004/25/2024Indicate Ulf Wiinberg as Independent DirectorDIRECTOR ELECTIONSCORPORATE GOVERNANCEISSUER60546.0000000FOR60546.000000FORS000002088UCB SAB93562120BE000373953004/25/2024Elect Charles-Antoine Janssen as DirectorDIRECTOR ELECTIONSISSUER60546.0000000FOR60546.000000FORS000002088UCB SAB93562120BE000373953004/25/2024Elect Nefertiti Greene as DirectorDIRECTOR ELECTIONSISSUER60546.0000000FOR60546.000000FORS000002088UCB SAB93562120BE000373953004/25/2024Indicate Nefertiti Greene as Independent DirectorDIRECTOR ELECTIONSCORPORATE GOVERNANCEISSUER60546.0000000FOR60546.000000FORS000002088UCB SAB93562120BE000373953004/25/2024Elect Dolca Thomas as DirectorDIRECTOR ELECTIONSISSUER60546.0000000FOR60546.000000FORS000002088UCB SAB93562120BE000373953004/25/2024Indicate Dolca Thomas as Independent DirectorDIRECTOR ELECTIONSCORPORATE GOVERNANCEISSUER60546.0000000FOR60546.000000FORS000002088UCB SAB93562120BE000373953004/25/2024Elect Rodolfo Savitzky as DirectorDIRECTOR ELECTIONSISSUER60546.0000000FOR60546.000000FORS000002088UCB SAB93562120BE000373953004/25/2024Indicate Rodolfo Savitzky as Independent DirectorDIRECTOR ELECTIONSCORPORATE GOVERNANCEISSUER60546.0000000FOR60546.000000FORS000002088UCB SAB93562120BE000373953004/25/2024Ratify Mazars, Permanently Represented by Sebastien Schueremans, as Auditors and Approve Auditors' RemunerationAUDIT-RELATEDISSUER60546.0000000FOR60546.000000FORS000002088UCB SAB93562120BE000373953004/25/2024Approve Long-Term Incentive PlansCOMPENSATIONISSUER60546.0000000FOR60546.000000FORS000002088UCB SAB93562120BE000373953004/25/2024Approve Change-of-Control Clause Re: EMTN Program RenewalSHAREHOLDER RIGHTS AND DEFENSESCAPITAL STRUCTUREISSUER60546.0000000FOR60546.000000FORS000002088UCB SAB93562120BE000373953004/25/2024Approve Change-of-Control Clause Re: Schuldschein Loan Agreements Entered on 24 August 2023SHAREHOLDER RIGHTS AND DEFENSESCAPITAL STRUCTUREISSUER60546.0000000FOR60546.000000FORS000002088UCB SAB93562120BE000373953004/25/2024Renew Authorization to Increase Share Capital within the Framework of Authorized Capital and Amend Article 6 of the Articles of AssociationCAPITAL STRUCTUREISSUER60546.0000000FOR60546.000000FORS000002088UCB SAB93562120BE000373953004/25/2024Authorize Share Repurchase Program and Reissuance of Repurchased SharesCAPITAL STRUCTUREISSUER60546.0000000FOR60546.000000FORS000002088Biohaven Ltd.G1110E107VGG1110E107904/30/2024Election of Directors for a term expiring at the 2027 Annual Meeting of shareholders: Julia P. GregoryDIRECTOR ELECTIONSISSUER1712508.0000000FOR1712508.000000FORS000002088Biohaven Ltd.G1110E107VGG1110E107904/30/2024Election of Directors for a term expiring at the 2027 Annual Meeting of shareholders: John W. ChildsDIRECTOR ELECTIONSISSUER1712508.0000000FOR1712508.000000FORS000002088Biohaven Ltd.G1110E107VGG1110E107904/30/2024Election of Directors for a term expiring at the 2027 Annual Meeting of shareholders: Gregory H. Bailey, M.D.DIRECTOR ELECTIONSISSUER1712508.0000000FOR1712508.000000FORS000002088Biohaven Ltd.G1110E107VGG1110E107904/30/2024Ratification of appointment of Ernst & Young LLP as independent auditors for fiscal year 2024.AUDIT-RELATEDISSUER1712508.0000000FOR1712508.000000FORS000002088Biohaven Ltd.G1110E107VGG1110E107904/30/2024A non-binding advisory vote on the frequency of future advisory votes on the Company's named executive officer compensation.SECTION 14A SAY-ON-PAY VOTESISSUER1712508.0000000ONE YEAR1712508.000000FORS000002088Molina Healthcare, Inc.60855R100US60855R100505/01/2024To elect nine directors to hold office until the 2025 Annual Meeting: Barbara L. BrasierDIRECTOR ELECTIONSISSUER545471.0000000FOR545471.000000FORS000002088Molina Healthcare, Inc.60855R100US60855R100505/01/2024To elect nine directors to hold office until the 2025 Annual Meeting: Daniel CoopermanDIRECTOR ELECTIONSISSUER545471.0000000FOR545471.000000FORS000002088Molina Healthcare, Inc.60855R100US60855R100505/01/2024To elect nine directors to hold office until the 2025 Annual Meeting: Stephen H. LockhartDIRECTOR ELECTIONSISSUER545471.0000000FOR545471.000000FORS000002088Molina Healthcare, Inc.60855R100US60855R100505/01/2024To elect nine directors to hold office until the 2025 Annual Meeting: Steven J. OrlandoDIRECTOR ELECTIONSISSUER545471.0000000FOR545471.000000FORS000002088Molina Healthcare, Inc.60855R100US60855R100505/01/2024To elect nine directors to hold office until the 2025 Annual Meeting: Ronna E. RomneyDIRECTOR ELECTIONSISSUER545471.0000000FOR545471.000000FORS000002088Molina Healthcare, Inc.60855R100US60855R100505/01/2024To elect nine directors to hold office until the 2025 Annual Meeting: Richard M. SchapiroDIRECTOR ELECTIONSISSUER545471.0000000FOR545471.000000FORS000002088Molina Healthcare, Inc.60855R100US60855R100505/01/2024To elect nine directors to hold office until the 2025 Annual Meeting: Dale B. WolfDIRECTOR ELECTIONSISSUER545471.0000000FOR545471.000000FORS000002088Molina Healthcare, Inc.60855R100US60855R100505/01/2024To elect nine directors to hold office until the 2025 Annual Meeting: Richard C. ZoreticDIRECTOR ELECTIONSISSUER545471.0000000FOR545471.000000FORS000002088Molina Healthcare, Inc.60855R100US60855R100505/01/2024To elect nine directors to hold office until the 2025 Annual Meeting: Joseph M. ZubretskyDIRECTOR ELECTIONSISSUER545471.0000000FOR545471.000000FORS000002088Molina Healthcare, Inc.60855R100US60855R100505/01/2024To consider and approve, on a non-binding, advisory basis the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER545471.0000000FOR545471.000000FORS000002088Molina Healthcare, Inc.60855R100US60855R100505/01/2024To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for 2024.AUDIT-RELATEDISSUER545471.0000000FOR545471.000000FORS000002088Molina Healthcare, Inc.60855R100US60855R100505/01/2024Shareholder proposal regarding simple majority voting, if properly presented.CORPORATE GOVERNANCESECURITY HOLDER545471.0000000AGAINST545471.000000FORS000002088Boston Scientific Corporation101137107US101137107705/02/2024Proposal to elect nine Directors: Charles J. DockendorffDIRECTOR ELECTIONSISSUER2258476.0000000FOR2258476.000000FORS000002088Boston Scientific Corporation101137107US101137107705/02/2024Proposal to elect nine Directors: Yoshiaki FujimoriDIRECTOR ELECTIONSISSUER2258476.0000000FOR2258476.000000FORS000002088Boston Scientific Corporation101137107US101137107705/02/2024Proposal to elect nine Directors: Edward J. LudwigDIRECTOR ELECTIONSISSUER2258476.0000000FOR2258476.000000FORS000002088Boston Scientific Corporation101137107US101137107705/02/2024Proposal to elect nine Directors: Michael F. MahoneyDIRECTOR ELECTIONSISSUER2258476.0000000FOR2258476.000000FORS000002088Boston Scientific Corporation101137107US101137107705/02/2024Proposal to elect nine Directors: Jessica L. MegaDIRECTOR ELECTIONSISSUER2258476.0000000FOR2258476.000000FORS000002088Boston Scientific Corporation101137107US101137107705/02/2024Proposal to elect nine Directors: Susan E. MoranoDIRECTOR ELECTIONSISSUER2258476.0000000FOR2258476.000000FORS000002088Boston Scientific Corporation101137107US101137107705/02/2024Proposal to elect nine Directors: John E. SununuDIRECTOR ELECTIONSISSUER2258476.0000000FOR2258476.000000FORS000002088Boston Scientific Corporation101137107US101137107705/02/2024Proposal to elect nine Directors: David S. WichmannDIRECTOR ELECTIONSISSUER2258476.0000000FOR2258476.000000FORS000002088Boston Scientific Corporation101137107US101137107705/02/2024Proposal to elect nine Directors: Ellen M. ZaneDIRECTOR ELECTIONSISSUER2258476.0000000FOR2258476.000000FORS000002088Boston Scientific Corporation101137107US101137107705/02/2024To approve, on a non-binding, advisory basis, the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER2258476.0000000FOR2258476.000000FORS000002088Boston Scientific Corporation101137107US101137107705/02/2024To approve an amendment and restatement of our By-Laws to provide for advance notice and universal proxy rule updates.SHAREHOLDER RIGHTS AND DEFENSESISSUER2258476.0000000FOR2258476.000000FORS000002088Boston Scientific Corporation101137107US101137107705/02/2024To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the 2024 fiscal year.AUDIT-RELATEDISSUER2258476.0000000FOR2258476.000000FORS000002088Inspire Medical Systems, Inc.457730109US457730109005/02/2024Election of Class III Directors: Shelley G. BroaderDIRECTOR ELECTIONSISSUER183016.0000000FOR183016.000000FORS000002088Inspire Medical Systems, Inc.457730109US457730109005/02/2024Election of Class III Directors: Myriam J. Curet, M.D.DIRECTOR ELECTIONSISSUER183016.0000000FOR183016.000000FORS000002088Inspire Medical Systems, Inc.457730109US457730109005/02/2024Election of Class III Directors: Casey M. TanseyDIRECTOR ELECTIONSISSUER183016.0000000FOR183016.000000FORS000002088Inspire Medical Systems, Inc.457730109US457730109005/02/2024Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for 2024.AUDIT-RELATEDISSUER183016.0000000FOR183016.000000FORS000002088Inspire Medical Systems, Inc.457730109US457730109005/02/2024Approval, on an advisory (non-binding) basis, of the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER183016.0000000FOR183016.000000FORS000002088AbbVie Inc.00287Y109US00287Y109105/03/2024Election of Class III Directors: Roxanne S. AustinDIRECTOR ELECTIONSISSUER451760.0000000FOR451760.000000FORS000002088AbbVie Inc.00287Y109US00287Y109105/03/2024Election of Class III Directors: Richard A. GonzalezDIRECTOR ELECTIONSISSUER451760.0000000FOR451760.000000FORS000002088AbbVie Inc.00287Y109US00287Y109105/03/2024Election of Class III Directors: Susan E. QuagginDIRECTOR ELECTIONSISSUER451760.0000000FOR451760.000000FORS000002088AbbVie Inc.00287Y109US00287Y109105/03/2024Election of Class III Directors: Rebecca B. RobertsDIRECTOR ELECTIONSISSUER451760.0000000FOR451760.000000FORS000002088AbbVie Inc.00287Y109US00287Y109105/03/2024Election of Class III Directors: Glenn F. TiltonDIRECTOR ELECTIONSISSUER451760.0000000FOR451760.000000FORS000002088AbbVie Inc.00287Y109US00287Y109105/03/2024Ratification of Ernst & Young LLP as AbbVie's independent registered public accounting firm for 2024AUDIT-RELATEDISSUER451760.0000000FOR451760.000000FORS000002088AbbVie Inc.00287Y109US00287Y109105/03/2024Say on Pay - An advisory vote on the approval of executive compensationSECTION 14A SAY-ON-PAY VOTESISSUER451760.0000000FOR451760.000000FORS000002088AbbVie Inc.00287Y109US00287Y109105/03/2024Say on Pay - An advisory vote on the frequency of the advisory vote to approve executive compensationSECTION 14A SAY-ON-PAY VOTESISSUER451760.0000000ONE YEAR451760.000000FORS000002088AbbVie Inc.00287Y109US00287Y109105/03/2024Approval of a management proposal regarding amendment of the certificate of incorporation to eliminate supermajority votingCORPORATE GOVERNANCEISSUER451760.0000000FOR451760.000000FORS000002088AbbVie Inc.00287Y109US00287Y109105/03/2024Stockholder Proposal - to Implement Simple Majority VoteCORPORATE GOVERNANCESECURITY HOLDER451760.0000000AGAINST451760.000000FORS000002088AbbVie Inc.00287Y109US00287Y109105/03/2024Stockholder Proposal - to Issue Annual Report on LobbyingOTHER SOCIAL ISSUESSECURITY HOLDER451760.0000000AGAINST451760.000000FORS000002088AbbVie Inc.00287Y109US00287Y109105/03/2024Stockholder Proposal - to Issue a Report on Patent ProcessOTHER SOCIAL ISSUESSECURITY HOLDER451760.0000000AGAINST451760.000000FORS000002088Teleflex Incorporated879369106US879369106905/03/2024Election of Directors: Candace H. DuncanDIRECTOR ELECTIONSISSUER49493.0000000FOR49493.000000FORS000002088Teleflex Incorporated879369106US879369106905/03/2024Election of Directors: Gretchen R. HaggertyDIRECTOR ELECTIONSISSUER49493.0000000FOR49493.000000FORS000002088Teleflex Incorporated879369106US879369106905/03/2024Election of Directors: Liam J. KellyDIRECTOR ELECTIONSISSUER49493.0000000FOR49493.000000FORS000002088Teleflex Incorporated879369106US879369106905/03/2024Election of Directors: Stephen K. KlaskoDIRECTOR ELECTIONSISSUER49493.0000000FOR49493.000000FORS000002088Teleflex Incorporated879369106US879369106905/03/2024Election of Directors: Stuart A. RandleDIRECTOR ELECTIONSISSUER49493.0000000FOR49493.000000FORS000002088Teleflex Incorporated879369106US879369106905/03/2024Election of Directors: Jaewon RyuDIRECTOR ELECTIONSISSUER49493.0000000FOR49493.000000FORS000002088Teleflex Incorporated879369106US879369106905/03/2024Approval, on an advisory basis, of named executive officer compensation.SECTION 14A SAY-ON-PAY VOTESISSUER49493.0000000FOR49493.000000FORS000002088Teleflex Incorporated879369106US879369106905/03/2024Ratification of the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for 2024.AUDIT-RELATEDISSUER49493.0000000FOR49493.000000FORS000002088Teleflex Incorporated879369106US879369106905/03/2024Stockholder proposal, if properly presented at the Annual Meeting, to reduce the ownership threshold to call a special stockholder meeting.CORPORATE GOVERNANCESECURITY HOLDER49493.0000000AGAINST49493.000000FORS000002088Eli Lilly and Company532457108US532457108305/06/2024Election of the following directors, each to serve a three-year term: Katherine Baicker, Ph.D.DIRECTOR ELECTIONSISSUER2015368.0000000FOR2015368.000000FORS000002088Eli Lilly and Company532457108US532457108305/06/2024Election of the following directors, each to serve a three-year term: J. Erik FyrwaldDIRECTOR ELECTIONSISSUER2015368.0000000FOR2015368.000000FORS000002088Eli Lilly and Company532457108US532457108305/06/2024Election of the following directors, each to serve a three-year term: Jamere JacksonDIRECTOR ELECTIONSISSUER2015368.0000000FOR2015368.000000FORS000002088Eli Lilly and Company532457108US532457108305/06/2024Election of the following directors, each to serve a three-year term: Gabrielle SulzbergerDIRECTOR ELECTIONSISSUER2015368.0000000FOR2015368.000000FORS000002088Eli Lilly and Company532457108US532457108305/06/2024Approval, on an advisory basis, of the compensation paid to the company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER2015368.0000000FOR2015368.000000FORS000002088Eli Lilly and Company532457108US532457108305/06/2024Ratification of the appointment of Ernst & Young LLP as the independent auditor for 2024.AUDIT-RELATEDISSUER2015368.0000000FOR2015368.000000FORS000002088Eli Lilly and Company532457108US532457108305/06/2024Approval of amendments to the company's Articles of Incorporation to eliminate the classified board structure.SHAREHOLDER RIGHTS AND DEFENSESISSUER2015368.0000000FOR2015368.000000FORS000002088Eli Lilly and Company532457108US532457108305/06/2024Approval of amendments to the company's Articles of Incorporation to eliminate supermajority voting provisions.CORPORATE GOVERNANCEISSUER2015368.0000000FOR2015368.000000FORS000002088Eli Lilly and Company532457108US532457108305/06/2024Shareholder proposal to publish an annual report disclosing lobbying activities.OTHER SOCIAL ISSUESSECURITY HOLDER2015368.0000000AGAINST2015368.000000FORS000002088Eli Lilly and Company532457108US532457108305/06/2024Shareholder proposal to report on effectiveness of the company's diversity, equity, and inclusion efforts.DIVERSITY, EQUITY, AND INCLUSIONSECURITY HOLDER2015368.0000000AGAINST2015368.000000FORS000002088Eli Lilly and Company532457108US532457108305/06/2024Shareholder proposal to establish and report on a process by which the impact of extended patent exclusivities on product access would be considered in deciding whether to apply for secondary and tertiary patents.OTHER SOCIAL ISSUESSECURITY HOLDER2015368.0000000AGAINST2015368.000000FORS000002088Eli Lilly and Company532457108US532457108305/06/2024Shareholder proposal to adopt a comprehensive human rights policyHUMAN RIGHTS OR HUMAN CAPITAL/WORKFORCESECURITY HOLDER2015368.0000000AGAINST2015368.000000FORS000002088argenx SE04016X101US04016X101905/07/2024Approve Remuneration ReportCOMPENSATIONISSUER785003.0000000FOR785003.000000FORS000002088argenx SE04016X101US04016X101905/07/2024Adopt Financial Statements and Statutory ReportsCORPORATE GOVERNANCEISSUER785003.0000000FOR785003.000000FORS000002088argenx SE04016X101US04016X101905/07/2024Approve Allocation of Losses to the Retained Earnings of the CompanyCAPITAL STRUCTUREISSUER785003.0000000FOR785003.000000FORS000002088argenx SE04016X101US04016X101905/07/2024Approve Discharge of DirectorsCORPORATE GOVERNANCEISSUER785003.0000000FOR785003.000000FORS000002088argenx SE04016X101US04016X101905/07/2024Approve Remuneration PolicyCOMPENSATIONISSUER785003.0000000FOR785003.000000FORS000002088argenx SE04016X101US04016X101905/07/2024Elect Brian L. Kotzin as Non-Executive DirectorDIRECTOR ELECTIONSISSUER785003.0000000FOR785003.000000FORS000002088argenx SE04016X101US04016X101905/07/2024Reelect Peter Verhaeghe as Non-Executive DirectorDIRECTOR ELECTIONSISSUER785003.0000000FOR785003.000000FORS000002088argenx SE04016X101US04016X101905/07/2024Reelect Pamela Klein as Non-Executive DirectorDIRECTOR ELECTIONSISSUER785003.0000000FOR785003.000000FORS000002088argenx SE04016X101US04016X101905/07/2024Grant Board Authority to Issue Shares Up To 10 Percent of Issued Capital and Exclude Pre-emptive RightsCAPITAL STRUCTUREISSUER785003.0000000FOR785003.000000FORS000002088argenx SE04016X101US04016X101905/07/2024Amend Articles of Association and Authorization to Execute the Deed of AmendmentCORPORATE GOVERNANCEISSUER785003.0000000FOR785003.000000FORS000002088argenx SE04016X101US04016X101905/07/2024Ratify Deloitte Accountants B.V. as Auditors for the 2024 Financial YearAUDIT-RELATEDISSUER785003.0000000FOR785003.000000FORS000002088argenx SE04016X101US04016X101905/07/2024Ratify Ernst & Young Accountants LLP as Auditors for the 2025 Financial YearAUDIT-RELATEDISSUER785003.0000000FOR785003.000000FORS000002088Danaher Corporation235851102US235851102805/07/2024To elect the thirteen directors named in the attached Proxy Statement to hold office until the 2025 Annual Meeting of Shareholders and until their successors are elected and qualified: Rainer M. BlairDIRECTOR ELECTIONSISSUER1828579.0000000FOR1828579.000000FORS000002088Danaher Corporation235851102US235851102805/07/2024To elect the thirteen directors named in the attached Proxy Statement to hold office until the 2025 Annual Meeting of Shareholders and until their successors are elected and qualified: Feroz DewanDIRECTOR ELECTIONSISSUER1828579.0000000FOR1828579.000000FORS000002088Danaher Corporation235851102US235851102805/07/2024To elect the thirteen directors named in the attached Proxy Statement to hold office until the 2025 Annual Meeting of Shareholders and until their successors are elected and qualified: Linda FillerDIRECTOR ELECTIONSISSUER1828579.0000000FOR1828579.000000FORS000002088Danaher Corporation235851102US235851102805/07/2024To elect the thirteen directors named in the attached Proxy Statement to hold office until the 2025 Annual Meeting of Shareholders and until their successors are elected and qualified: Teri ListDIRECTOR ELECTIONSISSUER1828579.0000000FOR1828579.000000FORS000002088Danaher Corporation235851102US235851102805/07/2024To elect the thirteen directors named in the attached Proxy Statement to hold office until the 2025 Annual Meeting of Shareholders and until their successors are elected and qualified: Jessica L. Mega, MD, MPHDIRECTOR ELECTIONSISSUER1828579.0000000FOR1828579.000000FORS000002088Danaher Corporation235851102US235851102805/07/2024To elect the thirteen directors named in the attached Proxy Statement to hold office until the 2025 Annual Meeting of Shareholders and until their successors are elected and qualified: Mitchell P. RalesDIRECTOR ELECTIONSISSUER1828579.0000000FOR1828579.000000FORS000002088Danaher Corporation235851102US235851102805/07/2024To elect the thirteen directors named in the attached Proxy Statement to hold office until the 2025 Annual Meeting of Shareholders and until their successors are elected and qualified: Steven M. RalesDIRECTOR ELECTIONSISSUER1828579.0000000FOR1828579.000000FORS000002088Danaher Corporation235851102US235851102805/07/2024To elect the thirteen directors named in the attached Proxy Statement to hold office until the 2025 Annual Meeting of Shareholders and until their successors are elected and qualified: Pardis C. Sabeti, MD, D. PHILDIRECTOR ELECTIONSISSUER1828579.0000000FOR1828579.000000FORS000002088Danaher Corporation235851102US235851102805/07/2024To elect the thirteen directors named in the attached Proxy Statement to hold office until the 2025 Annual Meeting of Shareholders and until their successors are elected and qualified: A. Shane SandersDIRECTOR ELECTIONSISSUER1828579.0000000FOR1828579.000000FORS000002088Danaher Corporation235851102US235851102805/07/2024To elect the thirteen directors named in the attached Proxy Statement to hold office until the 2025 Annual Meeting of Shareholders and until their successors are elected and qualified: John T. SchwietersDIRECTOR ELECTIONSISSUER1828579.0000000FOR1828579.000000FORS000002088Danaher Corporation235851102US235851102805/07/2024To elect the thirteen directors named in the attached Proxy Statement to hold office until the 2025 Annual Meeting of Shareholders and until their successors are elected and qualified: Alan G. SpoonDIRECTOR ELECTIONSISSUER1828579.0000000FOR1828579.000000FORS000002088Danaher Corporation235851102US235851102805/07/2024To elect the thirteen directors named in the attached Proxy Statement to hold office until the 2025 Annual Meeting of Shareholders and until their successors are elected and qualified: Raymond C. Stevens, Ph.DDIRECTOR ELECTIONSISSUER1828579.0000000FOR1828579.000000FORS000002088Danaher Corporation235851102US235851102805/07/2024To elect the thirteen directors named in the attached Proxy Statement to hold office until the 2025 Annual Meeting of Shareholders and until their successors are elected and qualified: Elias A. Zerhouni, MDDIRECTOR ELECTIONSISSUER1828579.0000000FOR1828579.000000FORS000002088Danaher Corporation235851102US235851102805/07/2024To ratify the selection of Ernst & Young LLP as Danaher's independent registered public accounting firm for the year ending December 31, 2024.AUDIT-RELATEDISSUER1828579.0000000FOR1828579.000000FORS000002088Danaher Corporation235851102US235851102805/07/2024To approve on an advisory basis the Company's named executive officer compensation.SECTION 14A SAY-ON-PAY VOTESISSUER1828579.0000000FOR1828579.000000FORS000002088Danaher Corporation235851102US235851102805/07/2024To act upon a shareholder proposal requesting that Danaher amend its governing documents to reduce the percentage of shares required for shareholders to call a special meeting of shareholders from 25% to 15%.CORPORATE GOVERNANCESECURITY HOLDER1828579.0000000AGAINST1828579.000000FORS000002088Danaher Corporation235851102US235851102805/07/2024To act upon a shareholder proposal requesting a report to shareholders on the effectiveness of the Company's diversity, equity and inclusion efforts.DIVERSITY, EQUITY, AND INCLUSIONSECURITY HOLDER1828579.0000000AGAINST1828579.000000FORS000002088Edwards Lifesciences Corporation28176E108US28176E108205/07/2024Election of Directors: Leslie C. DavisDIRECTOR ELECTIONSISSUER1955971.0000000FOR1955971.000000FORS000002088Edwards Lifesciences Corporation28176E108US28176E108205/07/2024Election of Directors: Kieran T. GallahueDIRECTOR ELECTIONSISSUER1955971.0000000FOR1955971.000000FORS000002088Edwards Lifesciences Corporation28176E108US28176E108205/07/2024Election of Directors: Leslie S. HeiszDIRECTOR ELECTIONSISSUER1955971.0000000FOR1955971.000000FORS000002088Edwards Lifesciences Corporation28176E108US28176E108205/07/2024Election of Directors: Paul A. LaVioletteDIRECTOR ELECTIONSISSUER1955971.0000000FOR1955971.000000FORS000002088Edwards Lifesciences Corporation28176E108US28176E108205/07/2024Election of Directors: Steven R. LorangerDIRECTOR ELECTIONSISSUER1955971.0000000FOR1955971.000000FORS000002088Edwards Lifesciences Corporation28176E108US28176E108205/07/2024Election of Directors: Ramona SequeiraDIRECTOR ELECTIONSISSUER1955971.0000000FOR1955971.000000FORS000002088Edwards Lifesciences Corporation28176E108US28176E108205/07/2024Election of Directors: Nicholas J. ValerianiDIRECTOR ELECTIONSISSUER1955971.0000000FOR1955971.000000FORS000002088Edwards Lifesciences Corporation28176E108US28176E108205/07/2024Election of Directors: Bernard J. ZovighianDIRECTOR ELECTIONSISSUER1955971.0000000FOR1955971.000000FORS000002088Edwards Lifesciences Corporation28176E108US28176E108205/07/2024Advisory Vote to Approve Named Executive Officer CompensationSECTION 14A SAY-ON-PAY VOTESISSUER1955971.0000000FOR1955971.000000FORS000002088Edwards Lifesciences Corporation28176E108US28176E108205/07/2024Ratification of Appointment of Independent Registered Public Accounting FirmAUDIT-RELATEDISSUER1955971.0000000FOR1955971.000000FORS000002088Edwards Lifesciences Corporation28176E108US28176E108205/07/2024Approval of the Amended and Restated Long-Term Stock Incentive CompensationCOMPENSATIONISSUER1955971.0000000FOR1955971.000000FORS000002088Merus N.V.N5749R100NL001160626405/07/2024Adoption of Merus N.V.'s Dutch statutory annual accounts in the English language for the financial year 2023,CORPORATE GOVERNANCEISSUER802228.0000000FOR802228.000000FORS000002088Merus N.V.N5749R100NL001160626405/07/2024Appointment of KPMG Accountants N.V. as Merus N.V.'s external auditor for the financial year 2024 for purposes of Dutch law.AUDIT-RELATEDISSUER802228.0000000FOR802228.000000FORS000002088Merus N.V.N5749R100NL001160626405/07/2024Release of each member of Merus N.V.'s board of directors from liability for the exercise of their duties during the financial year 2023.CORPORATE GOVERNANCEISSUER802228.0000000FOR802228.000000FORS000002088Merus N.V.N5749R100NL001160626405/07/2024Re-appointment of Mark Iwicki as non-executive director.DIRECTOR ELECTIONSISSUER802228.0000000AGAINST802228.000000AGAINSTS000002088Merus N.V.N5749R100NL001160626405/07/2024Re-appointment of Paolo Pucci as non-executive director.DIRECTOR ELECTIONSISSUER802228.0000000FOR802228.000000FORS000002088Merus N.V.N5749R100NL001160626405/07/2024Appointment of Jason Haddock as non-executive director.DIRECTOR ELECTIONSISSUER802228.0000000FOR802228.000000FORS000002088Merus N.V.N5749R100NL001160626405/07/2024Articles Amendment A - Approval of the amendment of the Articles of Association to increase the authorized share capital to the amount of EUR 18,900,000 and divided into 105,000,000 common shares and 105,000,000 preferred shares and authorization to implement such amendment.CAPITAL STRUCTUREISSUER802228.0000000AGAINST802228.000000AGAINSTS000002088Merus N.V.N5749R100NL001160626405/07/2024Articles Amendment B - Approval of the amendment of the Articles of Association to reflect the Large Company Regime and authorization to implement such amendment.CORPORATE GOVERNANCEISSUER802228.0000000AGAINST802228.000000AGAINSTS000002088Merus N.V.N5749R100NL001160626405/07/2024Granting authorization to Menus N.V.'s board of directors to acquire shares (or depository receipts for such shares) in Merus N.V.'s capital.CAPITAL STRUCTUREISSUER802228.0000000FOR802228.000000FORS000002088Merus N.V.N5749R100NL001160626405/07/2024Approval, on an advisory (non-binding) basis, of the compensation of Merus N.V.'s named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER802228.0000000FOR802228.000000FORS000002088Merus N.V.N5749R100NL001160626405/07/2024Approval of the amendment of the Merus N.V.'s Non- Executive Director Compensation Program ("NED Program") to allow the board of directors to determine the number of common shares that may be awarded to a non-executive director for initial and annual awards under the NED Program to more closely align with the 50th percentile of the Company's peer group.COMPENSATIONISSUER802228.0000000AGAINST802228.000000AGAINSTS000002088Merus N.V.N5749R100NL001160626405/07/2024Approval of the amendment and restatement of the Merus NV. 2016 Incentive Award Plan (the "2016 Plan"), to extend the term of the 2016 Plan to December 31, 2031, which includes a corresponding extension to the annual "evergreen" feature from and including January 1, 2026, to January 1, 2029, along with other minor amendments updated for best practices.COMPENSATIONISSUER802228.0000000AGAINST802228.000000AGAINSTS000002088Charles River Laboratories International, Inc.159864107US159864107405/08/2024Election of Directors: James C. FosterDIRECTOR ELECTIONSISSUER267006.0000000FOR267006.000000FORS000002088Charles River Laboratories International, Inc.159864107US159864107405/08/2024Election of Directors: Nancy C. AndrewsDIRECTOR ELECTIONSISSUER267006.0000000FOR267006.000000FORS000002088Charles River Laboratories International, Inc.159864107US159864107405/08/2024Election of Directors: Robert BertoliniDIRECTOR ELECTIONSISSUER267006.0000000FOR267006.000000FORS000002088Charles River Laboratories International, Inc.159864107US159864107405/08/2024Election of Directors: Reshema Kemps-PolancoDIRECTOR ELECTIONSISSUER267006.0000000FOR267006.000000FORS000002088Charles River Laboratories International, Inc.159864107US159864107405/08/2024Election of Directors: Deborah T. KochevarDIRECTOR ELECTIONSISSUER267006.0000000FOR267006.000000FORS000002088Charles River Laboratories International, Inc.159864107US159864107405/08/2024Election of Directors: George Llado, Sr.DIRECTOR ELECTIONSISSUER267006.0000000FOR267006.000000FORS000002088Charles River Laboratories International, Inc.159864107US159864107405/08/2024Election of Directors: Martin W. MackayDIRECTOR ELECTIONSISSUER267006.0000000FOR267006.000000FORS000002088Charles River Laboratories International, Inc.159864107US159864107405/08/2024Election of Directors: George E. MassaroDIRECTOR ELECTIONSISSUER267006.0000000FOR267006.000000FORS000002088Charles River Laboratories International, Inc.159864107US159864107405/08/2024Election of Directors: Craig B. ThompsonDIRECTOR ELECTIONSISSUER267006.0000000FOR267006.000000FORS000002088Charles River Laboratories International, Inc.159864107US159864107405/08/2024Election of Directors: Richard F. WallmanDIRECTOR ELECTIONSISSUER267006.0000000FOR267006.000000FORS000002088Charles River Laboratories International, Inc.159864107US159864107405/08/2024Election of Directors: Virginia M. WilsonDIRECTOR ELECTIONSISSUER267006.0000000FOR267006.000000FORS000002088Charles River Laboratories International, Inc.159864107US159864107405/08/2024Advisory Approval of 2023 Executive Officer CompensationSECTION 14A SAY-ON-PAY VOTESISSUER267006.0000000FOR267006.000000FORS000002088Charles River Laboratories International, Inc.159864107US159864107405/08/2024Ratification of PricewaterhouseCoopers LLC as independent registered public accounting firm for 2024AUDIT-RELATEDISSUER267006.0000000FOR267006.000000FORS000002088Charles River Laboratories International, Inc.159864107US159864107405/08/2024Proposal to publish a report on non-human primates imported by Charles River Laboratories International, Inc.OTHER SOCIAL ISSUESSECURITY HOLDER267006.0000000AGAINST267006.000000FORS000002088Stryker Corporation863667101US863667101305/09/2024Election of Ten Directors: Mary K. BrainerdDIRECTOR ELECTIONSISSUER1564418.0000000FOR1564418.000000FORS000002088Stryker Corporation863667101US863667101305/09/2024Election of Ten Directors: Giovanni Caforio, M.D.DIRECTOR ELECTIONSISSUER1564418.0000000FOR1564418.000000FORS000002088Stryker Corporation863667101US863667101305/09/2024Election of Ten Directors: Allan C. GolstonDIRECTOR ELECTIONSISSUER1564418.0000000FOR1564418.000000FORS000002088Stryker Corporation863667101US863667101305/09/2024Election of Ten Directors: Kevin A. LoboDIRECTOR ELECTIONSISSUER1564418.0000000FOR1564418.000000FORS000002088Stryker Corporation863667101US863667101305/09/2024Election of Ten Directors: Sherilyn S. McCoyDIRECTOR ELECTIONSISSUER1564418.0000000FOR1564418.000000FORS000002088Stryker Corporation863667101US863667101305/09/2024Election of Ten Directors: Rachel RuggeriDIRECTOR ELECTIONSISSUER1564418.0000000FOR1564418.000000FORS000002088Stryker Corporation863667101US863667101305/09/2024Election of Ten Directors: Andrew K. SilvernailDIRECTOR ELECTIONSISSUER1564418.0000000FOR1564418.000000FORS000002088Stryker Corporation863667101US863667101305/09/2024Election of Ten Directors: Lisa M. Skeete TatumDIRECTOR ELECTIONSISSUER1564418.0000000FOR1564418.000000FORS000002088Stryker Corporation863667101US863667101305/09/2024Election of Ten Directors: Ronda E. StrykerDIRECTOR ELECTIONSISSUER1564418.0000000FOR1564418.000000FORS000002088Stryker Corporation863667101US863667101305/09/2024Election of Ten Directors: Rajeev SuriDIRECTOR ELECTIONSISSUER1564418.0000000FOR1564418.000000FORS000002088Stryker Corporation863667101US863667101305/09/2024Ratification of Appointment of Ernst & Young LLP as Our Independent Registered Public Accounting Firm for 2024.AUDIT-RELATEDISSUER1564418.0000000FOR1564418.000000FORS000002088Stryker Corporation863667101US863667101305/09/2024Advisory Vote to Approve Named Executive Officer Compensation.SECTION 14A SAY-ON-PAY VOTESISSUER1564418.0000000FOR1564418.000000FORS000002088Stryker Corporation863667101US863667101305/09/2024Shareholder Proposal on Transparency in Political Spending.OTHER SOCIAL ISSUESSECURITY HOLDER1564418.0000000FOR1564418.000000AGAINSTS000002088Zimmer Biomet Holdings, Inc.98956P102US98956P102105/10/2024Election of Directors: Christopher B. BegleyDIRECTOR ELECTIONSISSUER596830.0000000FOR596830.000000FORS000002088Zimmer Biomet Holdings, Inc.98956P102US98956P102105/10/2024Election of Directors: Betsy J. BernardDIRECTOR ELECTIONSISSUER596830.0000000FOR596830.000000FORS000002088Zimmer Biomet Holdings, Inc.98956P102US98956P102105/10/2024Election of Directors: Michael J. FarrellDIRECTOR ELECTIONSISSUER596830.0000000FOR596830.000000FORS000002088Zimmer Biomet Holdings, Inc.98956P102US98956P102105/10/2024Election of Directors: Robert A. HagemannDIRECTOR ELECTIONSISSUER596830.0000000FOR596830.000000FORS000002088Zimmer Biomet Holdings, Inc.98956P102US98956P102105/10/2024Election of Directors: Arthur J. HigginsDIRECTOR ELECTIONSISSUER596830.0000000FOR596830.000000FORS000002088Zimmer Biomet Holdings, Inc.98956P102US98956P102105/10/2024Election of Directors: Maria Teresa HiladoDIRECTOR ELECTIONSISSUER596830.0000000FOR596830.000000FORS000002088Zimmer Biomet Holdings, Inc.98956P102US98956P102105/10/2024Election of Directors: Syed JafryDIRECTOR ELECTIONSISSUER596830.0000000FOR596830.000000FORS000002088Zimmer Biomet Holdings, Inc.98956P102US98956P102105/10/2024Election of Directors: Sreelakshmi KolliDIRECTOR ELECTIONSISSUER596830.0000000FOR596830.000000FORS000002088Zimmer Biomet Holdings, Inc.98956P102US98956P102105/10/2024Election of Directors: Louis ShapiroDIRECTOR ELECTIONSISSUER596830.0000000FOR596830.000000FORS000002088Zimmer Biomet Holdings, Inc.98956P102US98956P102105/10/2024Election of Directors: Ivan TornosDIRECTOR ELECTIONSISSUER596830.0000000FOR596830.000000FORS000002088Zimmer Biomet Holdings, Inc.98956P102US98956P102105/10/2024Ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for 2024.AUDIT-RELATEDISSUER596830.0000000FOR596830.000000FORS000002088Zimmer Biomet Holdings, Inc.98956P102US98956P102105/10/2024Approve, on a non-binding advisory basis, named executive officer compensation ("Say on Pay").SECTION 14A SAY-ON-PAY VOTESISSUER596830.0000000FOR596830.000000FORS000002088Zimmer Biomet Holdings, Inc.98956P102US98956P102105/10/2024Approve the amended Employee Stock Purchase Plan.COMPENSATIONISSUER596830.0000000FOR596830.000000FORS000002088Insmed Incorporated457669307US457669307505/13/2024Election of four Class III directors, David R. Brennan, Leo Lee, Carol A. Schafer, and Melvin Sharoky, M.D., to serve until the 2027 Annual Meeting of Shareholders: David R. BrennanDIRECTOR ELECTIONSISSUER2018105.0000000FOR2018105.000000FORS000002088Insmed Incorporated457669307US457669307505/13/2024Election of four Class III directors, David R. Brennan, Leo Lee, Carol A. Schafer, and Melvin Sharoky, M.D., to serve until the 2027 Annual Meeting of Shareholders: Leo LeeDIRECTOR ELECTIONSISSUER2018105.0000000FOR2018105.000000FORS000002088Insmed Incorporated457669307US457669307505/13/2024Election of four Class III directors, David R. Brennan, Leo Lee, Carol A. Schafer, and Melvin Sharoky, M.D., to serve until the 2027 Annual Meeting of Shareholders: Carol A. SchaferDIRECTOR ELECTIONSISSUER2018105.0000000FOR2018105.000000FORS000002088Insmed Incorporated457669307US457669307505/13/2024Election of four Class III directors, David R. Brennan, Leo Lee, Carol A. Schafer, and Melvin Sharoky, M.D., to serve until the 2027 Annual Meeting of Shareholders: Melvin Sharoky, M.D.DIRECTOR ELECTIONSISSUER2018105.0000000FOR2018105.000000FORS000002088Insmed Incorporated457669307US457669307505/13/2024An advisory vote on the 2023 compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER2018105.0000000FOR2018105.000000FORS000002088Insmed Incorporated457669307US457669307505/13/2024Ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for the year ending December 31, 2024.AUDIT-RELATEDISSUER2018105.0000000FOR2018105.000000FORS000002088Insmed Incorporated457669307US457669307505/13/2024Approval of Amendment No. 1 to the Insmed Incorporated Amended and Restated 2019 Incentive Plan.COMPENSATIONISSUER2018105.0000000FOR2018105.000000FORS000002088Spyre Therapeutics, Inc.00773J202US00773J202405/13/2024Election of Class II Directors for terms expiring in 2027: Jeffrey W. AlbersDIRECTOR ELECTIONSISSUER115496.0000000FOR115496.000000FORS000002088Spyre Therapeutics, Inc.00773J202US00773J202405/13/2024Election of Class II Directors for terms expiring in 2027: Tomas KiselakDIRECTOR ELECTIONSISSUER115496.0000000FOR115496.000000FORS000002088Spyre Therapeutics, Inc.00773J202US00773J202405/13/2024To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER115496.0000000FOR115496.000000FORS000002088Spyre Therapeutics, Inc.00773J202US00773J202405/13/2024To ratify the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the year ending December 31, 2024.AUDIT-RELATEDISSUER115496.0000000FOR115496.000000FORS000002088Spyre Therapeutics, Inc.00773J202US00773J202405/13/2024To approve, in accordance with Nasdaq Listing Rule 5635(a), the issuance of shares of the Company's common stock upon conversion of the Company's Series B Convertible Preferred Stock issued in December 2023.CAPITAL STRUCTUREISSUER115496.0000000FOR115496.000000FORS000002088Spyre Therapeutics, Inc.00773J202US00773J202405/13/2024To approve, in accordance with Nasdaq Listing Rule 5635(a), the issuance of shares of the Company's common stock upon conversion of the Company's Series B Convertible Preferred Stock issued in March 2024.CAPITAL STRUCTUREISSUER115496.0000000FOR115496.000000FORS000002088Spyre Therapeutics, Inc.00773J202US00773J202405/13/2024To approve an amendment to the Company's Amended and Restated Certificate of Incorporation to reflect Delaware law provisions regarding officer exculpation.CORPORATE GOVERNANCEISSUER115496.0000000FOR115496.000000FORS000002088Spyre Therapeutics, Inc.00773J202US00773J202405/13/2024To approve an adjournment of the Annual Meeting, if necessary or appropriate, to solicit additional proxies.CORPORATE GOVERNANCEISSUER115496.0000000AGAINST115496.000000AGAINSTS000002088Centene Corporation15135B101US15135B101705/14/2024ELECTION OF DIRECTORS: Jessica L. BlumeDIRECTOR ELECTIONSISSUER1246478.0000000FOR1246478.000000FORS000002088Centene Corporation15135B101US15135B101705/14/2024ELECTION OF DIRECTORS: Kenneth A. BurdickDIRECTOR ELECTIONSISSUER1246478.0000000FOR1246478.000000FORS000002088Centene Corporation15135B101US15135B101705/14/2024ELECTION OF DIRECTORS: Christopher J. CoughlinDIRECTOR ELECTIONSISSUER1246478.0000000FOR1246478.000000FORS000002088Centene Corporation15135B101US15135B101705/14/2024ELECTION OF DIRECTORS: H. James DallasDIRECTOR ELECTIONSISSUER1246478.0000000FOR1246478.000000FORS000002088Centene Corporation15135B101US15135B101705/14/2024ELECTION OF DIRECTORS: Wayne S. DeVeydtDIRECTOR ELECTIONSISSUER1246478.0000000FOR1246478.000000FORS000002088Centene Corporation15135B101US15135B101705/14/2024ELECTION OF DIRECTORS: Frederick H. EppingerDIRECTOR ELECTIONSISSUER1246478.0000000FOR1246478.000000FORS000002088Centene Corporation15135B101US15135B101705/14/2024ELECTION OF DIRECTORS: Monte E. FordDIRECTOR ELECTIONSISSUER1246478.0000000FOR1246478.000000FORS000002088Centene Corporation15135B101US15135B101705/14/2024ELECTION OF DIRECTORS: Sarah M. LondonDIRECTOR ELECTIONSISSUER1246478.0000000FOR1246478.000000FORS000002088Centene Corporation15135B101US15135B101705/14/2024ELECTION OF DIRECTORS: Lori J. RobinsonDIRECTOR ELECTIONSISSUER1246478.0000000FOR1246478.000000FORS000002088Centene Corporation15135B101US15135B101705/14/2024ELECTION OF DIRECTORS: Theodore R. SamuelsDIRECTOR ELECTIONSISSUER1246478.0000000FOR1246478.000000FORS000002088Centene Corporation15135B101US15135B101705/14/2024ADVISORY RESOLUTION TO APPROVE EXECUTIVE COMPENSATION.SECTION 14A SAY-ON-PAY VOTESISSUER1246478.0000000FOR1246478.000000FORS000002088Centene Corporation15135B101US15135B101705/14/2024RATIFICATION OF APPOINTMENT OF KPMG LLP AS OUR INDEPENDENT PUBLIC ACCOUNTING FIRM FOR THE YEAR ENDING DECEMBER 31, 2024.AUDIT-RELATEDISSUER1246478.0000000FOR1246478.000000FORS000002088Centene Corporation15135B101US15135B101705/14/2024STOCKHOLDER PROPOSAL FOR MANAGING CLIMATE RISK THROUGH SCIENCE-BASED TARGETS AND TRANSITION PLANNING.ENVIRONMENT OR CLIMATESECURITY HOLDER1246478.0000000AGAINST1246478.000000FORS000002088Prothena Corporation plcG72800108IE00B91XRN2005/14/2024To elect, by separate resolutions, four directors to hold office until no later than the Annual General Meeting of the Company's Shareholders in 2027, unless they resign, are removed from office, or are otherwise disqualified from serving as directors of the Company: Richard T. CollierDIRECTOR ELECTIONSISSUER748056.0000000FOR748056.000000FORS000002088Prothena Corporation plcG72800108IE00B91XRN2005/14/2024To elect, by separate resolutions, four directors to hold office until no later than the Annual General Meeting of the Company's Shareholders in 2027, unless they resign, are removed from office, or are otherwise disqualified from serving as directors of the Company: Shane M. CookeDIRECTOR ELECTIONSISSUER748056.0000000FOR748056.000000FORS000002088Prothena Corporation plcG72800108IE00B91XRN2005/14/2024To elect, by separate resolutions, four directors to hold office until no later than the Annual General Meeting of the Company's Shareholders in 2027, unless they resign, are removed from office, or are otherwise disqualified from serving as directors of the Company: William H. Dunn, Jr.DIRECTOR ELECTIONSISSUER748056.0000000FOR748056.000000FORS000002088Prothena Corporation plcG72800108IE00B91XRN2005/14/2024To elect, by separate resolutions, four directors to hold office until no later than the Annual General Meeting of the Company's Shareholders in 2027, unless they resign, are removed from office, or are otherwise disqualified from serving as directors of the Company: Daniel G. WelchDIRECTOR ELECTIONSISSUER748056.0000000FOR748056.000000FORS000002088Prothena Corporation plcG72800108IE00B91XRN2005/14/2024To ratify, in a non-binding vote, the appointment of KPMG LLP as the Company's independent registered public accounting firm for its fiscal year 2024 and to authorize, in a binding vote, the Company's Board of Directors, acting through its Audit Committee, to approve the remuneration of that auditor.AUDIT-RELATEDISSUER748056.0000000FOR748056.000000FORS000002088Prothena Corporation plcG72800108IE00B91XRN2005/14/2024To approve, in a non-binding advisory vote, the compensation of the executive officers named in the Company's Proxy Statement for the Annual General Meeting.SECTION 14A SAY-ON-PAY VOTESISSUER748056.0000000FOR748056.000000FORS000002088Prothena Corporation plcG72800108IE00B91XRN2005/14/2024To approve an amendment to the Company's 2018 Long Term Incentive Plan to increase the number of ordinary shares available for issuance under that Plan by 2,000,000 ordinary shares.COMPENSATIONISSUER748056.0000000FOR748056.000000FORS000002088Cytokinetics, Incorporated23282W605US23282W605705/15/2024To elect two Class II Directors: Robert I. BlumDIRECTOR ELECTIONSISSUER425850.0000000FOR425850.000000FORS000002088Cytokinetics, Incorporated23282W605US23282W605705/15/2024To elect two Class II Directors: Robert A. Hammington, M.D.DIRECTOR ELECTIONSISSUER425850.0000000WITHHOLD425850.000000AGAINSTS000002088Cytokinetics, Incorporated23282W605US23282W605705/15/2024To approve the amendment and restatement of the Company's Amended and Restated 2015 Employee Stock Purchase Plan to increase the number of authorized shares reserved for issuance under such plan by 300,000 shares of common stock.COMPENSATIONISSUER425850.0000000FOR425850.000000FORS000002088Cytokinetics, Incorporated23282W605US23282W605705/15/2024To ratify the appointment by the Audit Committee of the Board of Directors of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024.AUDIT-RELATEDISSUER425850.0000000FOR425850.000000FORS000002088Cytokinetics, Incorporated23282W605US23282W605705/15/2024To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the Proxy Statement.SECTION 14A SAY-ON-PAY VOTESISSUER425850.0000000FOR425850.000000FORS000002088Elevance Health, Inc.036752103US036752103805/15/2024Election of Directors: Lewis Hay, IIIDIRECTOR ELECTIONSISSUER1054893.0000000FOR1054893.000000FORS000002088Elevance Health, Inc.036752103US036752103805/15/2024Election of Directors: Antonio F. NeriDIRECTOR ELECTIONSISSUER1054893.0000000FOR1054893.000000FORS000002088Elevance Health, Inc.036752103US036752103805/15/2024Election of Directors: Ramiro G. PeruDIRECTOR ELECTIONSISSUER1054893.0000000FOR1054893.000000FORS000002088Elevance Health, Inc.036752103US036752103805/15/2024Advisory vote to approve the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER1054893.0000000FOR1054893.000000FORS000002088Elevance Health, Inc.036752103US036752103805/15/2024To ratify the appointment of Ernst & Young LLP as the independent registered public accounting firm for 2024.AUDIT-RELATEDISSUER1054893.0000000FOR1054893.000000FORS000002088Elevance Health, Inc.036752103US036752103805/15/2024Shareholder proposal to adopt a policy to require certain third-party organizations to annually report political activity expenditures prior to Elevance Health donating to the organizations.OTHER SOCIAL ISSUESSECURITY HOLDER1054893.0000000AGAINST1054893.000000FORS000002088Vera Therapeutics, Inc.92337R101US92337R101405/15/2024To elect the two Class III directors named below to hold office until the Company's 2027 annual meeting of stockholders: Andrew Cheng, M.D., Ph.D.DIRECTOR ELECTIONSISSUER763119.0000000WITHHOLD763119.000000AGAINSTS000002088Vera Therapeutics, Inc.92337R101US92337R101405/15/2024To elect the two Class III directors named below to hold office until the Company's 2027 annual meeting of stockholders: Scott MorrisonDIRECTOR ELECTIONSISSUER763119.0000000FOR763119.000000FORS000002088Vera Therapeutics, Inc.92337R101US92337R101405/15/2024To ratify the selection by the Audit Committee of the Board of Directors of KPMG LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2024.AUDIT-RELATEDISSUER763119.0000000FOR763119.000000FORS000002088Vertex Pharmaceuticals Incorporated92532F100US92532F100305/15/2024Election of Directors: Sangeeta BhatiaDIRECTOR ELECTIONSISSUER779144.0000000FOR779144.000000FORS000002088Vertex Pharmaceuticals Incorporated92532F100US92532F100305/15/2024Election of Directors: Lloyd CarneyDIRECTOR ELECTIONSISSUER779144.0000000FOR779144.000000FORS000002088Vertex Pharmaceuticals Incorporated92532F100US92532F100305/15/2024Election of Directors: Alan GarberDIRECTOR ELECTIONSISSUER779144.0000000FOR779144.000000FORS000002088Vertex Pharmaceuticals Incorporated92532F100US92532F100305/15/2024Election of Directors: Reshma KewalramaniDIRECTOR ELECTIONSISSUER779144.0000000FOR779144.000000FORS000002088Vertex Pharmaceuticals Incorporated92532F100US92532F100305/15/2024Election of Directors: Michel LagardeDIRECTOR ELECTIONSISSUER779144.0000000FOR779144.000000FORS000002088Vertex Pharmaceuticals Incorporated92532F100US92532F100305/15/2024Election of Directors: Jeffrey LeidenDIRECTOR ELECTIONSISSUER779144.0000000FOR779144.000000FORS000002088Vertex Pharmaceuticals Incorporated92532F100US92532F100305/15/2024Election of Directors: Diana McKenzieDIRECTOR ELECTIONSISSUER779144.0000000FOR779144.000000FORS000002088Vertex Pharmaceuticals Incorporated92532F100US92532F100305/15/2024Election of Directors: Bruce SachsDIRECTOR ELECTIONSISSUER779144.0000000FOR779144.000000FORS000002088Vertex Pharmaceuticals Incorporated92532F100US92532F100305/15/2024Election of Directors: Jennifer SchneiderDIRECTOR ELECTIONSISSUER779144.0000000FOR779144.000000FORS000002088Vertex Pharmaceuticals Incorporated92532F100US92532F100305/15/2024Election of Directors: Nancy ThornberryDIRECTOR ELECTIONSISSUER779144.0000000FOR779144.000000FORS000002088Vertex Pharmaceuticals Incorporated92532F100US92532F100305/15/2024Election of Directors: Suketu UpadhyayDIRECTOR ELECTIONSISSUER779144.0000000FOR779144.000000FORS000002088Vertex Pharmaceuticals Incorporated92532F100US92532F100305/15/2024Ratification of Ernst & Young LLP as independent Registered Public Accounting firm for the year ending December 31, 2024.AUDIT-RELATEDISSUER779144.0000000FOR779144.000000FORS000002088Vertex Pharmaceuticals Incorporated92532F100US92532F100305/15/2024Advisory vote to approve named executive office compensation.SECTION 14A SAY-ON-PAY VOTESISSUER779144.0000000FOR779144.000000FORS000002088Vertex Pharmaceuticals Incorporated92532F100US92532F100305/15/2024Shareholder proposal, if properly presented at the meeting, regarding special shareholder meeting improvement.CORPORATE GOVERNANCESECURITY HOLDER779144.0000000AGAINST779144.000000FORS000002088Vertex Pharmaceuticals Incorporated92532F100US92532F100305/15/2024Shareholder proposal, if properly presented at the meeting, regarding a report on racial and gender pay gaps.DIVERSITY, EQUITY, AND INCLUSIONSECURITY HOLDER779144.0000000AGAINST779144.000000FORS000002088Alnylam Pharmaceuticals, Inc.02043Q107US02043Q107605/16/2024To elect the following nominees as Class II directors of Alnylam: Dennis A. Ausiello, M.D.DIRECTOR ELECTIONSISSUER1362579.0000000AGAINST1362579.000000AGAINSTS000002088Alnylam Pharmaceuticals, Inc.02043Q107US02043Q107605/16/2024To elect the following nominees as Class II directors of Alnylam: Olivier Brandicourt, M.D.DIRECTOR ELECTIONSISSUER1362579.0000000AGAINST1362579.000000AGAINSTS000002088Alnylam Pharmaceuticals, Inc.02043Q107US02043Q107605/16/2024To elect the following nominees as Class II directors of Alnylam: Peter N. KelloggDIRECTOR ELECTIONSISSUER1362579.0000000AGAINST1362579.000000AGAINSTS000002088Alnylam Pharmaceuticals, Inc.02043Q107US02043Q107605/16/2024To elect the following nominees as Class II directors of Alnylam: David E.I. PyottDIRECTOR ELECTIONSISSUER1362579.0000000AGAINST1362579.000000AGAINSTS000002088Alnylam Pharmaceuticals, Inc.02043Q107US02043Q107605/16/2024To approve, in a non-binding advisory vote, the compensation of Alnylam's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER1362579.0000000FOR1362579.000000FORS000002088Alnylam Pharmaceuticals, Inc.02043Q107US02043Q107605/16/2024To ratify the appointment of PricewaterhouseCoopers LLP, an independent registered public accounting firm, as Alnylam's independent auditors for the fiscal year ending December 31, 2024.AUDIT-RELATEDISSUER1362579.0000000FOR1362579.000000FORS000002088Bicycle Therapeutics Plc088786108US088786108805/16/2024Ordinary Resolutions To re-elect as a director Kevin Lee, who retires in accordance with the Articles of AssociationDIRECTOR ELECTIONSISSUER310475.0000000FOR310475.000000FORS000002088Bicycle Therapeutics Plc088786108US088786108805/16/2024To re-elect as a director Jose-Carlos Gutierrez-Ramos, who retires in accordance with the Articles of AssociationDIRECTOR ELECTIONSISSUER310475.0000000FOR310475.000000FORS000002088Bicycle Therapeutics Plc088786108US088786108805/16/2024To approve, on advisory basis, the compensation of our named executive officers, as disclosed in the proxy statementSECTION 14A SAY-ON-PAY VOTESISSUER310475.0000000FOR310475.000000FORS000002088Bicycle Therapeutics Plc088786108US088786108805/16/2024To ratify the appointment of PricewaterhouseCoopers LLP, a limited liability partnership organized under the laws of England, as our U.S. independent registered public accounting firm for the year ending December 31, 2024AUDIT-RELATEDISSUER310475.0000000FOR310475.000000FORS000002088Bicycle Therapeutics Plc088786108US088786108805/16/2024To re-appoint PricewaterhouseCoopers LLP, a limited liability partnership organized under the laws of England, as our U.K. statutory auditors, to hold office until the conclusion of the next annual general meeting of shareholdersAUDIT-RELATEDISSUER310475.0000000FOR310475.000000FORS000002088Bicycle Therapeutics Plc088786108US088786108805/16/2024To authorize the Audit Committee to determine our U.K. statutory 31,2024 auditors' remuneration for the year ending December 31, 2024AUDIT-RELATEDISSUER310475.0000000FOR310475.000000FORS000002088Bicycle Therapeutics Plc088786108US088786108805/16/2024To receive and adopt our U.K. statutory annual accounts and reports for the year ended December 31, 2023 (the "2023 U.K. Annual Report")CORPORATE GOVERNANCEISSUER310475.0000000FOR310475.000000FORS000002088Bicycle Therapeutics Plc088786108US088786108805/16/2024To approve our directors' remuneration report for the year ended December 31, 2023 (the "directors' remuneration report"), which is set forth as Annex A to the proxy statementCOMPENSATIONISSUER310475.0000000FOR310475.000000FORS000002088Bicycle Therapeutics Plc088786108US088786108805/16/2024To authorize the Board of Directors to allot shares or to grant rights to subscribe for or convert any security into shares up to a maximum aggregate nominal amount of pounds1,000,000CAPITAL STRUCTUREISSUER310475.0000000AGAINST310475.000000AGAINSTS000002088Bicycle Therapeutics Plc088786108US088786108805/16/2024Special Resolutions To empower the Board of Directors to allot equity securities for cash up to a maximum aggregate nominal amount of pounds1,000,000 pursuant to the authorization in Resolution 9 as if U.K. statutory pre-emption rights did not applyCAPITAL STRUCTUREISSUER310475.0000000AGAINST310475.000000AGAINSTS000002088Bicycle Therapeutics Plc088786108US088786108805/16/2024To adopt new articles of association, which are set forth in Annex B to the proxy statementCORPORATE GOVERNANCEISSUER310475.0000000FOR310475.000000FORS000002088Corbus Pharmaceuticals Holdings, Inc.21833P301US21833P301005/16/2024Election of Directors: Yuval CohenDIRECTOR ELECTIONSISSUER97589.0000000FOR97589.000000FORS000002088Corbus Pharmaceuticals Holdings, Inc.21833P301US21833P301005/16/2024Election of Directors: Alan HolmerDIRECTOR ELECTIONSISSUER97589.0000000FOR97589.000000FORS000002088Corbus Pharmaceuticals Holdings, Inc.21833P301US21833P301005/16/2024Election of Directors: Avery W. CatlinDIRECTOR ELECTIONSISSUER97589.0000000FOR97589.000000FORS000002088Corbus Pharmaceuticals Holdings, Inc.21833P301US21833P301005/16/2024Election of Directors: Rachelle JacquesDIRECTOR ELECTIONSISSUER97589.0000000WITHHOLD97589.000000AGAINSTS000002088Corbus Pharmaceuticals Holdings, Inc.21833P301US21833P301005/16/2024Election of Directors: John JenkinsDIRECTOR ELECTIONSISSUER97589.0000000FOR97589.000000FORS000002088Corbus Pharmaceuticals Holdings, Inc.21833P301US21833P301005/16/2024Election of Directors: Peter SalzmannDIRECTOR ELECTIONSISSUER97589.0000000FOR97589.000000FORS000002088Corbus Pharmaceuticals Holdings, Inc.21833P301US21833P301005/16/2024Election of Directors: Anne AltmeyerDIRECTOR ELECTIONSISSUER97589.0000000FOR97589.000000FORS000002088Corbus Pharmaceuticals Holdings, Inc.21833P301US21833P301005/16/2024Election of Directors: Yong BenDIRECTOR ELECTIONSISSUER97589.0000000FOR97589.000000FORS000002088Corbus Pharmaceuticals Holdings, Inc.21833P301US21833P301005/16/2024Approval of the Company's 2024 Equity Compensation Plan.COMPENSATIONISSUER97589.0000000AGAINST97589.000000AGAINSTS000002088Corbus Pharmaceuticals Holdings, Inc.21833P301US21833P301005/16/2024Ratification of EisnerAmper LLP as the Company's independent registered public accounting firm for the year ending December 31, 2024.AUDIT-RELATEDISSUER97589.0000000FOR97589.000000FORS000002088Corbus Pharmaceuticals Holdings, Inc.21833P301US21833P301005/16/2024Approval, on an advisory basis, of the executive compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER97589.0000000FOR97589.000000FORS000002088Repligen Corporation759916109US759916109505/16/2024Election of Directors: Tony J. HuntDIRECTOR ELECTIONSISSUER257938.0000000FOR257938.000000FORS000002088Repligen Corporation759916109US759916109505/16/2024Election of Directors: Karen A. DawesDIRECTOR ELECTIONSISSUER257938.0000000FOR257938.000000FORS000002088Repligen Corporation759916109US759916109505/16/2024Election of Directors: Nicolas M. BarthelemyDIRECTOR ELECTIONSISSUER257938.0000000FOR257938.000000FORS000002088Repligen Corporation759916109US759916109505/16/2024Election of Directors: Carrie Eglinton MannerDIRECTOR ELECTIONSISSUER257938.0000000FOR257938.000000FORS000002088Repligen Corporation759916109US759916109505/16/2024Election of Directors: Konstantin Konstantinov, Ph.D.DIRECTOR ELECTIONSISSUER257938.0000000FOR257938.000000FORS000002088Repligen Corporation759916109US759916109505/16/2024Election of Directors: Martin D. Madaus, D.V.M., Ph.D.DIRECTOR ELECTIONSISSUER257938.0000000FOR257938.000000FORS000002088Repligen Corporation759916109US759916109505/16/2024Election of Directors: Rohin Mhatre, Ph.D.DIRECTOR ELECTIONSISSUER257938.0000000FOR257938.000000FORS000002088Repligen Corporation759916109US759916109505/16/2024Election of Directors: Glenn P. MuirDIRECTOR ELECTIONSISSUER257938.0000000FOR257938.000000FORS000002088Repligen Corporation759916109US759916109505/16/2024Election of Directors: Margaret A. PaxDIRECTOR ELECTIONSISSUER257938.0000000FOR257938.000000FORS000002088Repligen Corporation759916109US759916109505/16/2024Ratification of the selection of Ernst & Young LLP as Repligen Corporation's independent registered public accounting firm for the fiscal year ending December 31, 2024.AUDIT-RELATEDISSUER257938.0000000FOR257938.000000FORS000002088Repligen Corporation759916109US759916109505/16/2024Advisory vote to approve the compensation paid to Repligen Corporation's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER257938.0000000FOR257938.000000FORS000002088SpringWorks Therapeutics, Inc.85205L107US85205L107005/16/2024Election of Class II Director: Freda Lewis-HallDIRECTOR ELECTIONSISSUER1500680.0000000FOR1500680.000000FORS000002088SpringWorks Therapeutics, Inc.85205L107US85205L107005/16/2024Ratification of the appointment of Ernst & Young LLP as SpringWorks Therapeutics' independent registered public accounting firm for the fiscal year ending December 31, 2024AUDIT-RELATEDISSUER1500680.0000000FOR1500680.000000FORS000002088SpringWorks Therapeutics, Inc.85205L107US85205L107005/16/2024Non-binding advisory vote on executive compensationSECTION 14A SAY-ON-PAY VOTESISSUER1500680.0000000AGAINST1500680.000000AGAINSTS000002088Krystal Biotech, Inc.501147102US501147102705/17/2024Election of Class I Directors: Suma M. KrishnanDIRECTOR ELECTIONSISSUER402573.0000000FOR402573.000000FORS000002088Krystal Biotech, Inc.501147102US501147102705/17/2024Election of Class I Directors: Julian S. GangolliDIRECTOR ELECTIONSISSUER402573.0000000FOR402573.000000FORS000002088Krystal Biotech, Inc.501147102US501147102705/17/2024Election of Class I Directors: Catherine MazzaccoDIRECTOR ELECTIONSISSUER402573.0000000FOR402573.000000FORS000002088Krystal Biotech, Inc.501147102US501147102705/17/2024To ratify the appointment of KPMG LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2024.AUDIT-RELATEDISSUER402573.0000000FOR402573.000000FORS000002088Krystal Biotech, Inc.501147102US501147102705/17/2024Approval of the compensation of the Company's named executive officers, on a non-binding, advisory basis.SECTION 14A SAY-ON-PAY VOTESISSUER402573.0000000FOR402573.000000FORS000002088Enovis Corporation194014502US194014502205/20/2024Election of Directors: Matthew L. TrerotolaDIRECTOR ELECTIONSISSUER200116.0000000FOR200116.000000FORS000002088Enovis Corporation194014502US194014502205/20/2024Election of Directors: Barbara W. BodemDIRECTOR ELECTIONSISSUER200116.0000000AGAINST200116.000000AGAINSTS000002088Enovis Corporation194014502US194014502205/20/2024Election of Directors: Liam J. KellyDIRECTOR ELECTIONSISSUER200116.0000000AGAINST200116.000000AGAINSTS000002088Enovis Corporation194014502US194014502205/20/2024Election of Directors: Angela S. LalorDIRECTOR ELECTIONSISSUER200116.0000000AGAINST200116.000000AGAINSTS000002088Enovis Corporation194014502US194014502205/20/2024Election of Directors: Philip A. OkalaDIRECTOR ELECTIONSISSUER200116.0000000AGAINST200116.000000AGAINSTS000002088Enovis Corporation194014502US194014502205/20/2024Election of Directors: Christine OrtizDIRECTOR ELECTIONSISSUER200116.0000000AGAINST200116.000000AGAINSTS000002088Enovis Corporation194014502US194014502205/20/2024Election of Directors: A. Clayton PerfallDIRECTOR ELECTIONSISSUER200116.0000000AGAINST200116.000000AGAINSTS000002088Enovis Corporation194014502US194014502205/20/2024Election of Directors: Brady ShirleyDIRECTOR ELECTIONSISSUER200116.0000000AGAINST200116.000000AGAINSTS000002088Enovis Corporation194014502US194014502205/20/2024Election of Directors: Rajiv VinnakotaDIRECTOR ELECTIONSISSUER200116.0000000AGAINST200116.000000AGAINSTS000002088Enovis Corporation194014502US194014502205/20/2024Election of Directors: Sharon WienbarDIRECTOR ELECTIONSISSUER200116.0000000AGAINST200116.000000AGAINSTS000002088Enovis Corporation194014502US194014502205/20/2024To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024.AUDIT-RELATEDISSUER200116.0000000FOR200116.000000FORS000002088Enovis Corporation194014502US194014502205/20/2024To approve on an advisory basis the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER200116.0000000FOR200116.000000FORS000002088Enovis Corporation194014502US194014502205/20/2024To approve an amendment to the Enovis Corporation 2020 Omnibus Incentive Plan.COMPENSATIONISSUER200116.0000000FOR200116.000000FORS000002088Enovis Corporation194014502US194014502205/20/2024To approve an amendment to our Amended and Restated Certificate of Incorporation to reflect new Delaware law provisions regarding officer exculpation.CORPORATE GOVERNANCEISSUER200116.0000000FOR200116.000000FORS000002088BioMarin Pharmaceutical Inc.09061G101US09061G101305/21/2024Election of Directors: Elizabeth M. AndersonDIRECTOR ELECTIONSISSUER754903.0000000FOR754903.000000FORS000002088BioMarin Pharmaceutical Inc.09061G101US09061G101305/21/2024Election of Directors: Barbara W. BodemDIRECTOR ELECTIONSISSUER754903.0000000FOR754903.000000FORS000002088BioMarin Pharmaceutical Inc.09061G101US09061G101305/21/2024Election of Directors: Athena CountouriotisDIRECTOR ELECTIONSISSUER754903.0000000FOR754903.000000FORS000002088BioMarin Pharmaceutical Inc.09061G101US09061G101305/21/2024Election of Directors: Willard DereDIRECTOR ELECTIONSISSUER754903.0000000FOR754903.000000FORS000002088BioMarin Pharmaceutical Inc.09061G101US09061G101305/21/2024Election of Directors: Mark J. EnyedyDIRECTOR ELECTIONSISSUER754903.0000000FOR754903.000000FORS000002088BioMarin Pharmaceutical Inc.09061G101US09061G101305/21/2024Election of Directors: Alexander HardyDIRECTOR ELECTIONSISSUER754903.0000000FOR754903.000000FORS000002088BioMarin Pharmaceutical Inc.09061G101US09061G101305/21/2024Election of Directors: Elaine J. HeronDIRECTOR ELECTIONSISSUER754903.0000000FOR754903.000000FORS000002088BioMarin Pharmaceutical Inc.09061G101US09061G101305/21/2024Election of Directors: Maykin HoDIRECTOR ELECTIONSISSUER754903.0000000FOR754903.000000FORS000002088BioMarin Pharmaceutical Inc.09061G101US09061G101305/21/2024Election of Directors: Robert J. HombachDIRECTOR ELECTIONSISSUER754903.0000000FOR754903.000000FORS000002088BioMarin Pharmaceutical Inc.09061G101US09061G101305/21/2024Election of Directors: Richard A. MeierDIRECTOR ELECTIONSISSUER754903.0000000FOR754903.000000FORS000002088BioMarin Pharmaceutical Inc.09061G101US09061G101305/21/2024Election of Directors: David E.I. PyottDIRECTOR ELECTIONSISSUER754903.0000000FOR754903.000000FORS000002088BioMarin Pharmaceutical Inc.09061G101US09061G101305/21/2024To ratify the selection of KPMG LLP as the independent registered public accounting firm for the Company for the fiscal year ending December 31, 2024.AUDIT-RELATEDISSUER754903.0000000FOR754903.000000FORS000002088BioMarin Pharmaceutical Inc.09061G101US09061G101305/21/2024To approve, on an advisory basis, the compensation of the Company's Named Executive Officers as disclosed in the Proxy Statement.SECTION 14A SAY-ON-PAY VOTESISSUER754903.0000000FOR754903.000000FORS000002088MacroGenics, Inc.556099109US556099109405/21/2024To elect three Class II directors listed in the proxy materials to hold office until the 2027 Annual Meeting of Stockholders or until their successors are elected and qualified, or until their earlier death, resignation or removal: Scott JacksonDIRECTOR ELECTIONSISSUER1166934.0000000FOR1166934.000000FORS000002088MacroGenics, Inc.556099109US556099109405/21/2024To elect three Class II directors listed in the proxy materials to hold office until the 2027 Annual Meeting of Stockholders or until their successors are elected and qualified, or until their earlier death, resignation or removal: Margaret Liu, M.D.DIRECTOR ELECTIONSISSUER1166934.0000000FOR1166934.000000FORS000002088MacroGenics, Inc.556099109US556099109405/21/2024To elect three Class II directors listed in the proxy materials to hold office until the 2027 Annual Meeting of Stockholders or until their successors are elected and qualified, or until their earlier death, resignation or removal: David Stump, M.D.DIRECTOR ELECTIONSISSUER1166934.0000000FOR1166934.000000FORS000002088MacroGenics, Inc.556099109US556099109405/21/2024To ratify the selection by the Audit Committee of the Board of Directors of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2024.AUDIT-RELATEDISSUER1166934.0000000FOR1166934.000000FORS000002088MacroGenics, Inc.556099109US556099109405/21/2024To approve, on an advisory basis, the compensation of the Company's named executive officers as disclosed in the proxy materials.SECTION 14A SAY-ON-PAY VOTESISSUER1166934.0000000FOR1166934.000000FORS000002088MacroGenics, Inc.556099109US556099109405/21/2024To approve the amendment to the MacroGenics, Inc. 2023 Equity Incentive Plan, as disclosed in the proxy materials.COMPENSATIONISSUER1166934.0000000FOR1166934.000000FORS000002088Pharming Group NVN69603145NL001039102505/21/2024Approve Remuneration ReportCOMPENSATIONISSUER4912411.0000000FOR4912411.000000FORS000002088Pharming Group NVN69603145NL001039102505/21/2024Adopt Financial StatementsCORPORATE GOVERNANCEISSUER4912411.0000000FOR4912411.000000FORS000002088Pharming Group NVN69603145NL001039102505/21/2024Approve Discharge of DirectorsCORPORATE GOVERNANCEISSUER4912411.0000000FOR4912411.000000FORS000002088Pharming Group NVN69603145NL001039102505/21/2024Adopt Updated Remuneration PolicyCOMPENSATIONISSUER4912411.0000000FOR4912411.000000FORS000002088Pharming Group NVN69603145NL001039102505/21/2024Reelect Barbara Yanni as Non-Executive DirectorDIRECTOR ELECTIONSISSUER4912411.0000000FOR4912411.000000FORS000002088Pharming Group NVN69603145NL001039102505/21/2024Reelect Mark Pykett as Non-Executive DirectorDIRECTOR ELECTIONSISSUER4912411.0000000FOR4912411.000000FORS000002088Pharming Group NVN69603145NL001039102505/21/2024Grant Board Authority to Issue Shares Up To 10 Percent of Issued Capital for General Purposes Including Equity Incentive Plans and Exclude Pre-emptive RightsCAPITAL STRUCTUREISSUER4912411.0000000FOR4912411.000000FORS000002088Pharming Group NVN69603145NL001039102505/21/2024Authorize Repurchase of Up to 10 Percent of Issued Share CapitalCAPITAL STRUCTUREISSUER4912411.0000000FOR4912411.000000FORS000002088DexCom, Inc.252131107US252131107405/22/2024To elect ten nominees for director, each to hold office until our 2025 annual meeting of stockholders: Kevin R. SayerDIRECTOR ELECTIONSISSUER727577.0000000FOR727577.000000FORS000002088DexCom, Inc.252131107US252131107405/22/2024To elect ten nominees for director, each to hold office until our 2025 annual meeting of stockholders: Steven R. AltmanDIRECTOR ELECTIONSISSUER727577.0000000FOR727577.000000FORS000002088DexCom, Inc.252131107US252131107405/22/2024To elect ten nominees for director, each to hold office until our 2025 annual meeting of stockholders: Nicholas AugustinosDIRECTOR ELECTIONSISSUER727577.0000000FOR727577.000000FORS000002088DexCom, Inc.252131107US252131107405/22/2024To elect ten nominees for director, each to hold office until our 2025 annual meeting of stockholders: Richard A. CollinsDIRECTOR ELECTIONSISSUER727577.0000000FOR727577.000000FORS000002088DexCom, Inc.252131107US252131107405/22/2024To elect ten nominees for director, each to hold office until our 2025 annual meeting of stockholders: Karen DahutDIRECTOR ELECTIONSISSUER727577.0000000FOR727577.000000FORS000002088DexCom, Inc.252131107US252131107405/22/2024To elect ten nominees for director, each to hold office until our 2025 annual meeting of stockholders: Rimma DriscollDIRECTOR ELECTIONSISSUER727577.0000000FOR727577.000000FORS000002088DexCom, Inc.252131107US252131107405/22/2024To elect ten nominees for director, each to hold office until our 2025 annual meeting of stockholders: Mark G. FolettaDIRECTOR ELECTIONSISSUER727577.0000000FOR727577.000000FORS000002088DexCom, Inc.252131107US252131107405/22/2024To elect ten nominees for director, each to hold office until our 2025 annual meeting of stockholders: Bridgette P. HellerDIRECTOR ELECTIONSISSUER727577.0000000FOR727577.000000FORS000002088DexCom, Inc.252131107US252131107405/22/2024To elect ten nominees for director, each to hold office until our 2025 annual meeting of stockholders: Kyle MaladyDIRECTOR ELECTIONSISSUER727577.0000000FOR727577.000000FORS000002088DexCom, Inc.252131107US252131107405/22/2024To elect ten nominees for director, each to hold office until our 2025 annual meeting of stockholders: Eric J. Topol, M.D.DIRECTOR ELECTIONSISSUER727577.0000000FOR727577.000000FORS000002088DexCom, Inc.252131107US252131107405/22/2024To ratify the selection by the Audit Committee of our Board of Directors of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024.AUDIT-RELATEDISSUER727577.0000000FOR727577.000000FORS000002088DexCom, Inc.252131107US252131107405/22/2024To provide a non-binding advisory vote on the compensation of our named executive officers for the fiscal year ended December 31, 2023.SECTION 14A SAY-ON-PAY VOTESISSUER727577.0000000FOR727577.000000FORS000002088DexCom, Inc.252131107US252131107405/22/2024To provide a non-binding, advisory vote on pay equity disclosure.DIVERSITY, EQUITY, AND INCLUSIONSECURITY HOLDER727577.0000000AGAINST727577.000000FORS000002088DexCom, Inc.252131107US252131107405/22/2024To provide a non-binding, advisory vote on transparency in lobbying.OTHER SOCIAL ISSUESSECURITY HOLDER727577.0000000AGAINST727577.000000FORS000002088Dyne Therapeutics, Inc.26818M108US26818M108005/22/2024The election of three Class I directors, each to serve for a three-year term expiring at the 2027 annual meeting of stockholders and until his or her respective successor has been duly elected and qualified: Carlo Incerti, M.D.DIRECTOR ELECTIONSISSUER475898.0000000FOR475898.000000FORS000002088Dyne Therapeutics, Inc.26818M108US26818M108005/22/2024The election of three Class I directors, each to serve for a three-year term expiring at the 2027 annual meeting of stockholders and until his or her respective successor has been duly elected and qualified: Catherine Stehman-Breen, M.D.DIRECTOR ELECTIONSISSUER475898.0000000FOR475898.000000FORS000002088Dyne Therapeutics, Inc.26818M108US26818M108005/22/2024The election of three Class I directors, each to serve for a three-year term expiring at the 2027 annual meeting of stockholders and until his or her respective successor has been duly elected and qualified: John G. CoxDIRECTOR ELECTIONSISSUER475898.0000000FOR475898.000000FORS000002088Dyne Therapeutics, Inc.26818M108US26818M108005/22/2024The ratification of the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024.AUDIT-RELATEDISSUER475898.0000000FOR475898.000000FORS000002088Insulet Corporation45784P101US45784P101205/22/2024Election of Directors: Wayne A.I. FrederickDIRECTOR ELECTIONSISSUER167561.0000000WITHHOLD167561.000000AGAINSTS000002088Insulet Corporation45784P101US45784P101205/22/2024Election of Directors: Flavia H. PeaseDIRECTOR ELECTIONSISSUER167561.0000000FOR167561.000000FORS000002088Insulet Corporation45784P101US45784P101205/22/2024Election of Directors: Timothy J. ScannellDIRECTOR ELECTIONSISSUER167561.0000000WITHHOLD167561.000000AGAINSTS000002088Insulet Corporation45784P101US45784P101205/22/2024To approve, on a non-binding, advisory basis, the compensation of certain executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER167561.0000000FOR167561.000000FORS000002088Insulet Corporation45784P101US45784P101205/22/2024To ratify the appointment of Grant Thornton LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024.AUDIT-RELATEDISSUER167561.0000000FOR167561.000000FORS000002088Neurocrine Biosciences, Inc.64125C109US64125C109905/22/2024Election of Directors: William H. Rastetter, Ph.D.DIRECTOR ELECTIONSISSUER787567.0000000WITHHOLD787567.000000AGAINSTS000002088Neurocrine Biosciences, Inc.64125C109US64125C109905/22/2024Election of Directors: George J. MorrowDIRECTOR ELECTIONSISSUER787567.0000000WITHHOLD787567.000000AGAINSTS000002088Neurocrine Biosciences, Inc.64125C109US64125C109905/22/2024Election of Directors: Leslie V. NorwalkDIRECTOR ELECTIONSISSUER787567.0000000WITHHOLD787567.000000AGAINSTS000002088Neurocrine Biosciences, Inc.64125C109US64125C109905/22/2024Election of Directors: Christine A. PoonDIRECTOR ELECTIONSISSUER787567.0000000FOR787567.000000FORS000002088Neurocrine Biosciences, Inc.64125C109US64125C109905/22/2024Advisory vote on the compensation paid to the Company's named executive officers;SECTION 14A SAY-ON-PAY VOTESISSUER787567.0000000FOR787567.000000FORS000002088Neurocrine Biosciences, Inc.64125C109US64125C109905/22/2024To approve an amendment of the Company's 2020 Equity Incentive Plan to increase the number of shares of common stock reserved for issuance thereunder by 3,635,000 shares; andCOMPENSATIONISSUER787567.0000000FOR787567.000000FORS000002088Neurocrine Biosciences, Inc.64125C109US64125C109905/22/2024To ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024.AUDIT-RELATEDISSUER787567.0000000FOR787567.000000FORS000002088Rapt Therapeutics, Inc.75382E109US75382E109105/22/2024Election of Directors: William J. RieflinDIRECTOR ELECTIONSISSUER64030.0000000FOR64030.000000FORS000002088Rapt Therapeutics, Inc.75382E109US75382E109105/22/2024Election of Directors: Linda KozickDIRECTOR ELECTIONSISSUER64030.0000000FOR64030.000000FORS000002088Rapt Therapeutics, Inc.75382E109US75382E109105/22/2024Election of Directors: Lori Lyons-WilliamsDIRECTOR ELECTIONSISSUER64030.0000000FOR64030.000000FORS000002088Rapt Therapeutics, Inc.75382E109US75382E109105/22/2024Ratification of the appointment of Ernst & Young LLP as the independent registered public accounting firm of RAPT Therapeutics, Inc. for its fiscal year ending December 31, 2024.AUDIT-RELATEDISSUER64030.0000000FOR64030.000000FORS000002088Tenet Healthcare Corporation88033G407US88033G407305/22/2024Election of Directors: Saumya SutariaDIRECTOR ELECTIONSISSUER707557.0000000FOR707557.000000FORS000002088Tenet Healthcare Corporation88033G407US88033G407305/22/2024Election of Directors: J. Robert KerreyDIRECTOR ELECTIONSISSUER707557.0000000FOR707557.000000FORS000002088Tenet Healthcare Corporation88033G407US88033G407305/22/2024Election of Directors: Vineeta AgarwalaDIRECTOR ELECTIONSISSUER707557.0000000FOR707557.000000FORS000002088Tenet Healthcare Corporation88033G407US88033G407305/22/2024Election of Directors: James L. BiermanDIRECTOR ELECTIONSISSUER707557.0000000FOR707557.000000FORS000002088Tenet Healthcare Corporation88033G407US88033G407305/22/2024Election of Directors: Roy BluntDIRECTOR ELECTIONSISSUER707557.0000000FOR707557.000000FORS000002088Tenet Healthcare Corporation88033G407US88033G407305/22/2024Election of Directors: Richard W. FisherDIRECTOR ELECTIONSISSUER707557.0000000FOR707557.000000FORS000002088Tenet Healthcare Corporation88033G407US88033G407305/22/2024Election of Directors: Meghan M. FitzGeraldDIRECTOR ELECTIONSISSUER707557.0000000FOR707557.000000FORS000002088Tenet Healthcare Corporation88033G407US88033G407305/22/2024Election of Directors: Cecil D. HaneyDIRECTOR ELECTIONSISSUER707557.0000000FOR707557.000000FORS000002088Tenet Healthcare Corporation88033G407US88033G407305/22/2024Election of Directors: Christopher S. LynchDIRECTOR ELECTIONSISSUER707557.0000000FOR707557.000000FORS000002088Tenet Healthcare Corporation88033G407US88033G407305/22/2024Election of Directors: Richard J. MarkDIRECTOR ELECTIONSISSUER707557.0000000FOR707557.000000FORS000002088Tenet Healthcare Corporation88033G407US88033G407305/22/2024Election of Directors: Tammy RomoDIRECTOR ELECTIONSISSUER707557.0000000FOR707557.000000FORS000002088Tenet Healthcare Corporation88033G407US88033G407305/22/2024Election of Directors: Stephen H. RusckowskiDIRECTOR ELECTIONSISSUER707557.0000000FOR707557.000000FORS000002088Tenet Healthcare Corporation88033G407US88033G407305/22/2024Election of Directors: Nadja Y. WestDIRECTOR ELECTIONSISSUER707557.0000000FOR707557.000000FORS000002088Tenet Healthcare Corporation88033G407US88033G407305/22/2024To approve, on an advisory basis, the Company's executive compensation.SECTION 14A SAY-ON-PAY VOTESISSUER707557.0000000FOR707557.000000FORS000002088Tenet Healthcare Corporation88033G407US88033G407305/22/2024To ratify the selection of Deloitte & Touche LLP as the Company's independent registered public accountants for the year ending December 31, 2024.AUDIT-RELATEDISSUER707557.0000000FOR707557.000000FORS000002088Tenet Healthcare Corporation88033G407US88033G407305/22/2024To report on risk mitigation regarding state restrictions for emergency abortions.OTHER SOCIAL ISSUESSECURITY HOLDER707557.0000000AGAINST707557.000000FORS000002088Tenet Healthcare Corporation88033G407US88033G407305/22/2024To report on plans to integrate ESG metrics into executive compensation.COMPENSATIONCORPORATE GOVERNANCEENVIRONMENT OR CLIMATEHUMAN RIGHTS OR HUMAN CAPITAL/WORKFORCEDIVERSITY, EQUITY, AND INCLUSIONOTHER SOCIAL ISSUESSECURITY HOLDER707557.0000000AGAINST707557.000000FORS000002088Thermo Fisher Scientific Inc.883556102US883556102305/22/2024Election of Directors: Marc N. CasperDIRECTOR ELECTIONSISSUER1055126.0000000FOR1055126.000000FORS000002088Thermo Fisher Scientific Inc.883556102US883556102305/22/2024Election of Directors: Nelson J. ChaiDIRECTOR ELECTIONSISSUER1055126.0000000FOR1055126.000000FORS000002088Thermo Fisher Scientific Inc.883556102US883556102305/22/2024Election of Directors: Ruby R. ChandyDIRECTOR ELECTIONSISSUER1055126.0000000FOR1055126.000000FORS000002088Thermo Fisher Scientific Inc.883556102US883556102305/22/2024Election of Directors: C. Martin HarrisDIRECTOR ELECTIONSISSUER1055126.0000000FOR1055126.000000FORS000002088Thermo Fisher Scientific Inc.883556102US883556102305/22/2024Election of Directors: Tyler JacksDIRECTOR ELECTIONSISSUER1055126.0000000FOR1055126.000000FORS000002088Thermo Fisher Scientific Inc.883556102US883556102305/22/2024Election of Directors: Jennifer M. JohnsonDIRECTOR ELECTIONSISSUER1055126.0000000FOR1055126.000000FORS000002088Thermo Fisher Scientific Inc.883556102US883556102305/22/2024Election of Directors: R. Alexandra KeithDIRECTOR ELECTIONSISSUER1055126.0000000FOR1055126.000000FORS000002088Thermo Fisher Scientific Inc.883556102US883556102305/22/2024Election of Directors: James C. MullenDIRECTOR ELECTIONSISSUER1055126.0000000FOR1055126.000000FORS000002088Thermo Fisher Scientific Inc.883556102US883556102305/22/2024Election of Directors: Debora L. SparDIRECTOR ELECTIONSISSUER1055126.0000000FOR1055126.000000FORS000002088Thermo Fisher Scientific Inc.883556102US883556102305/22/2024Election of Directors: Scott M. SperlingDIRECTOR ELECTIONSISSUER1055126.0000000FOR1055126.000000FORS000002088Thermo Fisher Scientific Inc.883556102US883556102305/22/2024Election of Directors: Dion J. WeislerDIRECTOR ELECTIONSISSUER1055126.0000000FOR1055126.000000FORS000002088Thermo Fisher Scientific Inc.883556102US883556102305/22/2024An advisory vote to approve named executive officer compensation.SECTION 14A SAY-ON-PAY VOTESISSUER1055126.0000000FOR1055126.000000FORS000002088Thermo Fisher Scientific Inc.883556102US883556102305/22/2024Ratification of the Audit Committee's selection of PricewaterhouseCoopers LLP as the Company's independent auditors for 2024.AUDIT-RELATEDISSUER1055126.0000000FOR1055126.000000FORS000002088Thermo Fisher Scientific Inc.883556102US883556102305/22/2024Shareholder Proposal: Simple Majority Vote.CORPORATE GOVERNANCESECURITY HOLDER1055126.0000000AGAINST1055126.000000FORS000002088Zoetis Inc.98978V103US98978V103505/22/2024Election of Directors: Paul M. BisaroDIRECTOR ELECTIONSISSUER463794.0000000FOR463794.000000FORS000002088Zoetis Inc.98978V103US98978V103505/22/2024Election of Directors: Vanessa BroadhurstDIRECTOR ELECTIONSISSUER463794.0000000FOR463794.000000FORS000002088Zoetis Inc.98978V103US98978V103505/22/2024Election of Directors: Frank A. D'AmelioDIRECTOR ELECTIONSISSUER463794.0000000FOR463794.000000FORS000002088Zoetis Inc.98978V103US98978V103505/22/2024Election of Directors: Gavin D.K. HattersleyDIRECTOR ELECTIONSISSUER463794.0000000FOR463794.000000FORS000002088Zoetis Inc.98978V103US98978V103505/22/2024Election of Directors: Sanjay KhoslaDIRECTOR ELECTIONSISSUER463794.0000000FOR463794.000000FORS000002088Zoetis Inc.98978V103US98978V103505/22/2024Election of Directors: Antoinette R. LeatherberryDIRECTOR ELECTIONSISSUER463794.0000000FOR463794.000000FORS000002088Zoetis Inc.98978V103US98978V103505/22/2024Election of Directors: Michael B. McCallisterDIRECTOR ELECTIONSISSUER463794.0000000FOR463794.000000FORS000002088Zoetis Inc.98978V103US98978V103505/22/2024Election of Directors: Gregory NordenDIRECTOR ELECTIONSISSUER463794.0000000FOR463794.000000FORS000002088Zoetis Inc.98978V103US98978V103505/22/2024Election of Directors: Louise M. ParentDIRECTOR ELECTIONSISSUER463794.0000000FOR463794.000000FORS000002088Zoetis Inc.98978V103US98978V103505/22/2024Election of Directors: Kristin C. PeckDIRECTOR ELECTIONSISSUER463794.0000000FOR463794.000000FORS000002088Zoetis Inc.98978V103US98978V103505/22/2024Election of Directors: Willie M. ReedDIRECTOR ELECTIONSISSUER463794.0000000FOR463794.000000FORS000002088Zoetis Inc.98978V103US98978V103505/22/2024Election of Directors: Robert W. ScullyDIRECTOR ELECTIONSISSUER463794.0000000FOR463794.000000FORS000002088Zoetis Inc.98978V103US98978V103505/22/2024Advisory vote to approve our executive compensation.SECTION 14A SAY-ON-PAY VOTESISSUER463794.0000000FOR463794.000000FORS000002088Zoetis Inc.98978V103US98978V103505/22/2024Ratification of appointment of KPMG LLP as our independent registered public accounting firm for 2024.AUDIT-RELATEDISSUER463794.0000000FOR463794.000000FORS000002088Zoetis Inc.98978V103US98978V103505/22/2024Approval of an amendment to our Restated Certificate of Incorporation to provide for exculpation of officers as permitted by the Delaware General Corporation Law.CORPORATE GOVERNANCEISSUER463794.0000000FOR463794.000000FORS000002088Zoetis Inc.98978V103US98978V103505/22/2024Shareholder proposal regarding an improvement to our director resignation policy.CORPORATE GOVERNANCESECURITY HOLDER463794.0000000AGAINST463794.000000FORS000002088Day One Biopharmaceuticals, Inc.23954D109US23954D109005/23/2024Election of Class III Directors: Jeremy BenderDIRECTOR ELECTIONSISSUER57729.0000000FOR57729.000000FORS000002088Day One Biopharmaceuticals, Inc.23954D109US23954D109005/23/2024Election of Class III Directors: Habib DableDIRECTOR ELECTIONSISSUER57729.0000000FOR57729.000000FORS000002088Day One Biopharmaceuticals, Inc.23954D109US23954D109005/23/2024Election of Class III Directors: Saira RamasastryDIRECTOR ELECTIONSISSUER57729.0000000FOR57729.000000FORS000002088Day One Biopharmaceuticals, Inc.23954D109US23954D109005/23/2024Ratification of the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the year ending December 31, 2024.AUDIT-RELATEDISSUER57729.0000000FOR57729.000000FORS000002088Day One Biopharmaceuticals, Inc.23954D109US23954D109005/23/2024Approval, on a non-binding advisory basis, of the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER57729.0000000FOR57729.000000FORS000002088Day One Biopharmaceuticals, Inc.23954D109US23954D109005/23/2024Selection, on a non-binding advisory basis, of whether future advisory votes on the compensation of our named executive officers should be every one, two or three years.SECTION 14A SAY-ON-PAY VOTESISSUER57729.0000000ONE YEAR57729.000000FORS000002088Immunocore Holdings Plc45258D105US45258D105405/23/2024To re-appoint as a director Bahija Jallal, Ph.D., who retires in accordance with the articles of association.DIRECTOR ELECTIONSISSUER1214407.0000000FOR1214407.000000FORS000002088Immunocore Holdings Plc45258D105US45258D105405/23/2024To re-appoint as a director Professor Sir John Bell, who retires in accordance with the articles of association.DIRECTOR ELECTIONSISSUER1214407.0000000FOR1214407.000000FORS000002088Immunocore Holdings Plc45258D105US45258D105405/23/2024To approve, on advisory basis, the compensation of the Company's named executive officers, as disclosed in the proxy statement.SECTION 14A SAY-ON-PAY VOTESISSUER1214407.0000000FOR1214407.000000FORS000002088Immunocore Holdings Plc45258D105US45258D105405/23/2024To indicate, on an advisory basis, the preferred frequency of shareholder advisory votes on the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER1214407.0000000ONE YEAR1214407.000000FORS000002088Immunocore Holdings Plc45258D105US45258D105405/23/2024To ratify the appointment of Deloitte LLP, a limited liability partnership organized under the laws of England, as the Company's U.S. independent registered public accounting firm for the year ending December 31, 2024.AUDIT-RELATEDISSUER1214407.0000000FOR1214407.000000FORS000002088Immunocore Holdings Plc45258D105US45258D105405/23/2024To re-appoint Deloitte LLP, a limited liability partnership organized under the laws of England, as the Company's U.K. statutory auditors, to hold office until the conclusion of the next annual general meeting of shareholders.AUDIT-RELATEDISSUER1214407.0000000FOR1214407.000000FORS000002088Immunocore Holdings Plc45258D105US45258D105405/23/2024To authorize the directors to determine the U.K. statutory auditors' remuneration for the year ending December 31, 2024.AUDIT-RELATEDISSUER1214407.0000000FOR1214407.000000FORS000002088Immunocore Holdings Plc45258D105US45258D105405/23/2024To receive and adopt the U.K. statutory annual accounts and reports for the year ended December 31, 2023 (the "2023 U.K. Annual Report").CORPORATE GOVERNANCEISSUER1214407.0000000FOR1214407.000000FORS000002088Immunocore Holdings Plc45258D105US45258D105405/23/2024To approve the directors' remuneration report for the year ended December 31, 2023, which is set forth as Annex A to the proxy statement and on pages 20 to 47 (inclusive) of the 2023 U.K. Annual Report.COMPENSATIONISSUER1214407.0000000FOR1214407.000000FORS000002088Immunocore Holdings Plc45258D105US45258D105405/23/2024To authorise the Company to make political donations/ incur political expenditure.OTHER SOCIAL ISSUESISSUER1214407.0000000FOR1214407.000000FORS000002088Immunocore Holdings Plc45258D105US45258D105405/23/2024That, with effect from the conclusion of the AGM, the draft articles of association produced to the AGM and, for the purpose of identification, initialed by the Chairman, be adopted as the articles of association of the Company in substitution for, and to the exclusion of, the Company's existing articles of association.CORPORATE GOVERNANCEISSUER1214407.0000000FOR1214407.000000FORS000002088Longboard Pharmaceuticals, Inc.54300N103US54300N103705/23/2024To elect the two Class III directors named herein to hold office until the Company's 2027 annual meeting of stockholders: Paul J. SekhriDIRECTOR ELECTIONSISSUER839317.0000000WITHHOLD839317.000000AGAINSTS000002088Longboard Pharmaceuticals, Inc.54300N103US54300N103705/23/2024To elect the two Class III directors named herein to hold office until the Company's 2027 annual meeting of stockholders: Phillip M. SchneiderDIRECTOR ELECTIONSISSUER839317.0000000FOR839317.000000FORS000002088Longboard Pharmaceuticals, Inc.54300N103US54300N103705/23/2024To approve an amendment to the Company's Amended and Restated Certificate of Incorporation to limit the liability of officers of the Company to the maximum extent permitted by law as permitted pursuant to Section 102(b)(7) of the Delaware General Corporation Law.CORPORATE GOVERNANCEISSUER839317.0000000FOR839317.000000FORS000002088Longboard Pharmaceuticals, Inc.54300N103US54300N103705/23/2024To ratify the selection by the Audit Committee of the Board of Directors of KPMG LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2024.AUDIT-RELATEDISSUER839317.0000000FOR839317.000000FORS000002088Arcellx, Inc.03940C100US03940C100905/24/2024To elect three Class II directors to hold office until our 2027 annual meeting of stockholders and until their respective successors are elected and qualified: Jill CarrollDIRECTOR ELECTIONSISSUER380799.0000000FOR380799.000000FORS000002088Arcellx, Inc.03940C100US03940C100905/24/2024To elect three Class II directors to hold office until our 2027 annual meeting of stockholders and until their respective successors are elected and qualified: Kavita PatelDIRECTOR ELECTIONSISSUER380799.0000000FOR380799.000000FORS000002088Arcellx, Inc.03940C100US03940C100905/24/2024To elect three Class II directors to hold office until our 2027 annual meeting of stockholders and until their respective successors are elected and qualified: Olivia WareDIRECTOR ELECTIONSISSUER380799.0000000FOR380799.000000FORS000002088Arcellx, Inc.03940C100US03940C100905/24/2024To approve, on an advisory basis, the compensation of the named executive officers identified in the 2023 Summary Compensation Table in the "Executive Compensation" section of the proxy statement (the "Say-on-Pay Vote").SECTION 14A SAY-ON-PAY VOTESISSUER380799.0000000AGAINST380799.000000AGAINSTS000002088Arcellx, Inc.03940C100US03940C100905/24/2024To approve, on an advisory basis, the frequency of future Say-on-Pay Votes.SECTION 14A SAY-ON-PAY VOTESISSUER380799.0000000ONE YEAR380799.000000FORS000002088Arcellx, Inc.03940C100US03940C100905/24/2024To ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2024.AUDIT-RELATEDISSUER380799.0000000FOR380799.000000FORS000002088Merck & Co., Inc.58933Y105US58933Y105505/28/2024Election of Directors: Douglas M. Baker, Jr.DIRECTOR ELECTIONSISSUER4718074.0000000FOR4718074.000000FORS000002088Merck & Co., Inc.58933Y105US58933Y105505/28/2024Election of Directors: Mary Ellen CoeDIRECTOR ELECTIONSISSUER4718074.0000000FOR4718074.000000FORS000002088Merck & Co., Inc.58933Y105US58933Y105505/28/2024Election of Directors: Pamela J. CraigDIRECTOR ELECTIONSISSUER4718074.0000000FOR4718074.000000FORS000002088Merck & Co., Inc.58933Y105US58933Y105505/28/2024Election of Directors: Robert M. DavisDIRECTOR ELECTIONSISSUER4718074.0000000FOR4718074.000000FORS000002088Merck & Co., Inc.58933Y105US58933Y105505/28/2024Election of Directors: Thomas H. GlocerDIRECTOR ELECTIONSISSUER4718074.0000000FOR4718074.000000FORS000002088Merck & Co., Inc.58933Y105US58933Y105505/28/2024Election of Directors: Risa J. Lavizzo-Mourey, M.D.DIRECTOR ELECTIONSISSUER4718074.0000000FOR4718074.000000FORS000002088Merck & Co., Inc.58933Y105US58933Y105505/28/2024Election of Directors: Stephen L. Mayo, Ph.D.DIRECTOR ELECTIONSISSUER4718074.0000000FOR4718074.000000FORS000002088Merck & Co., Inc.58933Y105US58933Y105505/28/2024Election of Directors: Paul B. Rothman, M.D.DIRECTOR ELECTIONSISSUER4718074.0000000FOR4718074.000000FORS000002088Merck & Co., Inc.58933Y105US58933Y105505/28/2024Election of Directors: Patricia F. RussoDIRECTOR ELECTIONSISSUER4718074.0000000FOR4718074.000000FORS000002088Merck & Co., Inc.58933Y105US58933Y105505/28/2024Election of Directors: Christine E. Seidman, M.D.DIRECTOR ELECTIONSISSUER4718074.0000000FOR4718074.000000FORS000002088Merck & Co., Inc.58933Y105US58933Y105505/28/2024Election of Directors: Inge G. ThulinDIRECTOR ELECTIONSISSUER4718074.0000000FOR4718074.000000FORS000002088Merck & Co., Inc.58933Y105US58933Y105505/28/2024Election of Directors: Kathy J. WardenDIRECTOR ELECTIONSISSUER4718074.0000000FOR4718074.000000FORS000002088Merck & Co., Inc.58933Y105US58933Y105505/28/2024Non-binding advisory vote to approve the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER4718074.0000000FOR4718074.000000FORS000002088Merck & Co., Inc.58933Y105US58933Y105505/28/2024Ratification of the appointment of the Company's independent registered public accounting firm for 2024.AUDIT-RELATEDISSUER4718074.0000000FOR4718074.000000FORS000002088Merck & Co., Inc.58933Y105US58933Y105505/28/2024Shareholder proposal regarding a shareholder right to act by written consentCORPORATE GOVERNANCESECURITY HOLDER4718074.0000000AGAINST4718074.000000FORS000002088Merck & Co., Inc.58933Y105US58933Y105505/28/2024Shareholder proposal regarding a government censorship transparency report.OTHER SOCIAL ISSUESSECURITY HOLDER4718074.0000000AGAINST4718074.000000FORS000002088Merck & Co., Inc.58933Y105US58933Y105505/28/2024Shareholder proposal regarding a report on respecting workforce civil liberties.ENVIRONMENT OR CLIMATEDIVERSITY, EQUITY, AND INCLUSIONOTHER SOCIAL ISSUESSECURITY HOLDER4718074.0000000AGAINST4718074.000000FORS000002088Acadia Pharmaceuticals Inc.004225108US004225108405/29/2024To elect three Class II directors to hold office until the Company's 2027 Annual Meeting of Stockholders: Julian C. BakerDIRECTOR ELECTIONSISSUER619378.0000000WITHHOLD619378.000000AGAINSTS000002088Acadia Pharmaceuticals Inc.004225108US004225108405/29/2024To elect three Class II directors to hold office until the Company's 2027 Annual Meeting of Stockholders: Stephen R. Biggar, M.D., Ph.D.DIRECTOR ELECTIONSISSUER619378.0000000WITHHOLD619378.000000AGAINSTS000002088Acadia Pharmaceuticals Inc.004225108US004225108405/29/2024To elect three Class II directors to hold office until the Company's 2027 Annual Meeting of Stockholders: Daniel B. SolandDIRECTOR ELECTIONSISSUER619378.0000000WITHHOLD619378.000000AGAINSTS000002088Acadia Pharmaceuticals Inc.004225108US004225108405/29/2024To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in this proxy statement.SECTION 14A SAY-ON-PAY VOTESISSUER619378.0000000FOR619378.000000FORS000002088Acadia Pharmaceuticals Inc.004225108US004225108405/29/2024To approve the Company's 2024 Equity Incentive Plan.COMPENSATIONISSUER619378.0000000FOR619378.000000FORS000002088Acadia Pharmaceuticals Inc.004225108US004225108405/29/2024To ratify the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024.AUDIT-RELATEDISSUER619378.0000000FOR619378.000000FORS000002088agilon health, inc.00857U107US00857U107905/29/2024Election of Class III Directors: Ravi SachdevDIRECTOR ELECTIONSISSUER831930.0000000FOR831930.000000FORS000002088agilon health, inc.00857U107US00857U107905/29/2024Election of Class III Directors: Steven J. SellDIRECTOR ELECTIONSISSUER831930.0000000FOR831930.000000FORS000002088agilon health, inc.00857U107US00857U107905/29/2024Election of Class III Directors: William Wulf, M.D.DIRECTOR ELECTIONSISSUER831930.0000000FOR831930.000000FORS000002088agilon health, inc.00857U107US00857U107905/29/2024Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the year ending December 31, 2024.AUDIT-RELATEDISSUER831930.0000000FOR831930.000000FORS000002088agilon health, inc.00857U107US00857U107905/29/2024To approve, by advisory vote, the compensation paid to the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER831930.0000000FOR831930.000000FORS000002088Arvinas, Inc.04335A105US04335A105105/29/2024Election of Directors: Edward Kennedy, Jr.DIRECTOR ELECTIONSISSUER1176792.0000000FOR1176792.000000FORS000002088Arvinas, Inc.04335A105US04335A105105/29/2024Election of Directors: Everett CunninghamDIRECTOR ELECTIONSISSUER1176792.0000000FOR1176792.000000FORS000002088Arvinas, Inc.04335A105US04335A105105/29/2024Election of Directors: Briggs Morrison, M.D.DIRECTOR ELECTIONSISSUER1176792.0000000FOR1176792.000000FORS000002088Arvinas, Inc.04335A105US04335A105105/29/2024To approve, on an advisory basis, the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER1176792.0000000FOR1176792.000000FORS000002088Arvinas, Inc.04335A105US04335A105105/29/2024Ratification of the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024.AUDIT-RELATEDISSUER1176792.0000000FOR1176792.000000FORS000002088Sensorion SAF8312Z102FR001259646805/29/2024Approve Financial Statements and Discharge DirectorsCAPITAL STRUCTURECORPORATE GOVERNANCEISSUER10026597.0000000FOR10026597.000000FORS000002088Sensorion SAF8312Z102FR001259646805/29/2024Approve Consolidated Financial Statements and Statutory ReportsCORPORATE GOVERNANCEISSUER10026597.0000000FOR10026597.000000FORS000002088Sensorion SAF8312Z102FR001259646805/29/2024Approve Treatment of LossesCAPITAL STRUCTUREISSUER10026597.0000000FOR10026597.000000FORS000002088Sensorion SAF8312Z102FR001259646805/29/2024Approve Auditors' Special Report on Related-Party Transactions Regarding One New TransactionCORPORATE GOVERNANCEISSUER10026597.0000000FOR10026597.000000FORS000002088Sensorion SAF8312Z102FR001259646805/29/2024Reelect Health Opportunities as DirectorDIRECTOR ELECTIONSISSUER10026597.0000000FOR10026597.000000FORS000002088Sensorion SAF8312Z102FR001259646805/29/2024Ratify Appointment of Federico Mingozzi as DirectorDIRECTOR ELECTIONSISSUER10026597.0000000FOR10026597.000000FORS000002088Sensorion SAF8312Z102FR001259646805/29/2024Authorize Repurchase of Up to 10 Percent of Issued Share CapitalCAPITAL STRUCTUREISSUER10026597.0000000AGAINST10026597.000000AGAINSTS000002088Sensorion SAF8312Z102FR001259646805/29/2024Authorize Decrease in Share Capital via Cancellation of Repurchased SharesCAPITAL STRUCTUREISSUER10026597.0000000FOR10026597.000000FORS000002088Sensorion SAF8312Z102FR001259646805/29/2024Authorize Issuance of Equity or Equity-Linked Securities without Preemptive Rights up to Aggregate Nominal Amount of EUR 25 MillionCAPITAL STRUCTUREISSUER10026597.0000000AGAINST10026597.000000AGAINSTS000002088Sensorion SAF8312Z102FR001259646805/29/2024Approve Issuance of Equity or Equity-Linked Securities for Private Placements, up to Aggregate Nominal Amount of EUR 25 MillionCAPITAL STRUCTUREISSUER10026597.0000000AGAINST10026597.000000AGAINSTS000002088Sensorion SAF8312Z102FR001259646805/29/2024Approve Issuance of Equity or Equity-Linked Securities Reserved for Specific Beneficiaries, up to Aggregate Nominal Amount of EUR 25 MillionCAPITAL STRUCTUREISSUER10026597.0000000AGAINST10026597.000000AGAINSTS000002088Sensorion SAF8312Z102FR001259646805/29/2024Approve Issuance of Equity or Equity-Linked Securities Reserved for Specific Beneficiaries, up to Aggregate Nominal Amount of EUR 25 MillionCAPITAL STRUCTUREISSUER10026597.0000000AGAINST10026597.000000AGAINSTS000002088Sensorion SAF8312Z102FR001259646805/29/2024Authorize Issuance of Equity or Equity-Linked Securities with Preemptive Rights up to Aggregate Nominal Amount of EUR 25 MillionCAPITAL STRUCTUREISSUER10026597.0000000FOR10026597.000000FORS000002088Sensorion SAF8312Z102FR001259646805/29/2024Authorize Capitalization of Reserves of Up to EUR 25 Million for Bonus Issue or Increase in Par ValueCAPITAL STRUCTUREISSUER10026597.0000000FOR10026597.000000FORS000002088Sensorion SAF8312Z102FR001259646805/29/2024Authorize Board to Increase Capital in the Event of Additional Demand Related to Delegation Submitted to Shareholder Vote Under Items 9-13CAPITAL STRUCTUREISSUER10026597.0000000AGAINST10026597.000000AGAINSTS000002088Sensorion SAF8312Z102FR001259646805/29/2024Set Total Limit for Capital Increase to Result from Issuance Requests Under Items 19-13 at EUR 25 MillionCAPITAL STRUCTUREISSUER10026597.0000000FOR10026597.000000FORS000002088Sensorion SAF8312Z102FR001259646805/29/2024Approve Issuance of 7 Million Warrants (BSA 2024) without Preemptive Rights Reserved for Specific BeneficiariesCOMPENSATIONISSUER10026597.0000000AGAINST10026597.000000AGAINSTS000002088Sensorion SAF8312Z102FR001259646805/29/2024Approve Issuance of 7 Million Warrants (BSPCE 2024) without Preemptive Rights Reserved for Specific BeneficiariesCOMPENSATIONISSUER10026597.0000000AGAINST10026597.000000AGAINSTS000002088Sensorion SAF8312Z102FR001259646805/29/2024Authorize up to 7 Million Shares for Use in Stock Option PlansCOMPENSATIONISSUER10026597.0000000AGAINST10026597.000000AGAINSTS000002088Sensorion SAF8312Z102FR001259646805/29/2024Authorize up to 700,000 Shares of Issued Capital for Use in Restricted Stock PlansCOMPENSATIONISSUER10026597.0000000AGAINST10026597.000000AGAINSTS000002088Sensorion SAF8312Z102FR001259646805/29/2024Authorize Capital Issuances for Use in Employee Stock Purchase PlansCOMPENSATIONISSUER10026597.0000000FOR10026597.000000FORS000002088Sensorion SAF8312Z102FR001259646805/29/2024Authorize Filing of Required Documents/Other FormalitiesCORPORATE GOVERNANCEISSUER10026597.0000000FOR10026597.000000FORS000002088Shockwave Medical, Inc.82489T104US82489T104305/29/2024To adopt the Agreement and Plan of Merger (as it may be amended from time to time, the "Merger Agreement"), dated April 4, 2024, by and among Shockwave Medical, Inc., a Delaware corporation ("Shockwave"), Johnson & Johnson, a New Jersey corporation ("Johnson & Johnson"), and Sweep Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Johnson & Johnson ("Merger Sub"), pursuant to which the Merger Sub will merge with and into Shockwave (the "Merger"), with Shockwave surviving the Merger as a wholly owned subsidiary of Johnson & Johnson.EXTRAORDINARY TRANSACTIONSISSUER141825.0000000FOR141825.000000FORS000002088Shockwave Medical, Inc.82489T104US82489T104305/29/2024To approve, on a non-binding advisory basis, the compensation that may be paid or become payable to Shockwave's named executive officers that is based on or otherwise relates to the Merger.SECTION 14A SAY-ON-PAY VOTESISSUER141825.0000000AGAINST141825.000000AGAINSTS000002088Shockwave Medical, Inc.82489T104US82489T104305/29/2024To adjourn the Special Meeting of Stockholders to a later date or dates as provided in the Merger Agreement, if necessary or appropriate, including to solicit additional votes if there are insufficient votes to adopt the Merger Agreement at the time of the Special Meeting of Stockholders.CORPORATE GOVERNANCEISSUER141825.0000000AGAINST141825.000000AGAINSTS000002088Taysha Gene Therapies, Inc.877619106US877619106105/29/2024To elect the Board's Class I Director nominees, Sean Stalfort and Alison Long, MD, PhD to the Board of Directors to hold office until the 2027 Annual Meeting of Stockholders: Sean StalfortDIRECTOR ELECTIONSISSUER840584.0000000FOR840584.000000FORS000002088Taysha Gene Therapies, Inc.877619106US877619106105/29/2024To elect the Board's Class I Director nominees, Sean Stalfort and Alison Long, MD, PhD to the Board of Directors to hold office until the 2027 Annual Meeting of Stockholders: Alison Long, MD, PhDDIRECTOR ELECTIONSISSUER840584.0000000FOR840584.000000FORS000002088Taysha Gene Therapies, Inc.877619106US877619106105/29/2024To ratify the selection by the Audit Committee of the Board of Directors of Deloitte & Touche LLP as the independent registered public accounting firm of the Company for the year ending December 31, 2024.AUDIT-RELATEDISSUER840584.0000000FOR840584.000000FORS000002088Ascendis Pharma A/S04351P101US04351P101205/30/2024Elect Chairman of MeetingCORPORATE GOVERNANCEISSUER708012.0000000FOR708012.000000FORS000002088Ascendis Pharma A/S04351P101US04351P101205/30/2024Approve Company Activity ReportCORPORATE GOVERNANCEISSUER708012.0000000FOR708012.000000FORS000002088Ascendis Pharma A/S04351P101US04351P101205/30/2024Accept Financial Statements and Statutory Reports; Approve Discharge of Management and BoardCAPITAL STRUCTURECORPORATE GOVERNANCEISSUER708012.0000000FOR708012.000000FORS000002088Ascendis Pharma A/S04351P101US04351P101205/30/2024Approve Treatment of Net LossCAPITAL STRUCTUREISSUER708012.0000000FOR708012.000000FORS000002088Ascendis Pharma A/S04351P101US04351P101205/30/2024Reelect Albert Cha as Director For Two Years TermDIRECTOR ELECTIONSISSUER708012.0000000FOR708012.000000FORS000002088Ascendis Pharma A/S04351P101US04351P101205/30/2024Reelect Lars Holtug as Director For Two Years TermDIRECTOR ELECTIONSISSUER708012.0000000FOR708012.000000FORS000002088Ascendis Pharma A/S04351P101US04351P101205/30/2024Ratify Deloitte as AuditorsAUDIT-RELATEDISSUER708012.0000000FOR708012.000000FORS000002088Ascendis Pharma A/S04351P101US04351P101205/30/2024Amend Articles Re: Board-RelatedCORPORATE GOVERNANCEISSUER708012.0000000FOR708012.000000FORS000002088Ascendis Pharma A/S04351P101US04351P101205/30/2024Approve Creation of DKK 9 Million Pool of Capital with Preemptive RightsCAPITAL STRUCTUREISSUER708012.0000000FOR708012.000000FORS000002088Ascendis Pharma A/S04351P101US04351P101205/30/2024Approve Warrant Plan for Key EmployeesCOMPENSATIONISSUER708012.0000000FOR708012.000000FORS000002088Bruker Corporation116794108US116794108705/30/2024Election of three Class III directors to serve for a three-year term expiring in 2027: William A. LintonDIRECTOR ELECTIONSISSUER461123.0000000WITHHOLD461123.000000AGAINSTS000002088Bruker Corporation116794108US116794108705/30/2024Election of three Class III directors to serve for a three-year term expiring in 2027: Adelene Q. PerkinsDIRECTOR ELECTIONSISSUER461123.0000000WITHHOLD461123.000000AGAINSTS000002088Bruker Corporation116794108US116794108705/30/2024Election of three Class III directors to serve for a three-year term expiring in 2027: Robert J. RosenthalDIRECTOR ELECTIONSISSUER461123.0000000WITHHOLD461123.000000AGAINSTS000002088Bruker Corporation116794108US116794108705/30/2024Approval on an advisory basis of the 2023 compensation of our named executive officers, as discussed in the Proxy Statement.SECTION 14A SAY-ON-PAY VOTESISSUER461123.0000000FOR461123.000000FORS000002088Bruker Corporation116794108US116794108705/30/2024Ratification of the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024.AUDIT-RELATEDISSUER461123.0000000FOR461123.000000FORS000002088CRISPR Therapeutics AGH17182108CH033408113705/30/2024Approval of the Swiss management report, the consolidated financial statements and the statutory financial statements of the Company for the year ended December 31, 2023.CORPORATE GOVERNANCEISSUER20130.0000000FOR20130.000000FORS000002088CRISPR Therapeutics AGH17182108CH033408113705/30/2024Approval of the appropriation of financial results.CAPITAL STRUCTUREISSUER20130.0000000FOR20130.000000FORS000002088CRISPR Therapeutics AGH17182108CH033408113705/30/2024Discharge of the members of the Board of Directors and the Executive Committee.CORPORATE GOVERNANCEISSUER20130.0000000FOR20130.000000FORS000002088CRISPR Therapeutics AGH17182108CH033408113705/30/2024Election or re-election of the members to the Board of Directors and the Chairman: Re-election of Samarth Kulkarni, Ph.D., as member and election as ChairmanDIRECTOR ELECTIONSISSUER20130.0000000FOR20130.000000FORS000002088CRISPR Therapeutics AGH17182108CH033408113705/30/2024Election or re-election of the members to the Board of Directors and the Chairman: Re-election of Ali Behbahani, M.D.DIRECTOR ELECTIONSISSUER20130.0000000AGAINST20130.000000AGAINSTS000002088CRISPR Therapeutics AGH17182108CH033408113705/30/2024Election or re-election of the members to the Board of Directors and the Chairman: Re-election of Maria Fardis, Ph.D.DIRECTOR ELECTIONSISSUER20130.0000000FOR20130.000000FORS000002088CRISPR Therapeutics AGH17182108CH033408113705/30/2024Election or re-election of the members to the Board of Directors and the Chairman: Re-election of H. Edward Fleming, Jr., M.D.DIRECTOR ELECTIONSISSUER20130.0000000FOR20130.000000FORS000002088CRISPR Therapeutics AGH17182108CH033408113705/30/2024Election or re-election of the members to the Board of Directors and the Chairman: Re-election of Simeon J. George, M.D.DIRECTOR ELECTIONSISSUER20130.0000000FOR20130.000000FORS000002088CRISPR Therapeutics AGH17182108CH033408113705/30/2024Election or re-election of the members to the Board of Directors and the Chairman: Re-election of John T. GreeneDIRECTOR ELECTIONSISSUER20130.0000000FOR20130.000000FORS000002088CRISPR Therapeutics AGH17182108CH033408113705/30/2024Election or re-election of the members to the Board of Directors and the Chairman: Re-election of Katherine A. High, M.D.DIRECTOR ELECTIONSISSUER20130.0000000FOR20130.000000FORS000002088CRISPR Therapeutics AGH17182108CH033408113705/30/2024Election or re-election of the members to the Board of Directors and the Chairman: Re-election of Douglas A. Treco, Ph.D.DIRECTOR ELECTIONSISSUER20130.0000000FOR20130.000000FORS000002088CRISPR Therapeutics AGH17182108CH033408113705/30/2024Election or re-election of the members to the Board of Directors and the Chairman: Election of Sandesh Mahatme, LL.M.DIRECTOR ELECTIONSISSUER20130.0000000FOR20130.000000FORS000002088CRISPR Therapeutics AGH17182108CH033408113705/30/2024Election or re-election of the members to the Board of Directors and the Chairman: Election of Christian Rommel, Ph.D.DIRECTOR ELECTIONSISSUER20130.0000000FOR20130.000000FORS000002088CRISPR Therapeutics AGH17182108CH033408113705/30/2024Re-election of the members of the Compensation Committee: Re-election of Ali Behbahani, M.D.DIRECTOR ELECTIONSCORPORATE GOVERNANCEISSUER20130.0000000AGAINST20130.000000AGAINSTS000002088CRISPR Therapeutics AGH17182108CH033408113705/30/2024Re-election of the members of the Compensation Committee: Re-election of H. Edward Fleming, Jr., M.D.DIRECTOR ELECTIONSCORPORATE GOVERNANCEISSUER20130.0000000AGAINST20130.000000AGAINSTS000002088CRISPR Therapeutics AGH17182108CH033408113705/30/2024Re-election of the members of the Compensation Committee: Re-election of Simeon J. George, M.D.DIRECTOR ELECTIONSCORPORATE GOVERNANCEISSUER20130.0000000AGAINST20130.000000AGAINSTS000002088CRISPR Therapeutics AGH17182108CH033408113705/30/2024Re-election of the members of the Compensation Committee: Re-election of John T. GreeneDIRECTOR ELECTIONSCORPORATE GOVERNANCEISSUER20130.0000000AGAINST20130.000000AGAINSTS000002088CRISPR Therapeutics AGH17182108CH033408113705/30/2024Approval of the compensation for the Board of Directors and the Executive Committee and non-binding advisory vote on the 2023 Compensation Report: Binding vote on maximum non-performance-related compensation for members of the Board of Directors from the 2024 Annual General Meeting to the 2025 annual general meeting of shareholders.COMPENSATIONISSUER20130.0000000FOR20130.000000FORS000002088CRISPR Therapeutics AGH17182108CH033408113705/30/2024Binding vote on maximum equity for members of the Board of Directors from the 2024 Annual General Meeting to the 2025 annual general meeting of shareholders.COMPENSATIONISSUER20130.0000000AGAINST20130.000000AGAINSTS000002088CRISPR Therapeutics AGH17182108CH033408113705/30/2024Binding vote on maximum non-performance-related compensation for members of the Executive Committee from July 1, 2024 to June 30, 2025.COMPENSATIONISSUER20130.0000000AGAINST20130.000000AGAINSTS000002088CRISPR Therapeutics AGH17182108CH033408113705/30/2024Binding vote on maximum variable compensation for members of the Executive Committee for the current year ending December 31, 2024.COMPENSATIONISSUER20130.0000000AGAINST20130.000000AGAINSTS000002088CRISPR Therapeutics AGH17182108CH033408113705/30/2024Binding vote on maximum equity for members of the Executive Committee from the 2024 Annual General Meeting to the 2025 annual general meeting of shareholders.COMPENSATIONISSUER20130.0000000AGAINST20130.000000AGAINSTS000002088CRISPR Therapeutics AGH17182108CH033408113705/30/2024Non-binding advisory vote on the 2023 Compensation Report.COMPENSATIONISSUER20130.0000000AGAINST20130.000000AGAINSTS000002088CRISPR Therapeutics AGH17182108CH033408113705/30/2024Non-binding advisory vote on the compensation paid to the Company's named executive officers under U.S. securities law requirements.SECTION 14A SAY-ON-PAY VOTESISSUER20130.0000000AGAINST20130.000000AGAINSTS000002088CRISPR Therapeutics AGH17182108CH033408113705/30/2024Approval of an increase of the conditional share capital for employee equity plans.COMPENSATIONISSUER20130.0000000AGAINST20130.000000AGAINSTS000002088CRISPR Therapeutics AGH17182108CH033408113705/30/2024Approval of an amendment to the CRISPR Therapeutics AG 2018 Stock Option and Incentive Plan.COMPENSATIONISSUER20130.0000000AGAINST20130.000000AGAINSTS000002088CRISPR Therapeutics AGH17182108CH033408113705/30/2024Approval of amendments to the Articles of Association to facilitate the use of equity compensation and pension benefits programs consistent with current market practices.COMPENSATIONCORPORATE GOVERNANCEISSUER20130.0000000AGAINST20130.000000AGAINSTS000002088CRISPR Therapeutics AGH17182108CH033408113705/30/2024Approval of an increase and certain adjustments to the Company's capital band.CAPITAL STRUCTUREISSUER20130.0000000FOR20130.000000FORS000002088CRISPR Therapeutics AGH17182108CH033408113705/30/2024Re-election of the independent voting rights representative.CORPORATE GOVERNANCEISSUER20130.0000000FOR20130.000000FORS000002088CRISPR Therapeutics AGH17182108CH033408113705/30/2024Re-election of the auditors.AUDIT-RELATEDISSUER20130.0000000FOR20130.000000FORS000002088CRISPR Therapeutics AGH17182108CH033408113705/30/2024Transact any other business that may properly come before the 2024 Annual General Meeting or any adjournment or postponement thereof.CORPORATE GOVERNANCEISSUER20130.0000000AGAINST20130.000000AGAINSTS000002088Exelixis, Inc.30161Q104US30161Q104005/30/2024To elect the eleven nominees for director named in the accompanying Proxy Statement to hold office until the next Annual Meeting of Stockholders: Mary C. Beckerle, Ph.D.DIRECTOR ELECTIONSISSUER785011.0000000FOR785011.000000FORS000002088Exelixis, Inc.30161Q104US30161Q104005/30/2024To elect the eleven nominees for director named in the accompanying Proxy Statement to hold office until the next Annual Meeting of Stockholders: S. Gail Eckhardt, M.D.DIRECTOR ELECTIONSISSUER785011.0000000FOR785011.000000FORS000002088Exelixis, Inc.30161Q104US30161Q104005/30/2024To elect the eleven nominees for director named in the accompanying Proxy Statement to hold office until the next Annual Meeting of Stockholders: Maria C. Freire, Ph.D.DIRECTOR ELECTIONSISSUER785011.0000000FOR785011.000000FORS000002088Exelixis, Inc.30161Q104US30161Q104005/30/2024To elect the eleven nominees for director named in the accompanying Proxy Statement to hold office until the next Annual Meeting of Stockholders: Tomas J. HeymanDIRECTOR ELECTIONSISSUER785011.0000000FOR785011.000000FORS000002088Exelixis, Inc.30161Q104US30161Q104005/30/2024To elect the eleven nominees for director named in the accompanying Proxy Statement to hold office until the next Annual Meeting of Stockholders: David E. JohnsonDIRECTOR ELECTIONSISSUER785011.0000000FOR785011.000000FORS000002088Exelixis, Inc.30161Q104US30161Q104005/30/2024To elect the eleven nominees for director named in the accompanying Proxy Statement to hold office until the next Annual Meeting of Stockholders: Michael M. Morrissey, Ph.D.DIRECTOR ELECTIONSISSUER785011.0000000FOR785011.000000FORS000002088Exelixis, Inc.30161Q104US30161Q104005/30/2024To elect the eleven nominees for director named in the accompanying Proxy Statement to hold office until the next Annual Meeting of Stockholders: Robert L. Oliver, Jr.DIRECTOR ELECTIONSISSUER785011.0000000FOR785011.000000FORS000002088Exelixis, Inc.30161Q104US30161Q104005/30/2024To elect the eleven nominees for director named in the accompanying Proxy Statement to hold office until the next Annual Meeting of Stockholders: Stelios Papadopoulos, Ph.D.DIRECTOR ELECTIONSISSUER785011.0000000FOR785011.000000FORS000002088Exelixis, Inc.30161Q104US30161Q104005/30/2024To elect the eleven nominees for director named in the accompanying Proxy Statement to hold office until the next Annual Meeting of Stockholders: George Poste, DVM, Ph.D., FRSDIRECTOR ELECTIONSISSUER785011.0000000FOR785011.000000FORS000002088Exelixis, Inc.30161Q104US30161Q104005/30/2024To elect the eleven nominees for director named in the accompanying Proxy Statement to hold office until the next Annual Meeting of Stockholders: Julie Anne SmithDIRECTOR ELECTIONSISSUER785011.0000000FOR785011.000000FORS000002088Exelixis, Inc.30161Q104US30161Q104005/30/2024To elect the eleven nominees for director named in the accompanying Proxy Statement to hold office until the next Annual Meeting of Stockholders: Jack L. WyszomierskiDIRECTOR ELECTIONSISSUER785011.0000000FOR785011.000000FORS000002088Exelixis, Inc.30161Q104US30161Q104005/30/2024To ratify the selection by the Audit Committee of the Board of Directors of Ernst & Young LLP as Exelixis' independent registered public accounting firm for the focal year ending January 3, 2025.AUDIT-RELATEDISSUER785011.0000000FOR785011.000000FORS000002088Exelixis, Inc.30161Q104US30161Q104005/30/2024To amend and restate the Exelixis 2000 Employee Stock Purchase Plan to, among other things, increase the number of shares authorized for issuance by 6,000,000 shares.COMPENSATIONISSUER785011.0000000FOR785011.000000FORS000002088Exelixis, Inc.30161Q104US30161Q104005/30/2024To approve, on an advisory basis, the compensation of Exelixis' named executive officers, as disclosed in the accompanying Proxy StatementSECTION 14A SAY-ON-PAY VOTESISSUER785011.0000000FOR785011.000000FORS000002088Alkermes plcG01767105IE00B56GVS1505/31/2024To elect as directors to serve a one-year term until the Company's 2025 annual general meeting of shareholders: Emily Peterson AlvaDIRECTOR ELECTIONSISSUER1596763.0000000FOR1596763.000000FORS000002088Alkermes plcG01767105IE00B56GVS1505/31/2024To elect as directors to serve a one-year term until the Company's 2025 annual general meeting of shareholders: Shane M. CookeDIRECTOR ELECTIONSISSUER1596763.0000000FOR1596763.000000FORS000002088Alkermes plcG01767105IE00B56GVS1505/31/2024To elect as directors to serve a one-year term until the Company's 2025 annual general meeting of shareholders: David A. Daglio, Jr.DIRECTOR ELECTIONSISSUER1596763.0000000FOR1596763.000000FORS000002088Alkermes plcG01767105IE00B56GVS1505/31/2024To elect as directors to serve a one-year term until the Company's 2025 annual general meeting of shareholders: Richard B. Gaynor, M.DDIRECTOR ELECTIONSISSUER1596763.0000000FOR1596763.000000FORS000002088Alkermes plcG01767105IE00B56GVS1505/31/2024To elect as directors to serve a one-year term until the Company's 2025 annual general meeting of shareholders: Cato T. Laurencin, M.D., Ph.D.DIRECTOR ELECTIONSISSUER1596763.0000000FOR1596763.000000FORS000002088Alkermes plcG01767105IE00B56GVS1505/31/2024To elect as directors to serve a one-year term until the Company's 2025 annual general meeting of shareholders: Nancy S. LurkerDIRECTOR ELECTIONSISSUER1596763.0000000FOR1596763.000000FORS000002088Alkermes plcG01767105IE00B56GVS1505/31/2024To elect as directors to serve a one-year term until the Company's 2025 annual general meeting of shareholders: Brian P. McKeonDIRECTOR ELECTIONSISSUER1596763.0000000FOR1596763.000000FORS000002088Alkermes plcG01767105IE00B56GVS1505/31/2024To elect as directors to serve a one-year term until the Company's 2025 annual general meeting of shareholders: Richard F. PopsDIRECTOR ELECTIONSISSUER1596763.0000000FOR1596763.000000FORS000002088Alkermes plcG01767105IE00B56GVS1505/31/2024To elect as directors to serve a one-year term until the Company's 2025 annual general meeting of shareholders: Nancy L. Snyderman, M.D.DIRECTOR ELECTIONSISSUER1596763.0000000FOR1596763.000000FORS000002088Alkermes plcG01767105IE00B56GVS1505/31/2024To elect as directors to serve a one-year term until the Company's 2025 annual general meeting of shareholders: Frank Anders WilsonDIRECTOR ELECTIONSISSUER1596763.0000000FOR1596763.000000FORS000002088Alkermes plcG01767105IE00B56GVS1505/31/2024To elect as directors to serve a one-year term until the Company's 2025 annual general meeting of shareholders: Christopher I. Wright, M.D., Ph.D.DIRECTOR ELECTIONSISSUER1596763.0000000FOR1596763.000000FORS000002088Alkermes plcG01767105IE00B56GVS1505/31/2024To approve, in a non-binding, advisory vote, the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER1596763.0000000FOR1596763.000000FORS000002088Alkermes plcG01767105IE00B56GVS1505/31/2024To approve, in a non-binding, advisory vote, the frequency of future advisory votes on the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER1596763.0000000ONE YEAR1596763.000000FORS000002088Alkermes plcG01767105IE00B56GVS1505/31/2024To ratify, in a non-binding vote, the appointment of PricewaterhouseCoopers LLP as the independent auditor and accounting firm of the Company and to authorize, in a binding vote, the Audit and Risk Committee of the Board to set the independent auditor and accounting firm's remuneration.AUDIT-RELATEDISSUER1596763.0000000FOR1596763.000000FORS000002088Alkermes plcG01767105IE00B56GVS1505/31/2024To approve the Alkermes plc 2018 Stock Option and Incentive Plan, as amended.COMPENSATIONISSUER1596763.0000000FOR1596763.000000FORS000002088Alkermes plcG01767105IE00B56GVS1505/31/2024To renew Board authority to allot and issue shares under Irish law.CAPITAL STRUCTUREISSUER1596763.0000000FOR1596763.000000FORS000002088Alkermes plcG01767105IE00B56GVS1505/31/2024To renew Board authority to disapply the statutory pre-emption rights that would otherwise apply under Irish law.CAPITAL STRUCTUREISSUER1596763.0000000FOR1596763.000000FORS000002088Amgen Inc.031162100US031162100905/31/2024To elect twelve directors to the Board of Directors of Amgen Inc. for a term of office expiring at the 2025 annual meeting of stockholders. The nominees for election to the Board of Directors are: Dr. Wanda M. AustinDIRECTOR ELECTIONSISSUER866122.0000000FOR866122.000000FORS000002088Amgen Inc.031162100US031162100905/31/2024To elect twelve directors to the Board of Directors of Amgen Inc. for a term of office expiring at the 2025 annual meeting of stockholders. The nominees for election to the Board of Directors are: Mr. Robert A. BradwayDIRECTOR ELECTIONSISSUER866122.0000000FOR866122.000000FORS000002088Amgen Inc.031162100US031162100905/31/2024To elect twelve directors to the Board of Directors of Amgen Inc. for a term of office expiring at the 2025 annual meeting of stockholders. The nominees for election to the Board of Directors are: Dr. Michael V. DrakeDIRECTOR ELECTIONSISSUER866122.0000000FOR866122.000000FORS000002088Amgen Inc.031162100US031162100905/31/2024To elect twelve directors to the Board of Directors of Amgen Inc. for a term of office expiring at the 2025 annual meeting of stockholders. The nominees for election to the Board of Directors are: Dr. Brian J. DrukerDIRECTOR ELECTIONSISSUER866122.0000000FOR866122.000000FORS000002088Amgen Inc.031162100US031162100905/31/2024To elect twelve directors to the Board of Directors of Amgen Inc. for a term of office expiring at the 2025 annual meeting of stockholders. The nominees for election to the Board of Directors are: Mr. Robert A. EckertDIRECTOR ELECTIONSISSUER866122.0000000FOR866122.000000FORS000002088Amgen Inc.031162100US031162100905/31/2024To elect twelve directors to the Board of Directors of Amgen Inc. for a term of office expiring at the 2025 annual meeting of stockholders. The nominees for election to the Board of Directors are: Mr. Greg C. GarlandDIRECTOR ELECTIONSISSUER866122.0000000FOR866122.000000FORS000002088Amgen Inc.031162100US031162100905/31/2024To elect twelve directors to the Board of Directors of Amgen Inc. for a term of office expiring at the 2025 annual meeting of stockholders. The nominees for election to the Board of Directors are: Mr. Charles M. Holley, Jr.DIRECTOR ELECTIONSISSUER866122.0000000FOR866122.000000FORS000002088Amgen Inc.031162100US031162100905/31/2024To elect twelve directors to the Board of Directors of Amgen Inc. for a term of office expiring at the 2025 annual meeting of stockholders. The nominees for election to the Board of Directors are: Dr. S. Omar IshrakDIRECTOR ELECTIONSISSUER866122.0000000FOR866122.000000FORS000002088Amgen Inc.031162100US031162100905/31/2024To elect twelve directors to the Board of Directors of Amgen Inc. for a term of office expiring at the 2025 annual meeting of stockholders. The nominees for election to the Board of Directors are: Dr. Tyler JacksDIRECTOR ELECTIONSISSUER866122.0000000FOR866122.000000FORS000002088Amgen Inc.031162100US031162100905/31/2024To elect twelve directors to the Board of Directors of Amgen Inc. for a term of office expiring at the 2025 annual meeting of stockholders. The nominees for election to the Board of Directors are: Dr. Mary E. KlotmanDIRECTOR ELECTIONSISSUER866122.0000000FOR866122.000000FORS000002088Amgen Inc.031162100US031162100905/31/2024To elect twelve directors to the Board of Directors of Amgen Inc. for a term of office expiring at the 2025 annual meeting of stockholders. The nominees for election to the Board of Directors are: Ms. Ellen J. KullmanDIRECTOR ELECTIONSISSUER866122.0000000FOR866122.000000FORS000002088Amgen Inc.031162100US031162100905/31/2024To elect twelve directors to the Board of Directors of Amgen Inc. for a term of office expiring at the 2025 annual meeting of stockholders. The nominees for election to the Board of Directors are: Ms. Amy E. MilesDIRECTOR ELECTIONSISSUER866122.0000000FOR866122.000000FORS000002088Amgen Inc.031162100US031162100905/31/2024Advisory vote to approve our executive compensation.SECTION 14A SAY-ON-PAY VOTESISSUER866122.0000000FOR866122.000000FORS000002088Amgen Inc.031162100US031162100905/31/2024To approve our Amgen Inc. Second Amended and Restated 2009 Equity incentive Plan.COMPENSATIONISSUER866122.0000000FOR866122.000000FORS000002088Amgen Inc.031162100US031162100905/31/2024To ratify the selection of Ernst & Young LLP as our independent registered public accountants for the fiscal year ending December 31, 2024.AUDIT-RELATEDISSUER866122.0000000FOR866122.000000FORS000002088Denali Therapeutics Inc.24823R105US24823R105905/31/2024ELECTION OF DIRECTORS: Jay FlatleyDIRECTOR ELECTIONSISSUER936272.0000000FOR936272.000000FORS000002088Denali Therapeutics Inc.24823R105US24823R105905/31/2024ELECTION OF DIRECTORS: Marc Tessier-Lavigne, Ph.D.DIRECTOR ELECTIONSISSUER936272.0000000FOR936272.000000FORS000002088Denali Therapeutics Inc.24823R105US24823R105905/31/2024ELECTION OF DIRECTORS: Nancy ThornberryDIRECTOR ELECTIONSISSUER936272.0000000FOR936272.000000FORS000002088Denali Therapeutics Inc.24823R105US24823R105905/31/2024Ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2024AUDIT-RELATEDISSUER936272.0000000FOR936272.000000FORS000002088Denali Therapeutics Inc.24823R105US24823R105905/31/2024Advisory vote on executive compensationSECTION 14A SAY-ON-PAY VOTESISSUER936272.0000000FOR936272.000000FORS000002088IDEAYA Biosciences, Inc.45166A102US45166A102505/31/2024To elect two Class II directors to hold office until the 2027 annual meeting of stockholders or until their successors are elected: Terry J. Rosen, Ph.D.DIRECTOR ELECTIONSISSUER995825.0000000FOR995825.000000FORS000002088IDEAYA Biosciences, Inc.45166A102US45166A102505/31/2024To elect two Class II directors to hold office until the 2027 annual meeting of stockholders or until their successors are elected: Wendy L. YarnoDIRECTOR ELECTIONSISSUER995825.0000000FOR995825.000000FORS000002088IDEAYA Biosciences, Inc.45166A102US45166A102505/31/2024To ratify the selection, by the Audit Committee of the Company's Board of Directors, of PricewaterhouseCoopers LLP, as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2024; andAUDIT-RELATEDISSUER995825.0000000FOR995825.000000FORS000002088IDEAYA Biosciences, Inc.45166A102US45166A102505/31/2024To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement accompanying this Notice of Annual Meeting of Stockholders;SECTION 14A SAY-ON-PAY VOTESISSUER995825.0000000FOR995825.000000FORS000002088IDEAYA Biosciences, Inc.45166A102US45166A102505/31/2024To hold a non-binding advisory vote on the frequency of future advisory votes by stockholders on the compensation of the Company's named executive officers; andSECTION 14A SAY-ON-PAY VOTESISSUER995825.0000000ONE YEAR995825.000000FORS000002088Cabaletta Bio, Inc.12674W109US12674W109906/03/2024To elect two class II directors to our board of directors, to serve until the 2027 annual meeting of stockholders and until their successor has been duly elected and qualified, or until their earlier death, resignation or removal: Catherine Bollard, MBChB, M.D.DIRECTOR ELECTIONSISSUER450807.0000000FOR450807.000000FORS000002088Cabaletta Bio, Inc.12674W109US12674W109906/03/2024To elect two class II directors to our board of directors, to serve until the 2027 annual meeting of stockholders and until their successor has been duly elected and qualified, or until their earlier death, resignation or removal: Richard Henriques, MBADIRECTOR ELECTIONSISSUER450807.0000000FOR450807.000000FORS000002088Cabaletta Bio, Inc.12674W109US12674W109906/03/2024To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024.AUDIT-RELATEDISSUER450807.0000000FOR450807.000000FORS000002088Relay Therapeutics, Inc.75943R102US75943R102306/03/2024To elect two class I directors to our board of directors, to serve until the 2027 annual meeting of stockholders and until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation or removal: Sanjiv K. Patel, M.D.DIRECTOR ELECTIONSISSUER1947081.0000000FOR1947081.000000FORS000002088Relay Therapeutics, Inc.75943R102US75943R102306/03/2024To elect two class I directors to our board of directors, to serve until the 2027 annual meeting of stockholders and until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation or removal: Linda A. Hill, Ph.D.DIRECTOR ELECTIONSISSUER1947081.0000000FOR1947081.000000FORS000002088Relay Therapeutics, Inc.75943R102US75943R102306/03/2024To consider and act upon an advisory vote on the compensation of our named executive officers;SECTION 14A SAY-ON-PAY VOTESISSUER1947081.0000000AGAINST1947081.000000AGAINSTS000002088Relay Therapeutics, Inc.75943R102US75943R102306/03/2024To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024; andAUDIT-RELATEDISSUER1947081.0000000FOR1947081.000000FORS000002088UnitedHealth Group Incorporated91324P102US91324P102106/03/2024Election of Directors: Charles BakerDIRECTOR ELECTIONSISSUER1845141.0000000FOR1845141.000000FORS000002088UnitedHealth Group Incorporated91324P102US91324P102106/03/2024Election of Directors: Timothy FlynnDIRECTOR ELECTIONSISSUER1845141.0000000FOR1845141.000000FORS000002088UnitedHealth Group Incorporated91324P102US91324P102106/03/2024Election of Directors: Paul GarciaDIRECTOR ELECTIONSISSUER1845141.0000000FOR1845141.000000FORS000002088UnitedHealth Group Incorporated91324P102US91324P102106/03/2024Election of Directors: Kristen GilDIRECTOR ELECTIONSISSUER1845141.0000000FOR1845141.000000FORS000002088UnitedHealth Group Incorporated91324P102US91324P102106/03/2024Election of Directors: Stephen HemsleyDIRECTOR ELECTIONSISSUER1845141.0000000FOR1845141.000000FORS000002088UnitedHealth Group Incorporated91324P102US91324P102106/03/2024Election of Directors: Michele HooperDIRECTOR ELECTIONSISSUER1845141.0000000FOR1845141.000000FORS000002088UnitedHealth Group Incorporated91324P102US91324P102106/03/2024Election of Directors: F. William McNabb IIIDIRECTOR ELECTIONSISSUER1845141.0000000FOR1845141.000000FORS000002088UnitedHealth Group Incorporated91324P102US91324P102106/03/2024Election of Directors: Valerie Montgomery Rice, M.D.DIRECTOR ELECTIONSISSUER1845141.0000000FOR1845141.000000FORS000002088UnitedHealth Group Incorporated91324P102US91324P102106/03/2024Election of Directors: John Noseworthy, M.D.DIRECTOR ELECTIONSISSUER1845141.0000000FOR1845141.000000FORS000002088UnitedHealth Group Incorporated91324P102US91324P102106/03/2024Election of Directors: Andrew WittyDIRECTOR ELECTIONSISSUER1845141.0000000FOR1845141.000000FORS000002088UnitedHealth Group Incorporated91324P102US91324P102106/03/2024Advisory approval of the Company's executive compensation.SECTION 14A SAY-ON-PAY VOTESISSUER1845141.0000000FOR1845141.000000FORS000002088UnitedHealth Group Incorporated91324P102US91324P102106/03/2024Ratification of the appointment of Deloitte & Touche LLP as the independent registered public accounting firm for the Company for the year ending December 31, 2024.AUDIT-RELATEDISSUER1845141.0000000FOR1845141.000000FORS000002088UnitedHealth Group Incorporated91324P102US91324P102106/03/2024If properly presented at the 2024 Annual Meeting of Shareholders, the shareholder proposal requiring a political contributions congruency report.OTHER SOCIAL ISSUESSECURITY HOLDER1845141.0000000AGAINST1845141.000000FORS000002088Acumen Pharmaceuticals, Inc.00509G209US00509G209306/04/2024To elect two Class III directors to the Board of Directors, each to hold office until the 2027 Annual Meeting of Stockholders: Daniel O'ConnellDIRECTOR ELECTIONSISSUER866917.0000000FOR866917.000000FORS000002088Acumen Pharmaceuticals, Inc.00509G209US00509G209306/04/2024To elect two Class III directors to the Board of Directors, each to hold office until the 2027 Annual Meeting of Stockholders: Nathan Fountain, M.D.DIRECTOR ELECTIONSISSUER866917.0000000FOR866917.000000FORS000002088Acumen Pharmaceuticals, Inc.00509G209US00509G209306/04/2024To ratify the selection by the Audit Committee of the Board of Directors of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024.AUDIT-RELATEDISSUER866917.0000000FOR866917.000000FORS000002088CARGO Therapeutics, Inc.14179K101US14179K101606/04/2024To elect two Class I directors to hold office until the 2027 annual meeting of stockholders or until their successors are elected: Krishnan Viswanadhan, Pharm.D.DIRECTOR ELECTIONSISSUER1824733.0000000FOR1824733.000000FORS000002088CARGO Therapeutics, Inc.14179K101US14179K101606/04/2024To elect two Class I directors to hold office until the 2027 annual meeting of stockholders or until their successors are elected: Reid Huber, Ph.D.DIRECTOR ELECTIONSISSUER1824733.0000000FOR1824733.000000FORS000002088CARGO Therapeutics, Inc.14179K101US14179K101606/04/2024To ratify the appointment, by the Audit Committee of the Company's Board of Directors, of Deloitte & Touche LLP as the independent registered public accounting firm and independent auditor of the Company for the fiscal year ending December 31, 2024.AUDIT-RELATEDISSUER1824733.0000000FOR1824733.000000FORS000002088Morphic Holding, Inc.61775R105US61775R105906/04/2024Election of three Class II directors to our Board of Directors to serve until the 2027 Annual Meeting of Stockholders: Gustav Christensen, MBADIRECTOR ELECTIONSISSUER722196.0000000FOR722196.000000FORS000002088Morphic Holding, Inc.61775R105US61775R105906/04/2024Election of three Class II directors to our Board of Directors to serve until the 2027 Annual Meeting of Stockholders: Susannah Gray, MBADIRECTOR ELECTIONSISSUER722196.0000000FOR722196.000000FORS000002088Morphic Holding, Inc.61775R105US61775R105906/04/2024Election of three Class II directors to our Board of Directors to serve until the 2027 Annual Meeting of Stockholders: Amir Nashat, Sc.D.DIRECTOR ELECTIONSISSUER722196.0000000FOR722196.000000FORS000002088Morphic Holding, Inc.61775R105US61775R105906/04/2024Ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024.AUDIT-RELATEDISSUER722196.0000000FOR722196.000000FORS000002088Morphic Holding, Inc.61775R105US61775R105906/04/2024To approve, on a non-binding advisory basis, the compensation paid to the Company's Named Executive Officers.SECTION 14A SAY-ON-PAY VOTESISSUER722196.0000000FOR722196.000000FORS000002088PROCEPT BioRobotics Corporation74276L105US74276L105206/04/2024Election of Class III directors to serve until 2027 annual meeting of shareholders and until their successors are duly elected and qualified: Amy DodrillDIRECTOR ELECTIONSISSUER653581.0000000FOR653581.000000FORS000002088PROCEPT BioRobotics Corporation74276L105US74276L105206/04/2024Election of Class III directors to serve until 2027 annual meeting of shareholders and until their successors are duly elected and qualified: Taylor HarrisDIRECTOR ELECTIONSISSUER653581.0000000FOR653581.000000FORS000002088PROCEPT BioRobotics Corporation74276L105US74276L105206/04/2024Election of Class III directors to serve until 2027 annual meeting of shareholders and until their successors are duly elected and qualified: Reza Zadno, Ph.D.DIRECTOR ELECTIONSISSUER653581.0000000FOR653581.000000FORS000002088PROCEPT BioRobotics Corporation74276L105US74276L105206/04/2024Ratification of the selection of PricewaterhouseCoopers LLP as the Company's Independent Registered Public Accounting Firm.AUDIT-RELATEDISSUER653581.0000000FOR653581.000000FORS000002088PROCEPT BioRobotics Corporation74276L105US74276L105206/04/2024Approval, on a non-binding advisory basis, of the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER653581.0000000FOR653581.000000FORS000002088Allogene Therapeutics, Inc.019770106US019770106506/05/2024Election of Directors: John DeYoungDIRECTOR ELECTIONSISSUER3052112.0000000WITHHOLD3052112.000000AGAINSTS000002088Allogene Therapeutics, Inc.019770106US019770106506/05/2024Election of Directors: Franz Humer, Ph.D.DIRECTOR ELECTIONSISSUER3052112.0000000WITHHOLD3052112.000000AGAINSTS000002088Allogene Therapeutics, Inc.019770106US019770106506/05/2024Election of Directors: Joshua KazamDIRECTOR ELECTIONSISSUER3052112.0000000FOR3052112.000000FORS000002088Allogene Therapeutics, Inc.019770106US019770106506/05/2024Election of Directors: Stephen Mayo, Ph.D.DIRECTOR ELECTIONSISSUER3052112.0000000FOR3052112.000000FORS000002088Allogene Therapeutics, Inc.019770106US019770106506/05/2024To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the proxy statement.SECTION 14A SAY-ON-PAY VOTESISSUER3052112.0000000AGAINST3052112.000000AGAINSTS000002088Allogene Therapeutics, Inc.019770106US019770106506/05/2024To ratify the selection by the Audit Committee of the Board of Directors of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2024.AUDIT-RELATEDISSUER3052112.0000000FOR3052112.000000FORS000002088Annexon, Inc.03589W102US03589W102706/05/2024To elect the two nominees for director to serve as Class I directors to hold office until the 2027 annual meeting of stockholders: William H. Carson, M.D.DIRECTOR ELECTIONSISSUER1028531.0000000FOR1028531.000000FORS000002088Annexon, Inc.03589W102US03589W102706/05/2024To elect the two nominees for director to serve as Class I directors to hold office until the 2027 annual meeting of stockholders: Muneer A. SatterDIRECTOR ELECTIONSISSUER1028531.0000000FOR1028531.000000FORS000002088Annexon, Inc.03589W102US03589W102706/05/2024To ratify the selection of KPMG LLP as the Company's independent registered public accounting firm for the Company's fiscal year ending December 31, 2024.AUDIT-RELATEDISSUER1028531.0000000FOR1028531.000000FORS000002088Annexon, Inc.03589W102US03589W102706/05/2024To approve, on a non-binding advisory basis, the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER1028531.0000000FOR1028531.000000FORS000002088Apellis Pharmaceuticals, Inc.03753U106US03753U106006/05/2024Election of two Class I directors to hold office until the 2027 annual meeting of stockholders: Paul FonteyneDIRECTOR ELECTIONSISSUER1290512.0000000FOR1290512.000000FORS000002088Apellis Pharmaceuticals, Inc.03753U106US03753U106006/05/2024Election of two Class I directors to hold office until the 2027 annual meeting of stockholders: Stephanie Monaghan O'BrienDIRECTOR ELECTIONSISSUER1290512.0000000FOR1290512.000000FORS000002088Apellis Pharmaceuticals, Inc.03753U106US03753U106006/05/2024Ratification of the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024;AUDIT-RELATEDISSUER1290512.0000000FOR1290512.000000FORS000002088Apellis Pharmaceuticals, Inc.03753U106US03753U106006/05/2024Approval of an advisory vote on executive compensation; andSECTION 14A SAY-ON-PAY VOTESISSUER1290512.0000000FOR1290512.000000FORS000002088Apogee Therapeutics, Inc.03770N101US03770N101906/05/2024Election of Class I Directors for terms expiring in 2027: Andrew Gottesdiener, M.D.DIRECTOR ELECTIONSISSUER885129.0000000FOR885129.000000FORS000002088Apogee Therapeutics, Inc.03770N101US03770N101906/05/2024Election of Class I Directors for terms expiring in 2027: Peter HarwinDIRECTOR ELECTIONSISSUER885129.0000000FOR885129.000000FORS000002088Apogee Therapeutics, Inc.03770N101US03770N101906/05/2024Election of Class I Directors for terms expiring in 2027: Michael Henderson, M.D.DIRECTOR ELECTIONSISSUER885129.0000000FOR885129.000000FORS000002088Apogee Therapeutics, Inc.03770N101US03770N101906/05/2024Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the year ending December 31, 2024.AUDIT-RELATEDISSUER885129.0000000FOR885129.000000FORS000002088Apogee Therapeutics, Inc.03770N101US03770N101906/05/2024Approval of the grant of options to purchase 100,000 shares of the Company's common stock to a director, Mark C. McKenna.COMPENSATIONISSUER885129.0000000FOR885129.000000FORS000002088Beam Therapeutics Inc.07373V105US07373V105206/05/2024Election of the following nominee as a Class I Director for a three-year term ending at our Annual Meeting of Stockholders to be held in 2027: Graham CooperDIRECTOR ELECTIONSISSUER949715.0000000FOR949715.000000FORS000002088Beam Therapeutics Inc.07373V105US07373V105206/05/2024Ratify the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2024.AUDIT-RELATEDISSUER949715.0000000FOR949715.000000FORS000002088Beam Therapeutics Inc.07373V105US07373V105206/05/2024Approve, on an advisory basis, the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER949715.0000000FOR949715.000000FORS000002088BeiGene, Ltd.07725L102US07725L102606/05/2024Resolution 1 - Ordinary Resolution THAT Dr. Olivier Brandicourt be and is hereby re-elected to serve as a Class II director of the Company until the 2027 annual general meeting of shareholders and until his successor is duly elected and qualified, subject to his earlier resignation or removal.DIRECTOR ELECTIONSISSUER635877.0000000FOR635877.000000FORS000002088BeiGene, Ltd.07725L102US07725L102606/05/2024Resolution 2 - Ordinary Resolution THAT Donald W. Glazer be and is hereby re-elected to serve as a Class II director of the Company until the 2027 annual general meeting of shareholders and until his successor is duly elected and qualified, subject to his earlier resignation or removal.DIRECTOR ELECTIONSISSUER635877.0000000FOR635877.000000FORS000002088BeiGene, Ltd.07725L102US07725L102606/05/2024Resolution 3 - Ordinary Resolution THAT Michael Goller be and is hereby re-elected to serve as a Class II director of the Company until the 2027 annual general meeting of shareholders and until his successor is duly elected and qualified, subject to his earlier resignation or removal.DIRECTOR ELECTIONSISSUER635877.0000000FOR635877.000000FORS000002088BeiGene, Ltd.07725L102US07725L102606/05/2024Resolution 4 - Ordinary Resolution THAT Dr. Corazon (Corsee) D. Sanders be and is hereby re-elected to serve as a Class II director of the Company until the 2027 annual general meeting of shareholders and until her successor is duly elected and qualified, subject to her earlier resignation or removal.DIRECTOR ELECTIONSISSUER635877.0000000FOR635877.000000FORS000002088BeiGene, Ltd.07725L102US07725L102606/05/2024Resolution 5 - Ordinary Resolution THAT the appointment of Ernst & Young LLP, Ernst & Young and Ernst & Young Hua Ming LLP as the Company's independent auditors for the fiscal year ending December 31, 2024 be and is hereby approved, ratified and confirmed.AUDIT-RELATEDISSUER635877.0000000FOR635877.000000FORS000002088BeiGene, Ltd.07725L102US07725L102606/05/2024Resolution 6 - Ordinary Resolution THAT the Board of Directors is hereby authorized to fix the auditors' compensation for the fiscal year ending December 31, 2024.AUDIT-RELATEDISSUER635877.0000000FOR635877.000000FORS000002088BeiGene, Ltd.07725L102US07725L102606/05/2024Resolution 7 - Ordinary Resolution THAT the granting of a share issue mandate to the Board of Directors to issue, allot or deal with unissued ordinary shares and/or American Depositary Shares ("ADSs") (including any sale or transfer of treasury shares (which shall have the meaning ascribed to it under the HK Listing Rules coming into effect on June 11, 2024) out of treasury) not exceeding 20% of the total number of issued shares of the Company (excluding treasury shares) as of the date of passing of this ordinary resolution up to the next annual general meeting of shareholders of the Company be and is hereby approved.CAPITAL STRUCTUREISSUER635877.0000000AGAINST635877.000000AGAINSTS000002088BeiGene, Ltd.07725L102US07725L102606/05/2024Resolution 8 - Ordinary Resolution THAT the granting of a share repurchase mandate to the Board of Directors to repurchase an amount of ordinary shares (excluding RMB shares) and/or ADSs, not exceeding 10% of the total number of issued ordinary shares (excluding RMB shares and treasury shares) of the Company as of the date of passing of such ordinary resolution up to the next annual general meeting of shareholders of the Company be and is hereby approved.CAPITAL STRUCTUREISSUER635877.0000000FOR635877.000000FORS000002088BeiGene, Ltd.07725L102US07725L102606/05/2024Resolution 9 - Ordinary Resolution THAT the Company and its underwriters be and are hereby authorized, in their sole discretion, to allocate to each of Baker Bros. Advisors LP and Hillhouse Capital Management, Ltd. and parties affiliated with each of them (the "Existing Shareholders"), up to a maximum amount of shares in order to maintain the same shareholding percentage of each of the Existing Shareholders (based on the then-outstanding share capital of the Company) before and after the allocation of the corresponding securities issued pursuant to an offering conducted pursuant to the general mandate set forth in Resolution 7 for a period of five years, which period will be subject to an extension on a rolling basis each year.CAPITAL STRUCTUREISSUER635877.0000000AGAINST635877.000000AGAINSTS000002088BeiGene, Ltd.07725L102US07725L102606/05/2024Resolution 10 - Ordinary Resolution THAT the Company and its underwriters be and are hereby authorized, in their sole discretion, to allocate to Amgen Inc. ("Amgen"), up to a maximum amount of shares in order to maintain the same shareholding percentage of Amgen (based on the then-outstanding share capital of the Company) before and after the allocation of the corresponding securities issued pursuant to an offering conducted pursuant to the general mandate set forth in Resolution 7 for a period of five years, which period will be subject to an extension on a rolling basis each year.CAPITAL STRUCTUREISSUER635877.0000000AGAINST635877.000000AGAINSTS000002088BeiGene, Ltd.07725L102US07725L102606/05/2024Resolution 11 - Ordinary Resolution THAT the grant of restricted share units ("RSUs") with a grant date fair value of US$6,000,000 to Mr. John V. Oyler under the Second Amended and Restated 2016 Share Option and Incentive Plan (as amended, the "2016 Plan"), according to the terms and conditions described in the Proxy Statement, be and is hereby approved.COMPENSATIONISSUER635877.0000000AGAINST635877.000000AGAINSTS000002088BeiGene, Ltd.07725L102US07725L102606/05/2024Resolution 12 - Ordinary Resolution THAT the grant of performance share units ("PSUs") with a grant date fair value of US$6,000,000 to Mr. John V. Oyler under the 2016 Plan, according to the terms and conditions described in the Proxy Statement, be and is hereby approved.COMPENSATIONISSUER635877.0000000FOR635877.000000FORS000002088BeiGene, Ltd.07725L102US07725L102606/05/2024Resolution 13 - Ordinary Resolution THAT the grant of RSUs with a grant date fair value of US$1,333,333 to Dr. Xiaodong Wang under the 2016 Plan, according to the terms and conditions described in the Proxy Statement, be and is hereby approved.COMPENSATIONISSUER635877.0000000AGAINST635877.000000AGAINSTS000002088BeiGene, Ltd.07725L102US07725L102606/05/2024Resolution 14 - Ordinary Resolution THAT the grant of RSUs with a grant date fair value of US$200,000 to each of the independent non-executive directors, Dr. Olivier Brandicourt, Dr. Margaret Dugan, Mr. Donald W. Glazer, Mr. Michael Goller, Mr. Anthony C. Hooper, Mr. Ranjeev Krishana, Dr. Alessandro Riva, Dr. Corazon (Corsee) D. Sanders, and Mr. Qingqing Yi, under the 2016 Plan, according to the terms and conditions described in the Proxy Statement, be and is hereby approved.COMPENSATIONISSUER635877.0000000AGAINST635877.000000AGAINSTS000002088BeiGene, Ltd.07725L102US07725L102606/05/2024Resolution 15 - Ordinary Resolution THAT, on a non-binding, advisory basis, the compensation of the Company's named executive officers, as disclosed in the Proxy Statement, be and is hereby approved.SECTION 14A SAY-ON-PAY VOTESISSUER635877.0000000AGAINST635877.000000AGAINSTS000002088BeiGene, Ltd.07725L102US07725L102606/05/2024Resolution 16 - Ordinary Resolution THAT, on a non-binding, advisory basis, the frequency of future advisory votes on the compensation of the Company's named executive officers will be held at the frequency hereby approved.SECTION 14A SAY-ON-PAY VOTESISSUER635877.0000000ONE YEAR635877.000000FORS000002088BeiGene, Ltd.07725L102US07725L102606/05/2024Resolution 17(a) - Ordinary Resolution THAT the Third Amended and Restated 2016 Share Option and Incentive Plan of the Company, as described in the Proxy Statement, be and is hereby approved.COMPENSATIONISSUER635877.0000000AGAINST635877.000000AGAINSTS000002088BeiGene, Ltd.07725L102US07725L102606/05/2024Resolution 17(b) - Ordinary Resolution THAT the consultant sublimit set out in the Third Amended and Restated 2016 Share Option and Incentive Plan of the Company, as described in the Proxy Statement, be and is hereby approved.COMPENSATIONISSUER635877.0000000FOR635877.000000FORS000002088BeiGene, Ltd.07725L102US07725L102606/05/2024Resolution 18 - Ordinary Resolution THAT the Fourth Amended and Restated 2018 Employee Share Purchase Plan of the Company, as described in the Proxy Statement, be and is hereby approved.COMPENSATIONISSUER635877.0000000FOR635877.000000FORS000002088BeiGene, Ltd.07725L102US07725L102606/05/2024Resolution 19 - Ordinary Resolution THAT the adjournment of the Annual Meeting by the chairman, if necessary, to solicit additional proxies if there are insufficient votes at the time of the Annual Meeting to approve any of the proposals described above, be and is hereby approved.CORPORATE GOVERNANCEISSUER635877.0000000AGAINST635877.000000AGAINSTS000002088Mirum Pharmaceuticals, Inc.604749101US604749101306/05/2024Election of three Class II nominees for director to hold office until the Company's 2027 annual meeting of stockholders: Laurent Fischer, M.D.DIRECTOR ELECTIONSISSUER312611.0000000WITHHOLD312611.000000AGAINSTS000002088Mirum Pharmaceuticals, Inc.604749101US604749101306/05/2024Election of three Class II nominees for director to hold office until the Company's 2027 annual meeting of stockholders: Patrick J. HeronDIRECTOR ELECTIONSISSUER312611.0000000FOR312611.000000FORS000002088Mirum Pharmaceuticals, Inc.604749101US604749101306/05/2024Election of three Class II nominees for director to hold office until the Company's 2027 annual meeting of stockholders: Saira Ramasastry, M.S., M.Phil.DIRECTOR ELECTIONSISSUER312611.0000000FOR312611.000000FORS000002088Mirum Pharmaceuticals, Inc.604749101US604749101306/05/2024To ratify the selection by the Audit Committee of the Board of Directors of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2024.AUDIT-RELATEDISSUER312611.0000000FOR312611.000000FORS000002088Mirum Pharmaceuticals, Inc.604749101US604749101306/05/2024To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the proxy statement.SECTION 14A SAY-ON-PAY VOTESISSUER312611.0000000FOR312611.000000FORS000002088Mirum Pharmaceuticals, Inc.604749101US604749101306/05/2024To indicate, on an advisory basis, the preferred frequency of stockholder advisory votes on the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER312611.0000000ONE YEAR312611.000000FORS000002088MoonLake Immunotherapeutics61559X104KY61559X104506/05/2024Election of the two Class II director nominees to serve until the 2027 Annual General Meeting of Shareholders and until their successors are duly elected and qualified: Catherine MoukheibirDIRECTOR ELECTIONSISSUER1050238.0000000FOR1050238.000000FORS000002088MoonLake Immunotherapeutics61559X104KY61559X104506/05/2024Election of the two Class II director nominees to serve until the 2027 Annual General Meeting of Shareholders and until their successors are duly elected and qualified: Dr. Ramnik XavierDIRECTOR ELECTIONSISSUER1050238.0000000FOR1050238.000000FORS000002088MoonLake Immunotherapeutics61559X104KY61559X104506/05/2024Ratification, by ordinary resolution, of the selection of Baker Tilly US, LLP as the Company's independent registered public accounting firm for the year ending December 31, 2024.AUDIT-RELATEDISSUER1050238.0000000FOR1050238.000000FORS000002088MoonLake Immunotherapeutics61559X104KY61559X104506/05/2024Approval of, on an advisory basis, the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER1050238.0000000FOR1050238.000000FORS000002088MoonLake Immunotherapeutics61559X104KY61559X104506/05/2024Non-binding advisory vote on the frequency of future advisory votes on executive compensation.SECTION 14A SAY-ON-PAY VOTESISSUER1050238.0000000ONE YEAR1050238.000000FORS000002088NovoCure LimitedG6674U108JE00BYSS4X4806/05/2024Election of Directors: Asaf DanzigerDIRECTOR ELECTIONSISSUER1750715.0000000FOR1750715.000000FORS000002088NovoCure LimitedG6674U108JE00BYSS4X4806/05/2024Election of Directors: William DoyleDIRECTOR ELECTIONSISSUER1750715.0000000FOR1750715.000000FORS000002088NovoCure LimitedG6674U108JE00BYSS4X4806/05/2024Election of Directors: Jeryl HillemanDIRECTOR ELECTIONSISSUER1750715.0000000FOR1750715.000000FORS000002088NovoCure LimitedG6674U108JE00BYSS4X4806/05/2024Election of Directors: David HungDIRECTOR ELECTIONSISSUER1750715.0000000FOR1750715.000000FORS000002088NovoCure LimitedG6674U108JE00BYSS4X4806/05/2024Election of Directors: Kinyip Gabriel LeungDIRECTOR ELECTIONSISSUER1750715.0000000FOR1750715.000000FORS000002088NovoCure LimitedG6674U108JE00BYSS4X4806/05/2024Election of Directors: Martin MaddenDIRECTOR ELECTIONSISSUER1750715.0000000FOR1750715.000000FORS000002088NovoCure LimitedG6674U108JE00BYSS4X4806/05/2024Election of Directors: Allyson OceanDIRECTOR ELECTIONSISSUER1750715.0000000FOR1750715.000000FORS000002088NovoCure LimitedG6674U108JE00BYSS4X4806/05/2024Election of Directors: Timothy ScannellDIRECTOR ELECTIONSISSUER1750715.0000000FOR1750715.000000FORS000002088NovoCure LimitedG6674U108JE00BYSS4X4806/05/2024Election of Directors: Kristin StaffordDIRECTOR ELECTIONSISSUER1750715.0000000FOR1750715.000000FORS000002088NovoCure LimitedG6674U108JE00BYSS4X4806/05/2024Election of Directors: William VernonDIRECTOR ELECTIONSISSUER1750715.0000000FOR1750715.000000FORS000002088NovoCure LimitedG6674U108JE00BYSS4X4806/05/2024The approval and ratification of the appointment, by the Audit Committee of our Board of Directors, of Kost Forer Gabbay & Kasierer, a member of Ernst & Young Global, as the auditor and independent registered public accounting firm of the Company for the Company's fiscal year ending December 31, 2024AUDIT-RELATEDISSUER1750715.0000000FOR1750715.000000FORS000002088NovoCure LimitedG6674U108JE00BYSS4X4806/05/2024A non-binding advisory vote to approve executive compensation.SECTION 14A SAY-ON-PAY VOTESISSUER1750715.0000000FOR1750715.000000FORS000002088NovoCure LimitedG6674U108JE00BYSS4X4806/05/2024The approval of our 2024 Omnibus Incentive PlanCOMPENSATIONISSUER1750715.0000000FOR1750715.000000FORS000002088NovoCure LimitedG6674U108JE00BYSS4X4806/05/2024A non-binding advisory vote to approve the frequency of the advisory vote on execute compensation.SECTION 14A SAY-ON-PAY VOTESISSUER1750715.0000000ONE YEAR1750715.000000FORS000002088Penumbra, Inc.70975L107US70975L107006/05/2024To elect the nominees for Class III director to serve until the 2027 Annual Meeting of Stockholders and until their successors are duly elected and qualified: Adam ElsesserDIRECTOR ELECTIONSISSUER748610.0000000FOR748610.000000FORS000002088Penumbra, Inc.70975L107US70975L107006/05/2024To elect the nominees for Class III director to serve until the 2027 Annual Meeting of Stockholders and until their successors are duly elected and qualified: Harpreet GrewalDIRECTOR ELECTIONSISSUER748610.0000000FOR748610.000000FORS000002088Penumbra, Inc.70975L107US70975L107006/05/2024To ratify the selection of PricewaterhouseCoopers LLP as the independent registered public accounting firm for Penumbra, Inc. for the fiscal year ending December 31, 2024; andAUDIT-RELATEDISSUER748610.0000000FOR748610.000000FORS000002088Penumbra, Inc.70975L107US70975L107006/05/2024To approve, on an advisory basis, the compensation of Penumbra, Inc.'s named executive officers as disclosed in the proxy statement.SECTION 14A SAY-ON-PAY VOTESISSUER748610.0000000FOR748610.000000FORS000002088Praxis Precision Medicines, Inc.74006W207US74006W207006/05/2024Election of Class I Directors to serve until the 2027 Annual Meeting of Stockholders, and until their respective successors have been duly elected and qualified: Dean MitchellDIRECTOR ELECTIONSISSUER286278.0000000WITHHOLD286278.000000AGAINSTS000002088Praxis Precision Medicines, Inc.74006W207US74006W207006/05/2024Election of Class I Directors to serve until the 2027 Annual Meeting of Stockholders, and until their respective successors have been duly elected and qualified: Jill DeSimoneDIRECTOR ELECTIONSISSUER286278.0000000WITHHOLD286278.000000AGAINSTS000002088Praxis Precision Medicines, Inc.74006W207US74006W207006/05/2024To ratify the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024.AUDIT-RELATEDISSUER286278.0000000FOR286278.000000FORS000002088Praxis Precision Medicines, Inc.74006W207US74006W207006/05/2024To approve the amendment and restatement of the Company's 2020 Stock Option and Incentive Plan.COMPENSATIONISSUER286278.0000000AGAINST286278.000000AGAINSTS000002088Praxis Precision Medicines, Inc.74006W207US74006W207006/05/2024To approve, on an advisory (non-binding) basis, the compensation of the named executive officers as disclosed in the Company's proxy statement for the 2024 Annual Meeting of Stockholders pursuant to the applicable compensation disclosure rules of the SEC, including the compensation tables and narrative discussion.SECTION 14A SAY-ON-PAY VOTESISSUER286278.0000000AGAINST286278.000000AGAINSTS000002088Voyager Therapeutics, Inc.92915B106US92915B106106/05/2024To elect each of the following directors to serve as a Class III director until the 2027 Annual Meeting of Stockholders and until his or her successor is duly elected and qualified: Michael HigginsDIRECTOR ELECTIONSISSUER738066.0000000FOR738066.000000FORS000002088Voyager Therapeutics, Inc.92915B106US92915B106106/05/2024To elect each of the following directors to serve as a Class III director until the 2027 Annual Meeting of Stockholders and until his or her successor is duly elected and qualified: Jude OnyiaDIRECTOR ELECTIONSISSUER738066.0000000FOR738066.000000FORS000002088Voyager Therapeutics, Inc.92915B106US92915B106106/05/2024To elect each of the following directors to serve as a Class III director until the 2027 Annual Meeting of Stockholders and until his or her successor is duly elected and qualified: Nancy VitaleDIRECTOR ELECTIONSISSUER738066.0000000FOR738066.000000FORS000002088Voyager Therapeutics, Inc.92915B106US92915B106106/05/2024To approve, on a non-binding advisory basis, the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER738066.0000000FOR738066.000000FORS000002088Voyager Therapeutics, Inc.92915B106US92915B106106/05/2024To ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024.AUDIT-RELATEDISSUER738066.0000000FOR738066.000000FORS000002088Amylyx Pharmaceuticals, Inc.03237H101US03237H101406/06/2024Election of Directors: To elect the following persons to our board of directors, each to serve as a Class III director until the 2027 Annual Meeting of Stockholders and until their successor has been duly elected and qualified, or until such director's earlier death, resignation or removal: Joshua B. CohenDIRECTOR ELECTIONSISSUER691722.0000000FOR691722.000000FORS000002088Amylyx Pharmaceuticals, Inc.03237H101US03237H101406/06/2024Election of Directors: To elect the following persons to our board of directors, each to serve as a Class III director until the 2027 Annual Meeting of Stockholders and until their successor has been duly elected and qualified, or until such director's earlier death, resignation or removal: Daphne QuimiDIRECTOR ELECTIONSISSUER691722.0000000FOR691722.000000FORS000002088Amylyx Pharmaceuticals, Inc.03237H101US03237H101406/06/2024To ratify the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024.AUDIT-RELATEDISSUER691722.0000000FOR691722.000000FORS000002088Amylyx Pharmaceuticals, Inc.03237H101US03237H101406/06/2024To approve, on a non-binding, advisory basis, the compensation of our named executives officers.SECTION 14A SAY-ON-PAY VOTESISSUER691722.0000000FOR691722.000000FORS000002088Amylyx Pharmaceuticals, Inc.03237H101US03237H101406/06/2024To vote, on a non-binding, advisory basis, on the preferred frequency of future advisory votes on the compensation of our named executives officers.SECTION 14A SAY-ON-PAY VOTESISSUER691722.0000000ONE YEAR691722.000000FORS000002088Generation Bio Co.37148K100US37148K100706/06/2024Election of three Class I directors to our board of directors, each to serve until the 2027 Annual Meeting of Stockholders: Jeffrey JonasDIRECTOR ELECTIONSISSUER2086880.0000000FOR2086880.000000FORS000002088Generation Bio Co.37148K100US37148K100706/06/2024Election of three Class I directors to our board of directors, each to serve until the 2027 Annual Meeting of Stockholders: Geoff McDonoughDIRECTOR ELECTIONSISSUER2086880.0000000FOR2086880.000000FORS000002088Generation Bio Co.37148K100US37148K100706/06/2024Election of three Class I directors to our board of directors, each to serve until the 2027 Annual Meeting of Stockholders: Donald NicholsonDIRECTOR ELECTIONSISSUER2086880.0000000FOR2086880.000000FORS000002088Generation Bio Co.37148K100US37148K100706/06/2024Ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024.AUDIT-RELATEDISSUER2086880.0000000FOR2086880.000000FORS000002088Generation Bio Co.37148K100US37148K100706/06/2024Approval, on an advisory (non-binding) basis, of the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER2086880.0000000FOR2086880.000000FORS000002088Gossamer Bio, Inc.38341P102US38341P102106/06/2024Election of Class II Directors: Skye DrynanDIRECTOR ELECTIONSISSUER2140278.0000000FOR2140278.000000FORS000002088Gossamer Bio, Inc.38341P102US38341P102106/06/2024Election of Class II Directors: John Quisel, Ph.D., J.D.DIRECTOR ELECTIONSISSUER2140278.0000000FOR2140278.000000FORS000002088Gossamer Bio, Inc.38341P102US38341P102106/06/2024Ratification of the appointment of Ernst & Young LLP as our independent registered public accountants for the year ending December 31, 2024.AUDIT-RELATEDISSUER2140278.0000000FOR2140278.000000FORS000002088Gossamer Bio, Inc.38341P102US38341P102106/06/2024Approval, on an advisory basis, of the compensation of the Company's named executive officers as disclosed in the proxy statement.SECTION 14A SAY-ON-PAY VOTESISSUER2140278.0000000FOR2140278.000000FORS000002088Ionis Pharmaceuticals, Inc.462222100US462222100406/06/2024Election of Directors: Brett P. MoniaDIRECTOR ELECTIONSISSUER782450.0000000FOR782450.000000FORS000002088Ionis Pharmaceuticals, Inc.462222100US462222100406/06/2024Election of Directors: Michael YangDIRECTOR ELECTIONSISSUER782450.0000000FOR782450.000000FORS000002088Ionis Pharmaceuticals, Inc.462222100US462222100406/06/2024To make an advisory vote on executive compensation.SECTION 14A SAY-ON-PAY VOTESISSUER782450.0000000FOR782450.000000FORS000002088Ionis Pharmaceuticals, Inc.462222100US462222100406/06/2024To approve an amendment of the Ionis Pharmaceuticals, Inc. 2011 Equity Incentive Plan to increase the aggregate number of shares of common stock authorized for issuance under such plan by 3,300,000 shares to an aggregate of 38,500,000 shares and to prohibit certain share recycling on full value awards.COMPENSATIONISSUER782450.0000000FOR782450.000000FORS000002088Ionis Pharmaceuticals, Inc.462222100US462222100406/06/2024To ratify the Audit Committee's selection of Ernst & Young LLP as independent auditors for the 2024 fiscal year.AUDIT-RELATEDISSUER782450.0000000FOR782450.000000FORS000002088Oscar Health, Inc.687793109US687793109606/06/2024Election of Directors: Mark T. BertoliniDIRECTOR ELECTIONSISSUER2263825.0000000FOR2263825.000000FORS000002088Oscar Health, Inc.687793109US687793109606/06/2024Election of Directors: Jeffery H. BoydDIRECTOR ELECTIONSISSUER2263825.0000000FOR2263825.000000FORS000002088Oscar Health, Inc.687793109US687793109606/06/2024Election of Directors: William Gassen IIIDIRECTOR ELECTIONSISSUER2263825.0000000FOR2263825.000000FORS000002088Oscar Health, Inc.687793109US687793109606/06/2024Election of Directors: Joshua KushnerDIRECTOR ELECTIONSISSUER2263825.0000000WITHHOLD2263825.000000AGAINSTS000002088Oscar Health, Inc.687793109US687793109606/06/2024Election of Directors: Laura LangDIRECTOR ELECTIONSISSUER2263825.0000000FOR2263825.000000FORS000002088Oscar Health, Inc.687793109US687793109606/06/2024Election of Directors: David PlouffeDIRECTOR ELECTIONSISSUER2263825.0000000FOR2263825.000000FORS000002088Oscar Health, Inc.687793109US687793109606/06/2024Election of Directors: Elbert O. Robinson, Jr.DIRECTOR ELECTIONSISSUER2263825.0000000FOR2263825.000000FORS000002088Oscar Health, Inc.687793109US687793109606/06/2024Election of Directors: Siddhartha SankaranDIRECTOR ELECTIONSISSUER2263825.0000000FOR2263825.000000FORS000002088Oscar Health, Inc.687793109US687793109606/06/2024Election of Directors: Mario SchlosserDIRECTOR ELECTIONSISSUER2263825.0000000FOR2263825.000000FORS000002088Oscar Health, Inc.687793109US687793109606/06/2024Election of Directors: Vanessa A. WittmanDIRECTOR ELECTIONSISSUER2263825.0000000FOR2263825.000000FORS000002088Oscar Health, Inc.687793109US687793109606/06/2024Ratification of the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024.AUDIT-RELATEDISSUER2263825.0000000FOR2263825.000000FORS000002088Oscar Health, Inc.687793109US687793109606/06/2024Approval, on an advisory (non-binding) basis, of the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER2263825.0000000FOR2263825.000000FORS000002088Sana Biotechnology, Inc.799566104US799566104506/06/2024To elect three Class III directors to our Board of Directors, each to serve for a three-year term expiring at the 2027 annual meeting of stockholders or until his or her respective successor is duly elected and qualified. The three nominees for election are: Joshua H. Bilenker, M.D.DIRECTOR ELECTIONSISSUER2659295.0000000FOR2659295.000000FORS000002088Sana Biotechnology, Inc.799566104US799566104506/06/2024To elect three Class III directors to our Board of Directors, each to serve for a three-year term expiring at the 2027 annual meeting of stockholders or until his or her respective successor is duly elected and qualified. The three nominees for election are: Richard Mulligan, Ph.D.DIRECTOR ELECTIONSISSUER2659295.0000000FOR2659295.000000FORS000002088Sana Biotechnology, Inc.799566104US799566104506/06/2024To elect three Class III directors to our Board of Directors, each to serve for a three-year term expiring at the 2027 annual meeting of stockholders or until his or her respective successor is duly elected and qualified. The three nominees for election are: Mary Agnes (Maggie) WilderotterDIRECTOR ELECTIONSISSUER2659295.0000000FOR2659295.000000FORS000002088Sana Biotechnology, Inc.799566104US799566104506/06/2024To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024.AUDIT-RELATEDISSUER2659295.0000000FOR2659295.000000FORS000002088Sarepta Therapeutics, Inc.803607100US803607100406/06/2024to elect, as Class I directors to hold office until 2026 annual meeting of stockholders, or until their successors are earlier elected, the following director nominees: Douglas S. IngramDIRECTOR ELECTIONSISSUER253353.0000000FOR253353.000000FORS000002088Sarepta Therapeutics, Inc.803607100US803607100406/06/2024to elect, as Class I directors to hold office until 2026 annual meeting of stockholders, or until their successors are earlier elected, the following director nominees: Hans Wigzell, M.D., Ph.D.DIRECTOR ELECTIONSISSUER253353.0000000AGAINST253353.000000AGAINSTS000002088Sarepta Therapeutics, Inc.803607100US803607100406/06/2024to elect, as Class I directors to hold office until 2026 annual meeting of stockholders, or until their successors are earlier elected, the following director nominees: Kathryn J. Boor, Ph.D.DIRECTOR ELECTIONSISSUER253353.0000000AGAINST253353.000000AGAINSTS000002088Sarepta Therapeutics, Inc.803607100US803607100406/06/2024to elect, as Class I directors to hold office until 2026 annual meeting of stockholders, or until their successors are earlier elected, the following director nominees: Michael ChambersDIRECTOR ELECTIONSISSUER253353.0000000AGAINST253353.000000AGAINSTS000002088Sarepta Therapeutics, Inc.803607100US803607100406/06/2024advisory vote to approve, on a non-binding basis, name executive officer compensationSECTION 14A SAY-ON-PAY VOTESISSUER253353.0000000FOR253353.000000FORS000002088Sarepta Therapeutics, Inc.803607100US803607100406/06/2024ratify the selection of KPMG LLP as the Company's independent registered public accounting firm for the current year ending December 31, 2024AUDIT-RELATEDISSUER253353.0000000FOR253353.000000FORS000002088Soleno Therapeutics, Inc.834203309US834203309406/06/2024To elect one Class I director to serve until the 2027 Annual Meeting of stockholders or until his successor is duly elected and qualified: Andrew SinclairDIRECTOR ELECTIONSISSUER62594.0000000FOR62594.000000FORS000002088Soleno Therapeutics, Inc.834203309US834203309406/06/2024To ratify the appointment of Marcum LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024.AUDIT-RELATEDISSUER62594.0000000FOR62594.000000FORS000002088Soleno Therapeutics, Inc.834203309US834203309406/06/2024To approve the amended and restated 2014 Equity Incentive Plan.COMPENSATIONISSUER62594.0000000AGAINST62594.000000AGAINSTS000002088Surgery Partners, Inc.86881A100US86881A100706/06/2024Election of Class III Directors: Clifford G. AdlerzDIRECTOR ELECTIONSISSUER746708.0000000FOR746708.000000FORS000002088Surgery Partners, Inc.86881A100US86881A100706/06/2024Election of Class III Directors: J. Eric EvansDIRECTOR ELECTIONSISSUER746708.0000000FOR746708.000000FORS000002088Surgery Partners, Inc.86881A100US86881A100706/06/2024Election of Class III Directors: Blair E. HendrixDIRECTOR ELECTIONSISSUER746708.0000000WITHHOLD746708.000000AGAINSTS000002088Surgery Partners, Inc.86881A100US86881A100706/06/2024Election of Class III Directors: Andrew T. KaplanDIRECTOR ELECTIONSISSUER746708.0000000FOR746708.000000FORS000002088Surgery Partners, Inc.86881A100US86881A100706/06/2024Approval, on an advisory basis, of the compensation paid by the Company to its named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER746708.0000000FOR746708.000000FORS000002088Surgery Partners, Inc.86881A100US86881A100706/06/2024Approval of the Surgery Partners, Inc. Employee Stock Purchase Plan.COMPENSATIONISSUER746708.0000000FOR746708.000000FORS000002088Surgery Partners, Inc.86881A100US86881A100706/06/2024Ratification of the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024.AUDIT-RELATEDISSUER746708.0000000FOR746708.000000FORS000002088Vaxcyte, Inc.92243G108US92243G108506/06/2024Election of Class I Directors Nominees would serve until the 2027 Annual Meeting of Stockholders and until their successors have been duly elected and qualified, or, if sooner, until the director's death, resignation or removal: Annie DrapeauDIRECTOR ELECTIONSISSUER757364.0000000FOR757364.000000FORS000002088Vaxcyte, Inc.92243G108US92243G108506/06/2024Election of Class I Directors Nominees would serve until the 2027 Annual Meeting of Stockholders and until their successors have been duly elected and qualified, or, if sooner, until the director's death, resignation or removal: Teri LoxamDIRECTOR ELECTIONSISSUER757364.0000000FOR757364.000000FORS000002088Vaxcyte, Inc.92243G108US92243G108506/06/2024Election of Class I Directors Nominees would serve until the 2027 Annual Meeting of Stockholders and until their successors have been duly elected and qualified, or, if sooner, until the director's death, resignation or removal: Carlos Paya, M.D., Ph.D.DIRECTOR ELECTIONSISSUER757364.0000000FOR757364.000000FORS000002088Vaxcyte, Inc.92243G108US92243G108506/06/2024Ratification of the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024.AUDIT-RELATEDISSUER757364.0000000FOR757364.000000FORS000002088Vaxcyte, Inc.92243G108US92243G108506/06/2024Approval, on a non-binding, advisory basis, of the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER757364.0000000FOR757364.000000FORS000002088Akero Therapeutics, Inc.00973Y108US00973Y108206/07/2024Election of Class II Directors to serve until the 2027 annual meeting of stockholders and until his or her successor has been duly elected and qualified: Seth L. Harrison, M.D.DIRECTOR ELECTIONSISSUER712826.0000000WITHHOLD712826.000000AGAINSTS000002088Akero Therapeutics, Inc.00973Y108US00973Y108206/07/2024Election of Class II Directors to serve until the 2027 annual meeting of stockholders and until his or her successor has been duly elected and qualified: Graham Walmsley, M.D., Ph.DDIRECTOR ELECTIONSISSUER712826.0000000WITHHOLD712826.000000AGAINSTS000002088Akero Therapeutics, Inc.00973Y108US00973Y108206/07/2024Election of Class II Directors to serve until the 2027 annual meeting of stockholders and until his or her successor has been duly elected and qualified: Yuan Xu, Ph.DDIRECTOR ELECTIONSISSUER712826.0000000WITHHOLD712826.000000AGAINSTS000002088Akero Therapeutics, Inc.00973Y108US00973Y108206/07/2024To ratify the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024.AUDIT-RELATEDISSUER712826.0000000FOR712826.000000FORS000002088Akero Therapeutics, Inc.00973Y108US00973Y108206/07/2024To consider and act upon a non-binding, advisory vote to approve the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER712826.0000000FOR712826.000000FORS000002088Akero Therapeutics, Inc.00973Y108US00973Y108206/07/2024To approve an Amendment to our Fourth Amended and Restated Certificate of Incorporation, to limit the liability of certain officers of Akero Therapeutics, Inc., as permitted by recent amendments to Delaware law.CORPORATE GOVERNANCEISSUER712826.0000000FOR712826.000000FORS000002088Crinetics Pharmaceuticals, Inc.22663K107US22663K107906/07/2024To elect two directors to serve as Class III directors for a three-year term to expire at the 2027 annual meeting of stockholders: Camille Bedrosian, M.D.DIRECTOR ELECTIONSISSUER1044810.0000000FOR1044810.000000FORS000002088Crinetics Pharmaceuticals, Inc.22663K107US22663K107906/07/2024To elect two directors to serve as Class III directors for a three-year term to expire at the 2027 annual meeting of stockholders: Wendell Wierenga, Ph.D.DIRECTOR ELECTIONSISSUER1044810.0000000FOR1044810.000000FORS000002088Crinetics Pharmaceuticals, Inc.22663K107US22663K107906/07/2024To consider and vote upon the ratification of the selection of BDO USA, P.C. as our independent registered public accounting firm for the fiscal year ending December 31, 2024;AUDIT-RELATEDISSUER1044810.0000000FOR1044810.000000FORS000002088Crinetics Pharmaceuticals, Inc.22663K107US22663K107906/07/2024To consider and vote upon, on an advisory basis, the compensation of the Company's named executive officers as disclosed in the proxy statement pursuant to the compensation disclosure rules of the Securities and Exchange Commission; andSECTION 14A SAY-ON-PAY VOTESISSUER1044810.0000000FOR1044810.000000FORS000002088Fate Therapeutics, Inc.31189P102US31189P102106/07/2024Election of Class II Directors: William H. Rastetter, Ph.D.DIRECTOR ELECTIONSISSUER145535.0000000FOR145535.000000FORS000002088Fate Therapeutics, Inc.31189P102US31189P102106/07/2024Election of Class II Directors: Michael LeeDIRECTOR ELECTIONSISSUER145535.0000000FOR145535.000000FORS000002088Fate Therapeutics, Inc.31189P102US31189P102106/07/2024Election of Class II Directors: Yuan Xu, Ph.D.DIRECTOR ELECTIONSISSUER145535.0000000FOR145535.000000FORS000002088Fate Therapeutics, Inc.31189P102US31189P102106/07/2024To ratify the appointment of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2024.AUDIT-RELATEDISSUER145535.0000000FOR145535.000000FORS000002088Fate Therapeutics, Inc.31189P102US31189P102106/07/2024To approve, on an advisory basis, the compensation of the Company's named executive officers as disclosed in the proxy statement.SECTION 14A SAY-ON-PAY VOTESISSUER145535.0000000AGAINST145535.000000AGAINSTS000002088Fate Therapeutics, Inc.31189P102US31189P102106/07/2024To approve an amendment to the Company's Amended and Restated Certificate of Incorporation to include an officer exculpation provision that limits the liability of certain of its officers as permitted under current Delaware law.CORPORATE GOVERNANCEISSUER145535.0000000FOR145535.000000FORS000002088Fate Therapeutics, Inc.31189P102US31189P102106/07/2024To approve the amendment and restatement of the Company's 2022 Stock Option and Incentive Plan to increase the number of shares of common stock reserved for issuance thereunder.COMPENSATIONISSUER145535.0000000AGAINST145535.000000AGAINSTS000002088Fate Therapeutics, Inc.31189P102US31189P102106/07/2024To approve the adjournment of the Annual Meeting to the extent there are insufficient votes at the Annual Meeting to approve any of the above proposals.CORPORATE GOVERNANCEISSUER145535.0000000AGAINST145535.000000AGAINSTS000002088Atara Biotherapeutics, Inc.046513206US046513206806/10/2024Election of Directors: William K. HeidenDIRECTOR ELECTIONSISSUER3898350.0000000FOR3898350.000000FORS000002088Atara Biotherapeutics, Inc.046513206US046513206806/10/2024Election of Directors: Ameet MallikDIRECTOR ELECTIONSISSUER3898350.0000000FOR3898350.000000FORS000002088Atara Biotherapeutics, Inc.046513206US046513206806/10/2024To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the Proxy Statement.SECTION 14A SAY-ON-PAY VOTESISSUER3898350.0000000FOR3898350.000000FORS000002088Atara Biotherapeutics, Inc.046513206US046513206806/10/2024To ratify the selection of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024.AUDIT-RELATEDISSUER3898350.0000000FOR3898350.000000FORS000002088Atara Biotherapeutics, Inc.046513206US046513206806/10/2024To approve the Company's 2024 Equity Incentive Plan.COMPENSATIONISSUER3898350.0000000FOR3898350.000000FORS000002088Atara Biotherapeutics, Inc.046513206US046513206806/10/2024To approve an automatic annual increase to the Company's 2024 Equity Incentive Plan.COMPENSATIONISSUER3898350.0000000AGAINST3898350.000000AGAINSTS000002088Atara Biotherapeutics, Inc.046513206US046513206806/10/2024To approve an increase in the number of shares of common stock available for issuance under the Company's 2014 Employee Stock Purchase Plan.COMPENSATIONISSUER3898350.0000000FOR3898350.000000FORS000002088Atara Biotherapeutics, Inc.046513206US046513206806/10/2024To approve an amendment to the Company's amended and restated certificate of incorporation to effect a reverse stock split of the Company's common stock at a ratio ranging from any whole number between 1-for-4 and 1-for-30, as determined by the Board of Directors in its discretion, subject to the Board of Directors' authority to abandon such amendments (the "Charter Amendment Proposal").CAPITAL STRUCTUREISSUER3898350.0000000FOR3898350.000000FORS000002088Atara Biotherapeutics, Inc.046513206US046513206806/10/2024To approve the adjournment of the Annual Meeting to a later date or dates, if necessary, to permit further solicitation and vote of proxies in the event there are not sufficient votes in favor of the Charter Amendment Proposal.CORPORATE GOVERNANCEISSUER3898350.0000000AGAINST3898350.000000AGAINSTS000002088SAGE Therapeutics, Inc.78667J108US78667J108806/10/2024To elect two directors, Elizabeth Barrett and Geno Germano, each to serve as a Class I director until the 2027 Annual Meeting of Stockholders and until his or her successor is duly elected and qualified, subject to his or her earlier death, resignation, or removal: Elizabeth BarrettDIRECTOR ELECTIONSISSUER490075.0000000FOR490075.000000FORS000002088SAGE Therapeutics, Inc.78667J108US78667J108806/10/2024To elect two directors, Elizabeth Barrett and Geno Germano, each to serve as a Class I director until the 2027 Annual Meeting of Stockholders and until his or her successor is duly elected and qualified, subject to his or her earlier death, resignation, or removal: Geno GermanoDIRECTOR ELECTIONSISSUER490075.0000000FOR490075.000000FORS000002088SAGE Therapeutics, Inc.78667J108US78667J108806/10/2024To ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024AUDIT-RELATEDISSUER490075.0000000FOR490075.000000FORS000002088SAGE Therapeutics, Inc.78667J108US78667J108806/10/2024To hold a non-binding advisory vote to approve the compensation paid to our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER490075.0000000FOR490075.000000FORS000002088SAGE Therapeutics, Inc.78667J108US78667J108806/10/2024To approve the Sage Therapeutics, Inc. 2024 Equity Incentive Plan.COMPENSATIONISSUER490075.0000000FOR490075.000000FORS00000208810X Genomics, Inc.88025U109US88025U109706/11/2024Election of Directors: Election of the one Class II director listed in the accompanying proxy statement, to serve a three-year term expiring at the 2027 annual meeting of stockholders or until such director's successor is duly elected and qualified or until such director's earlier death, resignation, disqualification or removal; Kimberly J. PopovitsDIRECTOR ELECTIONSISSUER1814422.0000000AGAINST1814422.000000AGAINSTS00000208810X Genomics, Inc.88025U109US88025U109706/11/2024Ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024;AUDIT-RELATEDISSUER1814422.0000000FOR1814422.000000FORS00000208810X Genomics, Inc.88025U109US88025U109706/11/2024A vote to approve an amendment to our amended and restated bylaws such that the bylaws may be amended by our board of directors without requiring stockholder approval;CORPORATE GOVERNANCEISSUER1814422.0000000AGAINST1814422.000000AGAINSTS00000208810X Genomics, Inc.88025U109US88025U109706/11/2024A vote to approve, on a non-binding, advisory basis, the compensation of our named executive officers; andSECTION 14A SAY-ON-PAY VOTESISSUER1814422.0000000AGAINST1814422.000000AGAINSTS000002088IGM Biosciences, Inc.449585108US449585108506/11/2024Election of Directors: M. Kathleen Behrens, Ph.D.DIRECTOR ELECTIONSISSUER964738.0000000FOR964738.000000FORS000002088IGM Biosciences, Inc.449585108US449585108506/11/2024Election of Directors: Elizabeth H.Z. Thompson, Ph.D.DIRECTOR ELECTIONSISSUER964738.0000000FOR964738.000000FORS000002088IGM Biosciences, Inc.449585108US449585108506/11/2024Election of Directors: Christina Teng TopsoeDIRECTOR ELECTIONSISSUER964738.0000000FOR964738.000000FORS000002088IGM Biosciences, Inc.449585108US449585108506/11/2024Ratification of the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2024.AUDIT-RELATEDISSUER964738.0000000FOR964738.000000FORS000002088IGM Biosciences, Inc.449585108US449585108506/11/2024Approval of an amendment to our amended and restated certificate of incorporation to limit the liability of certain officers as permitted by Delaware law.CORPORATE GOVERNANCEISSUER964738.0000000FOR964738.000000FORS000002088IGM Biosciences, Inc.449585108US449585108506/11/2024Approval of a stock option exchange program for employees (excluding our chief executive officer and non-employee directors).COMPENSATIONISSUER964738.0000000FOR964738.000000FORS000002088Iovance Biotherapeutics, Inc.462260100US462260100706/11/2024To elect seven directors named in the proxy statement accompanying this notice to serve until the 2025 Annual Meeting of Stockholders: Iain Dukes, D. Phil.DIRECTOR ELECTIONSISSUER2590914.0000000FOR2590914.000000FORS000002088Iovance Biotherapeutics, Inc.462260100US462260100706/11/2024To elect seven directors named in the proxy statement accompanying this notice to serve until the 2025 Annual Meeting of Stockholders: Athena Countouriotis, M.D.DIRECTOR ELECTIONSISSUER2590914.0000000FOR2590914.000000FORS000002088Iovance Biotherapeutics, Inc.462260100US462260100706/11/2024To elect seven directors named in the proxy statement accompanying this notice to serve until the 2025 Annual Meeting of Stockholders: Ryan MaynardDIRECTOR ELECTIONSISSUER2590914.0000000FOR2590914.000000FORS000002088Iovance Biotherapeutics, Inc.462260100US462260100706/11/2024To elect seven directors named in the proxy statement accompanying this notice to serve until the 2025 Annual Meeting of Stockholders: Wayne P. RothbaumDIRECTOR ELECTIONSISSUER2590914.0000000FOR2590914.000000FORS000002088Iovance Biotherapeutics, Inc.462260100US462260100706/11/2024To elect seven directors named in the proxy statement accompanying this notice to serve until the 2025 Annual Meeting of Stockholders: Frederick G. Vogt, Ph.D., J.D.DIRECTOR ELECTIONSISSUER2590914.0000000FOR2590914.000000FORS000002088Iovance Biotherapeutics, Inc.462260100US462260100706/11/2024To elect seven directors named in the proxy statement accompanying this notice to serve until the 2025 Annual Meeting of Stockholders: Michael Weiser M.D., Ph.D.DIRECTOR ELECTIONSISSUER2590914.0000000FOR2590914.000000FORS000002088Iovance Biotherapeutics, Inc.462260100US462260100706/11/2024To elect seven directors named in the proxy statement accompanying this notice to serve until the 2025 Annual Meeting of Stockholders: Wendy YarnoDIRECTOR ELECTIONSISSUER2590914.0000000FOR2590914.000000FORS000002088Iovance Biotherapeutics, Inc.462260100US462260100706/11/2024To approve, by non-binding advisory vote, the compensation of our named executive officers;SECTION 14A SAY-ON-PAY VOTESISSUER2590914.0000000FOR2590914.000000FORS000002088Iovance Biotherapeutics, Inc.462260100US462260100706/11/2024To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2024;AUDIT-RELATEDISSUER2590914.0000000FOR2590914.000000FORS000002088Iovance Biotherapeutics, Inc.462260100US462260100706/11/2024To approve an amendment to our 2018 Equity Incentive Plan to increase the number of shares of the Company's common stock authorized for issuance thereunder from 29,700,000 shares to 36,700,000 shares and permit share recapture from our 2014 Equity Incentive Plan; andCOMPENSATIONISSUER2590914.0000000FOR2590914.000000FORS000002088Iovance Biotherapeutics, Inc.462260100US462260100706/11/2024To approve an amendment to our 2020 Employee Stock Purchase Plan to increase the number of shares of the Company's common stock authorized for issuance thereunder from 1,400,000 shares to 1,900,000 shares.COMPENSATIONISSUER2590914.0000000FOR2590914.000000FORS000002088Sonova Holding AGH8024W106CH001254978506/11/2024Accept Financial Statements and Statutory ReportsCORPORATE GOVERNANCEISSUER102065.0000000FOR102065.000000FORS000002088Sonova Holding AGH8024W106CH001254978506/11/2024Approve Non-Financial Report (Non-Binding)CORPORATE GOVERNANCEENVIRONMENT OR CLIMATEHUMAN RIGHTS OR HUMAN CAPITAL/WORKFORCEDIVERSITY, EQUITY, AND INCLUSIONOTHER SOCIAL ISSUESISSUER102065.0000000FOR102065.000000FORS000002088Sonova Holding AGH8024W106CH001254978506/11/2024Approve Remuneration Report (Non-Binding)COMPENSATIONISSUER102065.0000000AGAINST102065.000000AGAINSTS000002088Sonova Holding AGH8024W106CH001254978506/11/2024Approve Allocation of Income and Dividends of CHF 4.30 per ShareCAPITAL STRUCTUREISSUER102065.0000000FOR102065.000000FORS000002088Sonova Holding AGH8024W106CH001254978506/11/2024Approve Discharge of Board and Senior ManagementCORPORATE GOVERNANCEISSUER102065.0000000FOR102065.000000FORS000002088Sonova Holding AGH8024W106CH001254978506/11/2024Reelect Robert Spoerry as Director and Board ChairDIRECTOR ELECTIONSISSUER102065.0000000FOR102065.000000FORS000002088Sonova Holding AGH8024W106CH001254978506/11/2024Reelect Stacy Seng as DirectorDIRECTOR ELECTIONSISSUER102065.0000000FOR102065.000000FORS000002088Sonova Holding AGH8024W106CH001254978506/11/2024Reelect Gregory Behar as DirectorDIRECTOR ELECTIONSISSUER102065.0000000FOR102065.000000FORS000002088Sonova Holding AGH8024W106CH001254978506/11/2024Reelect Lynn Bleil as DirectorDIRECTOR ELECTIONSISSUER102065.0000000FOR102065.000000FORS000002088Sonova Holding AGH8024W106CH001254978506/11/2024Reelect Lukas Braunschweiler as DirectorDIRECTOR ELECTIONSISSUER102065.0000000FOR102065.000000FORS000002088Sonova Holding AGH8024W106CH001254978506/11/2024Reelect Roland Diggelmann as DirectorDIRECTOR ELECTIONSISSUER102065.0000000FOR102065.000000FORS000002088Sonova Holding AGH8024W106CH001254978506/11/2024Reelect Julie Tay as DirectorDIRECTOR ELECTIONSISSUER102065.0000000FOR102065.000000FORS000002088Sonova Holding AGH8024W106CH001254978506/11/2024Reelect Ronald van der Vis as DirectorDIRECTOR ELECTIONSISSUER102065.0000000FOR102065.000000FORS000002088Sonova Holding AGH8024W106CH001254978506/11/2024Reelect Adrian Widmer as DirectorDIRECTOR ELECTIONSISSUER102065.0000000FOR102065.000000FORS000002088Sonova Holding AGH8024W106CH001254978506/11/2024Elect Gilbert Achermann as DirectorDIRECTOR ELECTIONSISSUER102065.0000000FOR102065.000000FORS000002088Sonova Holding AGH8024W106CH001254978506/11/2024Reappoint Roland Diggelmann as Member of the Nomination and Compensation CommitteeDIRECTOR ELECTIONSCORPORATE GOVERNANCEISSUER102065.0000000FOR102065.000000FORS000002088Sonova Holding AGH8024W106CH001254978506/11/2024Reappoint Lukas Braunschweiler as Member of the Nomination and Compensation CommitteeDIRECTOR ELECTIONSCORPORATE GOVERNANCEISSUER102065.0000000FOR102065.000000FORS000002088Sonova Holding AGH8024W106CH001254978506/11/2024Reappoint Stacy Seng as Member of the Nomination and Compensation CommitteeDIRECTOR ELECTIONSCORPORATE GOVERNANCEISSUER102065.0000000FOR102065.000000FORS000002088Sonova Holding AGH8024W106CH001254978506/11/2024Reappoint Julie Tay as Member of the Nomination and Compensation CommitteeDIRECTOR ELECTIONSCORPORATE GOVERNANCEISSUER102065.0000000FOR102065.000000FORS000002088Sonova Holding AGH8024W106CH001254978506/11/2024Ratify Ernst & Young AG as AuditorsAUDIT-RELATEDISSUER102065.0000000FOR102065.000000FORS000002088Sonova Holding AGH8024W106CH001254978506/11/2024Designate Keller AG as Independent ProxyCORPORATE GOVERNANCEISSUER102065.0000000FOR102065.000000FORS000002088Sonova Holding AGH8024W106CH001254978506/11/2024Approve Remuneration of Directors in the Amount of CHF 3.5 MillionCOMPENSATIONISSUER102065.0000000FOR102065.000000FORS000002088Sonova Holding AGH8024W106CH001254978506/11/2024Approve Remuneration of Executive Committee in the Amount of CHF 16.8 MillionCOMPENSATIONISSUER102065.0000000FOR102065.000000FORS000002088Sonova Holding AGH8024W106CH001254978506/11/2024Transact Other Business (Voting)CORPORATE GOVERNANCEISSUER102065.0000000AGAINST102065.000000AGAINSTS000002088Alector, Inc.014442107US014442107206/12/2024ELECTION OF DIRECTORS: Louis J. Lavigne, Jr.DIRECTOR ELECTIONSISSUER598575.0000000FOR598575.000000FORS000002088Alector, Inc.014442107US014442107206/12/2024ELECTION OF DIRECTORS: Richard H. Scheller, Ph.D.DIRECTOR ELECTIONSISSUER598575.0000000FOR598575.000000FORS000002088Alector, Inc.014442107US014442107206/12/2024ELECTION OF DIRECTORS: Mark AltmeyerDIRECTOR ELECTIONSISSUER598575.0000000FOR598575.000000FORS000002088Alector, Inc.014442107US014442107206/12/2024Ratification of the appointment of Ernst & Young, LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2024.AUDIT-RELATEDISSUER598575.0000000FOR598575.000000FORS000002088Alector, Inc.014442107US014442107206/12/2024Advisory vote on executive compensation.SECTION 14A SAY-ON-PAY VOTESISSUER598575.0000000FOR598575.000000FORS000002088ALX Oncology Holdings, Inc.00166B105US00166B105206/12/2024Election of Directors: Corey Goodman, Ph.D.DIRECTOR ELECTIONSISSUER116315.0000000FOR116315.000000FORS000002088ALX Oncology Holdings, Inc.00166B105US00166B105206/12/2024Election of Directors: Jason LettmannDIRECTOR ELECTIONSISSUER116315.0000000WITHHOLD116315.000000AGAINSTS000002088ALX Oncology Holdings, Inc.00166B105US00166B105206/12/2024Election of Directors: Sophia Randolph, M.D., Ph.D.DIRECTOR ELECTIONSISSUER116315.0000000WITHHOLD116315.000000AGAINSTS000002088ALX Oncology Holdings, Inc.00166B105US00166B105206/12/2024Advisory vote to approve named executive officer compensation.SECTION 14A SAY-ON-PAY VOTESISSUER116315.0000000FOR116315.000000FORS000002088ALX Oncology Holdings, Inc.00166B105US00166B105206/12/2024Ratification of the appointment of KPMG LLP as the independent registered public accounting firm for our fiscal year ending December 31, 2024.AUDIT-RELATEDISSUER116315.0000000FOR116315.000000FORS000002088AnaptysBio, Inc.032724106US032724106506/12/2024To elect three Class I directors, each to serve three-year terms through the third annual meeting of stockholders following this meeting and until a successor has been elected and qualified or until earlier resignation or removal: Daniel FagaDIRECTOR ELECTIONSISSUER191030.0000000FOR191030.000000FORS000002088AnaptysBio, Inc.032724106US032724106506/12/2024To elect three Class I directors, each to serve three-year terms through the third annual meeting of stockholders following this meeting and until a successor has been elected and qualified or until earlier resignation or removal: Dennis Fenton, Ph.D.DIRECTOR ELECTIONSISSUER191030.0000000WITHHOLD191030.000000AGAINSTS000002088AnaptysBio, Inc.032724106US032724106506/12/2024To elect three Class I directors, each to serve three-year terms through the third annual meeting of stockholders following this meeting and until a successor has been elected and qualified or until earlier resignation or removal: Oleg NodelmanDIRECTOR ELECTIONSISSUER191030.0000000FOR191030.000000FORS000002088AnaptysBio, Inc.032724106US032724106506/12/2024To ratify the appointment of KPMG LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024.AUDIT-RELATEDISSUER191030.0000000FOR191030.000000FORS000002088AnaptysBio, Inc.032724106US032724106506/12/2024To conduct a non-binding advisory vote on the compensation of our named executive officers as disclosed in the accompanying materials.SECTION 14A SAY-ON-PAY VOTESISSUER191030.0000000AGAINST191030.000000AGAINSTS000002088AnaptysBio, Inc.032724106US032724106506/12/2024To approve the amendment and restatement of our 2017 Equity Incentive Plan.COMPENSATIONISSUER191030.0000000AGAINST191030.000000AGAINSTS000002088Blueprint Medicines Corporation09627Y109US09627Y109106/12/2024Election of Directors: Daniella BeckmanDIRECTOR ELECTIONSISSUER2143840.0000000FOR2143840.000000FORS000002088Blueprint Medicines Corporation09627Y109US09627Y109106/12/2024Election of Directors: Habib DableDIRECTOR ELECTIONSISSUER2143840.0000000FOR2143840.000000FORS000002088Blueprint Medicines Corporation09627Y109US09627Y109106/12/2024Election of Directors: Lynn SeelyDIRECTOR ELECTIONSISSUER2143840.0000000FOR2143840.000000FORS000002088Blueprint Medicines Corporation09627Y109US09627Y109106/12/2024Approval of a non-binding advisory vote on the frequency of future advisory votes on the compensation paid to our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER2143840.0000000ONE YEAR2143840.000000FORS000002088Blueprint Medicines Corporation09627Y109US09627Y109106/12/2024Approval of a non-binding advisory vote on the compensation paid to our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER2143840.0000000FOR2143840.000000FORS000002088Blueprint Medicines Corporation09627Y109US09627Y109106/12/2024Approval of the Blueprint Medicines Corporation 2024 Stock Incentive Plan.COMPENSATIONISSUER2143840.0000000FOR2143840.000000FORS000002088Blueprint Medicines Corporation09627Y109US09627Y109106/12/2024Ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024.AUDIT-RELATEDISSUER2143840.0000000FOR2143840.000000FORS000002088Disc Medicine, Inc.254604101US254604101106/12/2024ELECTION OF DIRECTORS: Mona AshiyaDIRECTOR ELECTIONSISSUER172151.0000000FOR172151.000000FORS000002088Disc Medicine, Inc.254604101US254604101106/12/2024ELECTION OF DIRECTORS: Kevin BittermanDIRECTOR ELECTIONSISSUER172151.0000000FOR172151.000000FORS000002088Disc Medicine, Inc.254604101US254604101106/12/2024To ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024.AUDIT-RELATEDISSUER172151.0000000FOR172151.000000FORS000002088Guardant Health, Inc.40131M109US40131M109906/12/2024Election of Class III Directors: Helmy EltoukhyDIRECTOR ELECTIONSISSUER569132.0000000FOR569132.000000FORS000002088Guardant Health, Inc.40131M109US40131M109906/12/2024Election of Class III Directors: Steve KrognesDIRECTOR ELECTIONSISSUER569132.0000000FOR569132.000000FORS000002088Guardant Health, Inc.40131M109US40131M109906/12/2024Election of Class III Directors: AmirAli TalasazDIRECTOR ELECTIONSISSUER569132.0000000FOR569132.000000FORS000002088Guardant Health, Inc.40131M109US40131M109906/12/2024Ratification of the appointment of Deloitte & Touche LLP as Guardant Health, Inc.'s independent registered public accounting firm for the year ending December 31, 2024.AUDIT-RELATEDISSUER569132.0000000FOR569132.000000FORS000002088Guardant Health, Inc.40131M109US40131M109906/12/2024Non-binding advisory vote to approve Guardant Health, Inc.'s named executive officer compensation.SECTION 14A SAY-ON-PAY VOTESISSUER569132.0000000FOR569132.000000FORS000002088Immuneering Corporation45254E107US45254E107306/12/2024Election of two Class III Directors: Robert J. CarpenterDIRECTOR ELECTIONSISSUER603701.0000000WITHHOLD603701.000000AGAINSTS000002088Immuneering Corporation45254E107US45254E107306/12/2024Election of two Class III Directors: Benjamin J. Zeskind, Ph.D.DIRECTOR ELECTIONSISSUER603701.0000000FOR603701.000000FORS000002088Immuneering Corporation45254E107US45254E107306/12/2024Ratify the appointment of RSM US LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024.AUDIT-RELATEDISSUER603701.0000000FOR603701.000000FORS000002088Immunome, Inc.45257U108US45257U108806/12/2024Election of the two nominees for Class I director named herein to hold office until the 2027 annual meeting of stockholders and until his or her respective successor has been duly elected and qualified, or until his or her respective earlier death, resignation or removal: Clay B. Siegall, Ph.D.DIRECTOR ELECTIONSISSUER1490119.0000000FOR1490119.000000FORS000002088Immunome, Inc.45257U108US45257U108806/12/2024Election of the two nominees for Class I director named herein to hold office until the 2027 annual meeting of stockholders and until his or her respective successor has been duly elected and qualified, or until his or her respective earlier death, resignation or removal: Carol SchaferDIRECTOR ELECTIONSISSUER1490119.0000000FOR1490119.000000FORS000002088Immunome, Inc.45257U108US45257U108806/12/2024To ratify, in a non-binding vote, the appointment by the Audit Committee of the Board of Directors of Ernst & Young LLP as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2024.AUDIT-RELATEDISSUER1490119.0000000FOR1490119.000000FORS000002088Incyte Corporation45337C102US45337C102706/12/2024Election of Directors: Julian C. BakerDIRECTOR ELECTIONSISSUER290290.0000000FOR290290.000000FORS000002088Incyte Corporation45337C102US45337C102706/12/2024Election of Directors: Jean-Jacques BienaimeDIRECTOR ELECTIONSISSUER290290.0000000FOR290290.000000FORS000002088Incyte Corporation45337C102US45337C102706/12/2024Election of Directors: Otis W. BrawleyDIRECTOR ELECTIONSISSUER290290.0000000FOR290290.000000FORS000002088Incyte Corporation45337C102US45337C102706/12/2024Election of Directors: Paul J. ClancyDIRECTOR ELECTIONSISSUER290290.0000000FOR290290.000000FORS000002088Incyte Corporation45337C102US45337C102706/12/2024Election of Directors: Jacqualyn A. FouseDIRECTOR ELECTIONSISSUER290290.0000000FOR290290.000000FORS000002088Incyte Corporation45337C102US45337C102706/12/2024Election of Directors: Edmund P. HarriganDIRECTOR ELECTIONSISSUER290290.0000000FOR290290.000000FORS000002088Incyte Corporation45337C102US45337C102706/12/2024Election of Directors: Katherine A. HighDIRECTOR ELECTIONSISSUER290290.0000000FOR290290.000000FORS000002088Incyte Corporation45337C102US45337C102706/12/2024Election of Directors: Herve HoppenotDIRECTOR ELECTIONSISSUER290290.0000000FOR290290.000000FORS000002088Incyte Corporation45337C102US45337C102706/12/2024Election of Directors: Susanne SchaffertDIRECTOR ELECTIONSISSUER290290.0000000FOR290290.000000FORS000002088Incyte Corporation45337C102US45337C102706/12/2024Approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER290290.0000000FOR290290.000000FORS000002088Incyte Corporation45337C102US45337C102706/12/2024Ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for 2024.AUDIT-RELATEDISSUER290290.0000000FOR290290.000000FORS000002088Intellia Therapeutics, Inc.45826J105US45826J105106/12/2024Election of Directors. Election of the following individuals nominated to serve as Class II directors, for a three-year term ending at the annual meeting of stockholders to be held in 2027: Fred Cohen, M.D., D.Phil.DIRECTOR ELECTIONSISSUER55317.0000000FOR55317.000000FORS000002088Intellia Therapeutics, Inc.45826J105US45826J105106/12/2024Election of Directors. Election of the following individuals nominated to serve as Class II directors, for a three-year term ending at the annual meeting of stockholders to be held in 2027: Frank Verwiel, M.D.DIRECTOR ELECTIONSISSUER55317.0000000FOR55317.000000FORS000002088Intellia Therapeutics, Inc.45826J105US45826J105106/12/2024Ratification of the appointment of Deloitte & Touche LLP as Intellia's independent registered public accounting firm for the fiscal year ending December 31, 2024AUDIT-RELATEDISSUER55317.0000000FOR55317.000000FORS000002088Intellia Therapeutics, Inc.45826J105US45826J105106/12/2024Approve, on a non-binding advisory basis, the compensation of the named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER55317.0000000FOR55317.000000FORS000002088Intellia Therapeutics, Inc.45826J105US45826J105106/12/2024Approval of a second amendment to our Second Amended and Restated Certificate of Incorporation, as amended, to limit the liability of certain officers of the Company as permitted by recent amendments to the Delaware General Corporation Law.CORPORATE GOVERNANCEISSUER55317.0000000FOR55317.000000FORS000002088Monte Rosa Therapeutics, Inc.61225M102US61225M102706/12/2024To elect two Class III director nominees to our board of directors, to serve until the Company's 2027 annual meeting of stockholders and until their successor has been duly elected and qualified, or until their earlier death, resignation or removal: Markus WarmuthDIRECTOR ELECTIONSISSUER818568.0000000FOR818568.000000FORS000002088Monte Rosa Therapeutics, Inc.61225M102US61225M102706/12/2024To elect two Class III director nominees to our board of directors, to serve until the Company's 2027 annual meeting of stockholders and until their successor has been duly elected and qualified, or until their earlier death, resignation or removal: Ali BehbahaniDIRECTOR ELECTIONSISSUER818568.0000000WITHHOLD818568.000000AGAINSTS000002088Monte Rosa Therapeutics, Inc.61225M102US61225M102706/12/2024To ratify the appointment of Deloitte & Touche, LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024 andAUDIT-RELATEDISSUER818568.0000000FOR818568.000000FORS000002088Nuvalent, Inc.670703107US670703107506/12/2024Election of the following nominees as Class III directors: Emily Drabant Conley, Ph.D.DIRECTOR ELECTIONSISSUER27470.0000000FOR27470.000000FORS000002088Nuvalent, Inc.670703107US670703107506/12/2024Election of the following nominees as Class III directors: Sapna Srivastava, Ph.D.DIRECTOR ELECTIONSISSUER27470.0000000FOR27470.000000FORS000002088Nuvalent, Inc.670703107US670703107506/12/2024Election of the following nominees as Class III directors: Cameron Wheeler, Ph.D.DIRECTOR ELECTIONSISSUER27470.0000000FOR27470.000000FORS000002088Nuvalent, Inc.670703107US670703107506/12/2024To approve, on an advisory basis, the compensation paid to our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER27470.0000000FOR27470.000000FORS000002088Nuvalent, Inc.670703107US670703107506/12/2024To approve, on an advisory basis, the frequency of future advisory votes to approve the compensation paid to our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER27470.0000000ONE YEAR27470.000000FORS000002088Nuvalent, Inc.670703107US670703107506/12/2024To ratify the appointment of KPMG LLP as Nuvalent, Inc.'s independent registered public accounting firm for the fiscal year ending December 31, 2024.AUDIT-RELATEDISSUER27470.0000000FOR27470.000000FORS000002088Ocular Therapeutix, Inc.67576A100US67576A100706/12/2024To elect two Class I directors, each to serve until the 2027 Annual Meeting of Stockholders and until his or her successor is duly elected and qualified: Adrienne L. Graves, Ph.D.DIRECTOR ELECTIONSISSUER745044.0000000FOR745044.000000FORS000002088Ocular Therapeutix, Inc.67576A100US67576A100706/12/2024To elect two Class I directors, each to serve until the 2027 Annual Meeting of Stockholders and until his or her successor is duly elected and qualified: Charles WardenDIRECTOR ELECTIONSISSUER745044.0000000FOR745044.000000FORS000002088Ocular Therapeutix, Inc.67576A100US67576A100706/12/2024To approve an advisory vote on named executive officer compensation.SECTION 14A SAY-ON-PAY VOTESISSUER745044.0000000FOR745044.000000FORS000002088Ocular Therapeutix, Inc.67576A100US67576A100706/12/2024To approve an amendment to the Ocular Therapeutix, Inc. 2021 Stock incentive Plan, as amended, to increase the number of shares of common stock issuable thereunder by 7,000,000 shares.COMPENSATIONISSUER745044.0000000FOR745044.000000FORS000002088Ocular Therapeutix, Inc.67576A100US67576A100706/12/2024To approve an amendment to our Restated Certificate of Incorporation, as amended, to increase the number of authorized shares of our common stock from 200,000,000 shares to 400,000,000 shares.CAPITAL STRUCTUREISSUER745044.0000000FOR745044.000000FORS000002088Ocular Therapeutix, Inc.67576A100US67576A100706/12/2024To ratify the appointment of PricewaterhouseCoopers LLP as Ocular Therapeutix's independent registered public accounting firm for the fiscal year ending December 31, 2024.AUDIT-RELATEDISSUER745044.0000000FOR745044.000000FORS000002088ORIC Pharmaceuticals, Inc.68622P109US68622P109306/12/2024Election of Directors: Richard Heyman, Ph.D.DIRECTOR ELECTIONSISSUER1162098.0000000FOR1162098.000000FORS000002088ORIC Pharmaceuticals, Inc.68622P109US68622P109306/12/2024Election of Directors: Lori Kunkel, M.D.DIRECTOR ELECTIONSISSUER1162098.0000000FOR1162098.000000FORS000002088ORIC Pharmaceuticals, Inc.68622P109US68622P109306/12/2024Ratify the appointment of KPMG LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2024.AUDIT-RELATEDISSUER1162098.0000000FOR1162098.000000FORS000002088Prime Medicine, Inc.74168J101US74168J101606/12/2024To elect Wendy Chung, M.D., Ph.D., Kaye Foster, Keith Gottesdiener, M.D., and Jeffrey Marrazzo as Class II Directors: Wendy Chung, M.D., Ph.D.DIRECTOR ELECTIONSISSUER276160.0000000FOR276160.000000FORS000002088Prime Medicine, Inc.74168J101US74168J101606/12/2024To elect Wendy Chung, M.D., Ph.D., Kaye Foster, Keith Gottesdiener, M.D., and Jeffrey Marrazzo as Class II Directors: Kaye FosterDIRECTOR ELECTIONSISSUER276160.0000000FOR276160.000000FORS000002088Prime Medicine, Inc.74168J101US74168J101606/12/2024To elect Wendy Chung, M.D., Ph.D., Kaye Foster, Keith Gottesdiener, M.D., and Jeffrey Marrazzo as Class II Directors: Keith Gottesdiener, M.D.DIRECTOR ELECTIONSISSUER276160.0000000FOR276160.000000FORS000002088Prime Medicine, Inc.74168J101US74168J101606/12/2024To elect Wendy Chung, M.D., Ph.D., Kaye Foster, Keith Gottesdiener, M.D., and Jeffrey Marrazzo as Class II Directors: Jeffrey MarrazzoDIRECTOR ELECTIONSISSUER276160.0000000FOR276160.000000FORS000002088Prime Medicine, Inc.74168J101US74168J101606/12/2024To approve an amendment to our Third Amended and Restated Certificate of Incorporation to limit the liability of certain of our officers as permitted by Delaware law.CORPORATE GOVERNANCEISSUER276160.0000000FOR276160.000000FORS000002088Prime Medicine, Inc.74168J101US74168J101606/12/2024To ratify the appointment of PricewaterhouseCoopers LLP as our Independent registered public accounting firm for the fiscal year ending December 31, 2024.AUDIT-RELATEDISSUER276160.0000000FOR276160.000000FORS000002088Veeva Systems Inc.922475108US922475108406/12/2024To elect the following to serve as directors until the annual meeting to be held in 2025 or until their successors are duly elected and qualified: Tim CabralDIRECTOR ELECTIONSISSUER330328.0000000FOR330328.000000FORS000002088Veeva Systems Inc.922475108US922475108406/12/2024To elect the following to serve as directors until the annual meeting to be held in 2025 or until their successors are duly elected and qualified: Mark CargesDIRECTOR ELECTIONSISSUER330328.0000000FOR330328.000000FORS000002088Veeva Systems Inc.922475108US922475108406/12/2024To elect the following to serve as directors until the annual meeting to be held in 2025 or until their successors are duly elected and qualified: Peter P. GassnerDIRECTOR ELECTIONSISSUER330328.0000000FOR330328.000000FORS000002088Veeva Systems Inc.922475108US922475108406/12/2024To elect the following to serve as directors until the annual meeting to be held in 2025 or until their successors are duly elected and qualified: Mary Lynne HedleyDIRECTOR ELECTIONSISSUER330328.0000000FOR330328.000000FORS000002088Veeva Systems Inc.922475108US922475108406/12/2024To elect the following to serve as directors until the annual meeting to be held in 2025 or until their successors are duly elected and qualified: Priscilla HungDIRECTOR ELECTIONSISSUER330328.0000000FOR330328.000000FORS000002088Veeva Systems Inc.922475108US922475108406/12/2024To elect the following to serve as directors until the annual meeting to be held in 2025 or until their successors are duly elected and qualified: Tina HuntDIRECTOR ELECTIONSISSUER330328.0000000FOR330328.000000FORS000002088Veeva Systems Inc.922475108US922475108406/12/2024To elect the following to serve as directors until the annual meeting to be held in 2025 or until their successors are duly elected and qualified: Marshall MohrDIRECTOR ELECTIONSISSUER330328.0000000FOR330328.000000FORS000002088Veeva Systems Inc.922475108US922475108406/12/2024To elect the following to serve as directors until the annual meeting to be held in 2025 or until their successors are duly elected and qualified: Gordon RitterDIRECTOR ELECTIONSISSUER330328.0000000FOR330328.000000FORS000002088Veeva Systems Inc.922475108US922475108406/12/2024To elect the following to serve as directors until the annual meeting to be held in 2025 or until their successors are duly elected and qualified: Paul SekhriDIRECTOR ELECTIONSISSUER330328.0000000AGAINST330328.000000AGAINSTS000002088Veeva Systems Inc.922475108US922475108406/12/2024To elect the following to serve as directors until the annual meeting to be held in 2025 or until their successors are duly elected and qualified: Matthew J. WallachDIRECTOR ELECTIONSISSUER330328.0000000AGAINST330328.000000AGAINSTS000002088Veeva Systems Inc.922475108US922475108406/12/2024To ratify the appointment of KPMG LLP as our independent registered public accounting firm for the fiscal year ending January 31, 2025.AUDIT-RELATEDISSUER330328.0000000FOR330328.000000FORS000002088Veeva Systems Inc.922475108US922475108406/12/2024To approve an amendment and restatement of our Certificate of Incorporation to reflect the Delaware law provisions regarding officer exculpation.CORPORATE GOVERNANCEISSUER330328.0000000FOR330328.000000FORS000002088Veeva Systems Inc.922475108US922475108406/12/2024To hold an advisory (non-binding) vote to approve named executive officer compensation.SECTION 14A SAY-ON-PAY VOTESISSUER330328.0000000FOR330328.000000FORS000002088Avidity Biosciences, Inc.05370A108US05370A108806/13/2024To elect three directors to serve as Class I directors for a three-year term expiring at the 2027 Annual Meeting of Stockholders and until their respective successors shall have been duly elected and qualified: Carsten BoessDIRECTOR ELECTIONSISSUER2901337.0000000FOR2901337.000000FORS000002088Avidity Biosciences, Inc.05370A108US05370A108806/13/2024To elect three directors to serve as Class I directors for a three-year term expiring at the 2027 Annual Meeting of Stockholders and until their respective successors shall have been duly elected and qualified: Sarah BoyceDIRECTOR ELECTIONSISSUER2901337.0000000FOR2901337.000000FORS000002088Avidity Biosciences, Inc.05370A108US05370A108806/13/2024To elect three directors to serve as Class I directors for a three-year term expiring at the 2027 Annual Meeting of Stockholders and until their respective successors shall have been duly elected and qualified: Dr. Troy WilsonDIRECTOR ELECTIONSISSUER2901337.0000000WITHHOLD2901337.000000AGAINSTS000002088Avidity Biosciences, Inc.05370A108US05370A108806/13/2024To ratify the appointment of BDO USA, P.C. as our independent registered public accounting firm for the fiscal year ending December 31, 2024;AUDIT-RELATEDISSUER2901337.0000000FOR2901337.000000FORS000002088Avidity Biosciences, Inc.05370A108US05370A108806/13/2024To consider and vote upon, on an advisory basis, the compensation of our named executive officers as disclosed in the related proxy statement pursuant to the compensation disclosure rules of the Securities and Exchange Commission; andSECTION 14A SAY-ON-PAY VOTESISSUER2901337.0000000FOR2901337.000000FORS000002088Celldex Therapeutics, Inc.15117B202US15117B202506/13/2024Election of Directors: Karen L. ShoosDIRECTOR ELECTIONSISSUER1351079.0000000FOR1351079.000000FORS000002088Celldex Therapeutics, Inc.15117B202US15117B202506/13/2024Election of Directors: Anthony S. MarucciDIRECTOR ELECTIONSISSUER1351079.0000000FOR1351079.000000FORS000002088Celldex Therapeutics, Inc.15117B202US15117B202506/13/2024Election of Directors: Keith L. BrownlieDIRECTOR ELECTIONSISSUER1351079.0000000FOR1351079.000000FORS000002088Celldex Therapeutics, Inc.15117B202US15117B202506/13/2024Election of Directors: Cheryl L. CohenDIRECTOR ELECTIONSISSUER1351079.0000000FOR1351079.000000FORS000002088Celldex Therapeutics, Inc.15117B202US15117B202506/13/2024Election of Directors: Herbert J. ConradDIRECTOR ELECTIONSISSUER1351079.0000000FOR1351079.000000FORS000002088Celldex Therapeutics, Inc.15117B202US15117B202506/13/2024Election of Directors: Rita I. Jain, M.D.DIRECTOR ELECTIONSISSUER1351079.0000000FOR1351079.000000FORS000002088Celldex Therapeutics, Inc.15117B202US15117B202506/13/2024Election of Directors: James J. MarinoDIRECTOR ELECTIONSISSUER1351079.0000000FOR1351079.000000FORS000002088Celldex Therapeutics, Inc.15117B202US15117B202506/13/2024Election of Directors: Garry Neil, M.D.DIRECTOR ELECTIONSISSUER1351079.0000000FOR1351079.000000FORS000002088Celldex Therapeutics, Inc.15117B202US15117B202506/13/2024Election of Directors: Harry H. Penner, Jr.DIRECTOR ELECTIONSISSUER1351079.0000000FOR1351079.000000FORS000002088Celldex Therapeutics, Inc.15117B202US15117B202506/13/2024To ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the year ending December 31, 2024.AUDIT-RELATEDISSUER1351079.0000000FOR1351079.000000FORS000002088Celldex Therapeutics, Inc.15117B202US15117B202506/13/2024To approve an amendment to our 2021 Omnibus Equity Incentive Plan, including an increase in the number of shares reserved for issuance thereunder by 3,200,000 shares to 7,500,000 shares.COMPENSATIONISSUER1351079.0000000FOR1351079.000000FORS000002088Celldex Therapeutics, Inc.15117B202US15117B202506/13/2024To approve, on an advisory basis, the compensation of the Company's Named Executive Officers as disclosed in this Proxy Statement.SECTION 14A SAY-ON-PAY VOTESISSUER1351079.0000000FOR1351079.000000FORS000002088Entrada Therapeutics, Inc.29384C108US29384C108006/13/2024Election of Director: Gina ChapmanDIRECTOR ELECTIONSISSUER314419.0000000FOR314419.000000FORS000002088Entrada Therapeutics, Inc.29384C108US29384C108006/13/2024Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024.AUDIT-RELATEDISSUER314419.0000000FOR314419.000000FORS000002088Entrada Therapeutics, Inc.29384C108US29384C108006/13/2024Approval of an amendment to the Company's Fourth Amended and Restated Certificate of Incorporation to limit the liability of certain officers of the Company as permitted by Delaware law.CORPORATE GOVERNANCEISSUER314419.0000000FOR314419.000000FORS000002088Exact Sciences Corporation30063P105US30063P105706/13/2024To elect three members of the Board of Directors to serve for one-year terms as Class III Directors: Michael BarberDIRECTOR ELECTIONSISSUER802417.0000000FOR802417.000000FORS000002088Exact Sciences Corporation30063P105US30063P105706/13/2024To elect three members of the Board of Directors to serve for one-year terms as Class III Directors: Paul ClancyDIRECTOR ELECTIONSISSUER802417.0000000FOR802417.000000FORS000002088Exact Sciences Corporation30063P105US30063P105706/13/2024To elect three members of the Board of Directors to serve for one-year terms as Class III Directors: Daniel LevangieDIRECTOR ELECTIONSISSUER802417.0000000FOR802417.000000FORS000002088Exact Sciences Corporation30063P105US30063P105706/13/2024To ratify the selection of PricewaterhouseCoopers LLP as our independent registered public accounting firm for 2024.AUDIT-RELATEDISSUER802417.0000000FOR802417.000000FORS000002088Exact Sciences Corporation30063P105US30063P105706/13/2024To approve, on an advisory basis, the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER802417.0000000FOR802417.000000FORS000002088Ginkgo Bioworks Holdings, Inc.37611X100US37611X100006/13/2024Election of Directors: Arie BelldegrunDIRECTOR ELECTIONSISSUER1653133.0000000FOR1653133.000000FORS000002088Ginkgo Bioworks Holdings, Inc.37611X100US37611X100006/13/2024Election of Directors: Ross FubiniDIRECTOR ELECTIONSISSUER1653133.0000000FOR1653133.000000FORS000002088Ginkgo Bioworks Holdings, Inc.37611X100US37611X100006/13/2024Election of Directors: Kathy Hopinkah HannanDIRECTOR ELECTIONSISSUER1653133.0000000FOR1653133.000000FORS000002088Ginkgo Bioworks Holdings, Inc.37611X100US37611X100006/13/2024Election of Directors: Christian HenryDIRECTOR ELECTIONSISSUER1653133.0000000AGAINST1653133.000000AGAINSTS000002088Ginkgo Bioworks Holdings, Inc.37611X100US37611X100006/13/2024Election of Directors: Myrtle PotterDIRECTOR ELECTIONSISSUER1653133.0000000FOR1653133.000000FORS000002088Ginkgo Bioworks Holdings, Inc.37611X100US37611X100006/13/2024Election of Directors: Shyam SankarDIRECTOR ELECTIONSISSUER1653133.0000000FOR1653133.000000FORS000002088Ginkgo Bioworks Holdings, Inc.37611X100US37611X100006/13/2024Election of Directors: Harry E. SloanDIRECTOR ELECTIONSISSUER1653133.0000000FOR1653133.000000FORS000002088Ginkgo Bioworks Holdings, Inc.37611X100US37611X100006/13/2024Ratification of the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024.AUDIT-RELATEDISSUER1653133.0000000FOR1653133.000000FORS000002088Ginkgo Bioworks Holdings, Inc.37611X100US37611X100006/13/2024Advisory vote to approve executive compensation.SECTION 14A SAY-ON-PAY VOTESISSUER1653133.0000000FOR1653133.000000FORS000002088Neumora Therapeutics, Inc.640979100US640979100006/13/2024To elect two Class I directors to hold office until the 2027 annual meeting of stockholders or until their successors are elected: Henry O. GosebruchDIRECTOR ELECTIONSISSUER937400.0000000FOR937400.000000FORS000002088Neumora Therapeutics, Inc.640979100US640979100006/13/2024To elect two Class I directors to hold office until the 2027 annual meeting of stockholders or until their successors are elected: Kristina BurowDIRECTOR ELECTIONSISSUER937400.0000000FOR937400.000000FORS000002088Neumora Therapeutics, Inc.640979100US640979100006/13/2024To ratify the appointment, by the Audit Committee of the Company's Board of Directors, of Ernst & Young LLP, as the independent registered public accounting firm and independent auditor of the Company for its year ending December 31, 2024.AUDIT-RELATEDISSUER937400.0000000FOR937400.000000FORS000002088Pliant Therapeutics, Inc.729139105US729139105706/13/2024To elect three class III directors named in the proxy statement to our Board of Directors: Hoyoung Huh, M.D., Ph.D.DIRECTOR ELECTIONSISSUER501130.0000000FOR501130.000000FORS000002088Pliant Therapeutics, Inc.729139105US729139105706/13/2024To elect three class III directors named in the proxy statement to our Board of Directors: Darren Cline, MBADIRECTOR ELECTIONSISSUER501130.0000000FOR501130.000000FORS000002088Pliant Therapeutics, Inc.729139105US729139105706/13/2024To elect three class III directors named in the proxy statement to our Board of Directors: David Pyott, MA, MBADIRECTOR ELECTIONSISSUER501130.0000000FOR501130.000000FORS000002088Pliant Therapeutics, Inc.729139105US729139105706/13/2024To approve, by non-binding advisory vote, the resolution approving named executive officer compensation.SECTION 14A SAY-ON-PAY VOTESISSUER501130.0000000AGAINST501130.000000AGAINSTS000002088Pliant Therapeutics, Inc.729139105US729139105706/13/2024To ratify the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2023.AUDIT-RELATEDISSUER501130.0000000FOR501130.000000FORS000002088Rocket Pharmaceuticals, Inc77313F106US77313F106606/13/2024Election of Directors: Elisabeth Bjork, M.D., Ph.D.DIRECTOR ELECTIONSISSUER969648.0000000FOR969648.000000FORS000002088Rocket Pharmaceuticals, Inc77313F106US77313F106606/13/2024Election of Directors: Carsten BoessDIRECTOR ELECTIONSISSUER969648.0000000FOR969648.000000FORS000002088Rocket Pharmaceuticals, Inc77313F106US77313F106606/13/2024Election of Directors: Pedro GranadilloDIRECTOR ELECTIONSISSUER969648.0000000FOR969648.000000FORS000002088Rocket Pharmaceuticals, Inc77313F106US77313F106606/13/2024Election of Directors: Gotham Makker, M.D.DIRECTOR ELECTIONSISSUER969648.0000000FOR969648.000000FORS000002088Rocket Pharmaceuticals, Inc77313F106US77313F106606/13/2024Election of Directors: Fady Malik, M.D., Ph.D.DIRECTOR ELECTIONSISSUER969648.0000000FOR969648.000000FORS000002088Rocket Pharmaceuticals, Inc77313F106US77313F106606/13/2024Election of Directors: Gaurav Shah, M.D.DIRECTOR ELECTIONSISSUER969648.0000000FOR969648.000000FORS000002088Rocket Pharmaceuticals, Inc77313F106US77313F106606/13/2024Election of Directors: David P. SouthwellDIRECTOR ELECTIONSISSUER969648.0000000FOR969648.000000FORS000002088Rocket Pharmaceuticals, Inc77313F106US77313F106606/13/2024Election of Directors: Roderick Wong, M.D.DIRECTOR ELECTIONSISSUER969648.0000000FOR969648.000000FORS000002088Rocket Pharmaceuticals, Inc77313F106US77313F106606/13/2024Election of Directors: R. Keith WoodsDIRECTOR ELECTIONSISSUER969648.0000000FOR969648.000000FORS000002088Rocket Pharmaceuticals, Inc77313F106US77313F106606/13/2024Election of Directors: Naveen Yalamanchi, M.D.DIRECTOR ELECTIONSISSUER969648.0000000FOR969648.000000FORS000002088Rocket Pharmaceuticals, Inc77313F106US77313F106606/13/2024Ratification of the appointment of EisnerAmper LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024.AUDIT-RELATEDISSUER969648.0000000FOR969648.000000FORS000002088Rocket Pharmaceuticals, Inc77313F106US77313F106606/13/2024Approval of the compensation of the Company's named executive officers, on a non-binding, advisory basis.SECTION 14A SAY-ON-PAY VOTESISSUER969648.0000000FOR969648.000000FORS000002088Rocket Pharmaceuticals, Inc77313F106US77313F106606/13/2024Approval of an amendment to the Company's Seventh Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock.CAPITAL STRUCTUREISSUER969648.0000000FOR969648.000000FORS000002088Tarsus Pharmaceuticals, Inc.87650L103US87650L103506/13/2024To re-elect the following two nominees as Class I directors, to serve until the 2027 annual meeting of stockholders or until their respective successor have been elected or appointed: Bhaskar ChaudhuriDIRECTOR ELECTIONSISSUER258460.0000000FOR258460.000000FORS000002088Tarsus Pharmaceuticals, Inc.87650L103US87650L103506/13/2024To re-elect the following two nominees as Class I directors, to serve until the 2027 annual meeting of stockholders or until their respective successor have been elected or appointed: William J. LinkDIRECTOR ELECTIONSISSUER258460.0000000FOR258460.000000FORS000002088Tarsus Pharmaceuticals, Inc.87650L103US87650L103506/13/2024Ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024.AUDIT-RELATEDISSUER258460.0000000FOR258460.000000FORS000002088Xencor, Inc.98401F105US98401F105706/13/2024To elect the eight nominees to the Board of Directors named in the accompanying Proxy Statement to serve until the next annual meeting and until their successors are duly elected and qualified: Dr. Bassil I. DahiyatDIRECTOR ELECTIONSISSUER837970.0000000FOR837970.000000FORS000002088Xencor, Inc.98401F105US98401F105706/13/2024To elect the eight nominees to the Board of Directors named in the accompanying Proxy Statement to serve until the next annual meeting and until their successors are duly elected and qualified: Dr. Ellen G. FeigalDIRECTOR ELECTIONSISSUER837970.0000000FOR837970.000000FORS000002088Xencor, Inc.98401F105US98401F105706/13/2024To elect the eight nominees to the Board of Directors named in the accompanying Proxy Statement to serve until the next annual meeting and until their successors are duly elected and qualified: Dr. Kevin C. GormanDIRECTOR ELECTIONSISSUER837970.0000000FOR837970.000000FORS000002088Xencor, Inc.98401F105US98401F105706/13/2024To elect the eight nominees to the Board of Directors named in the accompanying Proxy Statement to serve until the next annual meeting and until their successors are duly elected and qualified: Mr. Kurt A. GustafsonDIRECTOR ELECTIONSISSUER837970.0000000FOR837970.000000FORS000002088Xencor, Inc.98401F105US98401F105706/13/2024To elect the eight nominees to the Board of Directors named in the accompanying Proxy Statement to serve until the next annual meeting and until their successors are duly elected and qualified: Dr. Barbara KlenckeDIRECTOR ELECTIONSISSUER837970.0000000FOR837970.000000FORS000002088Xencor, Inc.98401F105US98401F105706/13/2024To elect the eight nominees to the Board of Directors named in the accompanying Proxy Statement to serve until the next annual meeting and until their successors are duly elected and qualified: Dr. A. Bruce MontgomeryDIRECTOR ELECTIONSISSUER837970.0000000FOR837970.000000FORS000002088Xencor, Inc.98401F105US98401F105706/13/2024To elect the eight nominees to the Board of Directors named in the accompanying Proxy Statement to serve until the next annual meeting and until their successors are duly elected and qualified: Mr. Richard J. RanieriDIRECTOR ELECTIONSISSUER837970.0000000FOR837970.000000FORS000002088Xencor, Inc.98401F105US98401F105706/13/2024To elect the eight nominees to the Board of Directors named in the accompanying Proxy Statement to serve until the next annual meeting and until their successors are duly elected and qualified: Ms. Dagmar Rosa-BjorkesonDIRECTOR ELECTIONSISSUER837970.0000000FOR837970.000000FORS000002088Xencor, Inc.98401F105US98401F105706/13/2024To ratify the selection by the Audit Committee of the Board of Directors of RSM US LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2024;AUDIT-RELATEDISSUER837970.0000000FOR837970.000000FORS000002088Xencor, Inc.98401F105US98401F105706/13/2024To approve, by non-binding advisory vote, the compensation of the Company's named executive officers, as disclosed in the accompanying Proxy Statement; andSECTION 14A SAY-ON-PAY VOTESISSUER837970.0000000FOR837970.000000FORS000002088Arcutis Biotherapeutics, Inc.03969K108US03969K108806/14/2024Election of Class I directors to hold office until the 2027 Annual Meeting of Stockholders or until their successors are elected: Terrie CurranDIRECTOR ELECTIONSISSUER260700.0000000FOR260700.000000FORS000002088Arcutis Biotherapeutics, Inc.03969K108US03969K108806/14/2024Election of Class I directors to hold office until the 2027 Annual Meeting of Stockholders or until their successors are elected: Halley E. GilbertDIRECTOR ELECTIONSISSUER260700.0000000FOR260700.000000FORS000002088Arcutis Biotherapeutics, Inc.03969K108US03969K108806/14/2024Election of Class I directors to hold office until the 2027 Annual Meeting of Stockholders or until their successors are elected: Keith R. Leonard, Jr.DIRECTOR ELECTIONSISSUER260700.0000000WITHHOLD260700.000000AGAINSTS000002088Arcutis Biotherapeutics, Inc.03969K108US03969K108806/14/2024To ratify the selection, by the Audit Committee of the Company's Board of Directors, of Ernst & Young LLP, as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2024.AUDIT-RELATEDISSUER260700.0000000FOR260700.000000FORS000002088Arcutis Biotherapeutics, Inc.03969K108US03969K108806/14/2024To approve, on a non-binding advisory basis, the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER260700.0000000AGAINST260700.000000AGAINSTS000002088Ardelyx, Inc.039697107US039697107106/14/2024To elect two Class I directors to hold office until the 2027 Annual Meeting of Stockholders and until their successors are elected and qualified: Onaiza Cadoret-ManierDIRECTOR ELECTIONSISSUER2946624.0000000FOR2946624.000000FORS000002088Ardelyx, Inc.039697107US039697107106/14/2024To elect two Class I directors to hold office until the 2027 Annual Meeting of Stockholders and until their successors are elected and qualified: William A. Bertrand, Jr., Esq.DIRECTOR ELECTIONSISSUER2946624.0000000FOR2946624.000000FORS000002088Ardelyx, Inc.039697107US039697107106/14/2024To approve the Amended and Restated 2014 Equity Incentive Award Plan;COMPENSATIONISSUER2946624.0000000AGAINST2946624.000000AGAINSTS000002088Ardelyx, Inc.039697107US039697107106/14/2024To approve the Amended and Restated 2014 Employee Stock Purchase Plan;COMPENSATIONISSUER2946624.0000000FOR2946624.000000FORS000002088Ardelyx, Inc.039697107US039697107106/14/2024To approve, on a non-binding, advisory basis, the compensation of our named executive officers as disclosed in the proxy statement accompanying this notice pursuant to the compensation disclosure rules of the Securities and Exchange Commission ("Say-on-Pay");SECTION 14A SAY-ON-PAY VOTESISSUER2946624.0000000FOR2946624.000000FORS000002088Ardelyx, Inc.039697107US039697107106/14/2024To ratify the selection, by the Audit and Compliance Committee of our Board of Directors, of Ernst & Young LLP as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2024; andAUDIT-RELATEDISSUER2946624.0000000FOR2946624.000000FORS000002088Intra-Cellular Therapies, Inc.46116X101US46116X101906/14/2024To elect one director to serve a three-year term expiring in 2027: Joel S. MarcusDIRECTOR ELECTIONSISSUER94194.0000000FOR94194.000000FORS000002088Intra-Cellular Therapies, Inc.46116X101US46116X101906/14/2024To approve the amendment and restatement of the Company's Amended and Restated 2018 Equity Incentive Plan.COMPENSATIONISSUER94194.0000000FOR94194.000000FORS000002088Intra-Cellular Therapies, Inc.46116X101US46116X101906/14/2024To ratify of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024.AUDIT-RELATEDISSUER94194.0000000FOR94194.000000FORS000002088Intra-Cellular Therapies, Inc.46116X101US46116X101906/14/2024To approve by an advisory vote the compensation of the Company's named executive officers, as disclosed in the proxy statement.SECTION 14A SAY-ON-PAY VOTESISSUER94194.0000000FOR94194.000000FORS000002088Lyell Immunopharma, Inc.55083R104US55083R104106/14/2024Election of Class III Directors: Elizabeth Nabel, M.D.DIRECTOR ELECTIONSISSUER5293498.0000000FOR5293498.000000FORS000002088Lyell Immunopharma, Inc.55083R104US55083R104106/14/2024Election of Class III Directors: Lynn Seely, M.D.DIRECTOR ELECTIONSISSUER5293498.0000000FOR5293498.000000FORS000002088Lyell Immunopharma, Inc.55083R104US55083R104106/14/2024Ratification of the appointment of Ernst & Young LLP as the company's independent registered public accounting firm for its fiscal year ending December 31, 2024.AUDIT-RELATEDISSUER5293498.0000000FOR5293498.000000FORS000002088Lyell Immunopharma, Inc.55083R104US55083R104106/14/2024Approval, on a non-binding advisory basis, of the compensation of the company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER5293498.0000000AGAINST5293498.000000AGAINSTS000002088Prelude Therapeutics Incorporated74065P101US74065P101206/14/2024Election of Class I Directors: Paul A. Friedman, M.D.DIRECTOR ELECTIONSISSUER669972.0000000FOR669972.000000FORS000002088Prelude Therapeutics Incorporated74065P101US74065P101206/14/2024Election of Class I Directors: David P. Bonita, M.D.DIRECTOR ELECTIONSISSUER669972.0000000FOR669972.000000FORS000002088Prelude Therapeutics Incorporated74065P101US74065P101206/14/2024Ratification of the appointment of Emst & Young LLP as the Independent registered public accounting firm of the company for its fiscal year ending December 31, 2024.AUDIT-RELATEDISSUER669972.0000000FOR669972.000000FORS000002088Regeneron Pharmaceuticals, Inc.75886F107US75886F107506/14/2024Election of Directors: N. Anthony Coles, M.D.DIRECTOR ELECTIONSISSUER433754.0000000AGAINST433754.000000AGAINSTS000002088Regeneron Pharmaceuticals, Inc.75886F107US75886F107506/14/2024Election of Directors: Kathryn Guarini, Ph.D.DIRECTOR ELECTIONSISSUER433754.0000000FOR433754.000000FORS000002088Regeneron Pharmaceuticals, Inc.75886F107US75886F107506/14/2024Election of Directors: Arthur F. RyanDIRECTOR ELECTIONSISSUER433754.0000000AGAINST433754.000000AGAINSTS000002088Regeneron Pharmaceuticals, Inc.75886F107US75886F107506/14/2024Election of Directors: David P. Schenkein, M.D.DIRECTOR ELECTIONSISSUER433754.0000000FOR433754.000000FORS000002088Regeneron Pharmaceuticals, Inc.75886F107US75886F107506/14/2024Election of Directors: George L. SingDIRECTOR ELECTIONSISSUER433754.0000000AGAINST433754.000000AGAINSTS000002088Regeneron Pharmaceuticals, Inc.75886F107US75886F107506/14/2024Ratification of the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024.AUDIT-RELATEDISSUER433754.0000000FOR433754.000000FORS000002088Regeneron Pharmaceuticals, Inc.75886F107US75886F107506/14/2024Proposal to approve, on an advisory basis, executive compensation.SECTION 14A SAY-ON-PAY VOTESISSUER433754.0000000FOR433754.000000FORS000002088Regeneron Pharmaceuticals, Inc.75886F107US75886F107506/14/2024Non-binding shareholder proposal requesting simple majority voting requirements, if properly presented.CORPORATE GOVERNANCESECURITY HOLDER433754.0000000AGAINST433754.000000FORS000002088Daiichi Sankyo Co., Ltd.J11257102JP347535000906/17/2024Approve Allocation of Income, with a Final Dividend of JPY 30CAPITAL STRUCTUREISSUER1001800.0000000FOR1001800.000000FORS000002088Daiichi Sankyo Co., Ltd.J11257102JP347535000906/17/2024Elect Director Manabe, SunaoDIRECTOR ELECTIONSISSUER1001800.0000000FOR1001800.000000FORS000002088Daiichi Sankyo Co., Ltd.J11257102JP347535000906/17/2024Elect Director Okuzawa, HiroyukiDIRECTOR ELECTIONSISSUER1001800.0000000FOR1001800.000000FORS000002088Daiichi Sankyo Co., Ltd.J11257102JP347535000906/17/2024Elect Director Hirashima, ShojiDIRECTOR ELECTIONSISSUER1001800.0000000FOR1001800.000000FORS000002088Daiichi Sankyo Co., Ltd.J11257102JP347535000906/17/2024Elect Director Fukuoka, TakashiDIRECTOR ELECTIONSISSUER1001800.0000000FOR1001800.000000FORS000002088Daiichi Sankyo Co., Ltd.J11257102JP347535000906/17/2024Elect Director Kama, KazuakiDIRECTOR ELECTIONSISSUER1001800.0000000FOR1001800.000000FORS000002088Daiichi Sankyo Co., Ltd.J11257102JP347535000906/17/2024Elect Director Nohara, SawakoDIRECTOR ELECTIONSISSUER1001800.0000000FOR1001800.000000FORS000002088Daiichi Sankyo Co., Ltd.J11257102JP347535000906/17/2024Elect Director Komatsu, YasuhiroDIRECTOR ELECTIONSISSUER1001800.0000000FOR1001800.000000FORS000002088Daiichi Sankyo Co., Ltd.J11257102JP347535000906/17/2024Elect Director Nishii, TakaakiDIRECTOR ELECTIONSISSUER1001800.0000000FOR1001800.000000FORS000002088Daiichi Sankyo Co., Ltd.J11257102JP347535000906/17/2024Elect Director Matsumoto, TakashiDIRECTOR ELECTIONSISSUER1001800.0000000FOR1001800.000000FORS000002088Daiichi Sankyo Co., Ltd.J11257102JP347535000906/17/2024Elect Director Homma, YoDIRECTOR ELECTIONSISSUER1001800.0000000FOR1001800.000000FORS000002088Kymera Therapeutics, Inc.501575104US501575104406/18/2024To elect three class I directors to our Board of Directors, to serve until the 2027 Annual Meeting of Shareholders and until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation or removal: Pamela Esposito, Ph.D.DIRECTOR ELECTIONSISSUER1275493.0000000FOR1275493.000000FORS000002088Kymera Therapeutics, Inc.501575104US501575104406/18/2024To elect three class I directors to our Board of Directors, to serve until the 2027 Annual Meeting of Shareholders and until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation or removal: Gorjan Hrustanovic, Ph.D.DIRECTOR ELECTIONSISSUER1275493.0000000FOR1275493.000000FORS000002088Kymera Therapeutics, Inc.501575104US501575104406/18/2024To elect three class I directors to our Board of Directors, to serve until the 2027 Annual Meeting of Shareholders and until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation or removal: Victor Sandor, M.D.C.M.DIRECTOR ELECTIONSISSUER1275493.0000000FOR1275493.000000FORS000002088Kymera Therapeutics, Inc.501575104US501575104406/18/2024To approve, on a non-binding advisory basis, the compensation of our named executive officers;SECTION 14A SAY-ON-PAY VOTESISSUER1275493.0000000FOR1275493.000000FORS000002088Kymera Therapeutics, Inc.501575104US501575104406/18/2024To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024; andAUDIT-RELATEDISSUER1275493.0000000FOR1275493.000000FORS000002088Kymera Therapeutics, Inc.501575104US501575104406/18/2024To approve an amendment to the Kymera Therapeutics, Inc. 2020 Stock Option and Incentive Plan.COMPENSATIONISSUER1275493.0000000AGAINST1275493.000000AGAINSTS000002088Pacific Biosciences of California, Inc.69404D108US69404D108106/18/2024Election of Directors: Randy LivingstonDIRECTOR ELECTIONSISSUER1255317.0000000FOR1255317.000000FORS000002088Pacific Biosciences of California, Inc.69404D108US69404D108106/18/2024Election of Directors: David MelineDIRECTOR ELECTIONSISSUER1255317.0000000FOR1255317.000000FORS000002088Pacific Biosciences of California, Inc.69404D108US69404D108106/18/2024Election of Directors: Marshall MohrDIRECTOR ELECTIONSISSUER1255317.0000000FOR1255317.000000FORS000002088Pacific Biosciences of California, Inc.69404D108US69404D108106/18/2024Election of Directors: Hannah A. Valantine, M.D.DIRECTOR ELECTIONSISSUER1255317.0000000FOR1255317.000000FORS000002088Pacific Biosciences of California, Inc.69404D108US69404D108106/18/2024To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the year ending December 31, 2024.AUDIT-RELATEDISSUER1255317.0000000FOR1255317.000000FORS000002088Pacific Biosciences of California, Inc.69404D108US69404D108106/18/2024To approve, on an advisory basis, the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER1255317.0000000FOR1255317.000000FORS000002088Pacific Biosciences of California, Inc.69404D108US69404D108106/18/2024To approve the amendment of our 2020 Equity Incentive Plan.COMPENSATIONISSUER1255317.0000000FOR1255317.000000FORS000002088Pacific Biosciences of California, Inc.69404D108US69404D108106/18/2024To approve an amendment to our certificate of incorporation to declassify our board of directors.SHAREHOLDER RIGHTS AND DEFENSESISSUER1255317.0000000FOR1255317.000000FORS000002088Pacific Biosciences of California, Inc.69404D108US69404D108106/18/2024To approve an amendment to our certificate of incorporation to limit the liability of officers as permitted by law.CORPORATE GOVERNANCEISSUER1255317.0000000FOR1255317.000000FORS000002088Pacific Biosciences of California, Inc.69404D108US69404D108106/18/2024To approve one or more adjournments of the meeting from time to time, if necessary or appropriate (as determined by our board of directors or the chairperson of the meeting), including to solicit additional proxies to vote in favor of any of Proposals 1-6 above in the event that there are insufficient votes at the time of the meeting to establish a quorum or approve any of Proposals 1-6 above.CORPORATE GOVERNANCEISSUER1255317.0000000AGAINST1255317.000000AGAINSTS000002088Ultragenyx Pharmaceutical Inc.90400D108US90400D108106/18/2024Nominees: Deborah Dunsire, M.D.DIRECTOR ELECTIONSISSUER1219644.0000000WITHHOLD1219644.000000AGAINSTS000002088Ultragenyx Pharmaceutical Inc.90400D108US90400D108106/18/2024Nominees: Michael NarachiDIRECTOR ELECTIONSISSUER1219644.0000000WITHHOLD1219644.000000AGAINSTS000002088Ultragenyx Pharmaceutical Inc.90400D108US90400D108106/18/2024Nominees: Corsee D. Sanders, Ph.D.DIRECTOR ELECTIONSISSUER1219644.0000000WITHHOLD1219644.000000AGAINSTS000002088Ultragenyx Pharmaceutical Inc.90400D108US90400D108106/18/2024Approval of the Amended and Restated 2023 Incentive Plan.COMPENSATIONISSUER1219644.0000000FOR1219644.000000FORS000002088Ultragenyx Pharmaceutical Inc.90400D108US90400D108106/18/2024Ratification of the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024.AUDIT-RELATEDISSUER1219644.0000000FOR1219644.000000FORS000002088Ultragenyx Pharmaceutical Inc.90400D108US90400D108106/18/2024Advisory (non-binding) vote to approve the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER1219644.0000000FOR1219644.000000FORS000002088Zai Lab Limited98887Q104US98887Q104006/18/2024An ordinary resolution to re-elect Samantha (Ying) Du to serve as a director until the 2025 annual general meeting of shareholders and until her successor is duly elected and qualified, subject to her earlier resignation or removal;DIRECTOR ELECTIONSISSUER1276837.0000000FOR1276837.000000FORS000002088Zai Lab Limited98887Q104US98887Q104006/18/2024An ordinary resolution to re-elect Kai-Xian Chen to serve as a director until the 2025 annual general meeting of shareholders and until his successor is duly elected and qualified, subject to his earlier resignation or removal;DIRECTOR ELECTIONSISSUER1276837.0000000FOR1276837.000000FORS000002088Zai Lab Limited98887Q104US98887Q104006/18/2024An ordinary resolution to re-elect John D. Diekman to serve as a director until the 2025 annual general meeting of shareholders and until his successor is duly elected and qualified, subject to his earlier resignation or removal;DIRECTOR ELECTIONSISSUER1276837.0000000FOR1276837.000000FORS000002088Zai Lab Limited98887Q104US98887Q104006/18/2024An ordinary resolution to re-elect Richard Gaynor to serve as a director until the 2025 annual general meeting of shareholders and until his successor is duly elected and qualified, subject to his earlier resignation or removal;DIRECTOR ELECTIONSISSUER1276837.0000000FOR1276837.000000FORS000002088Zai Lab Limited98887Q104US98887Q104006/18/2024An ordinary resolution to re-elect Nisa Leung to serve as a director until the 2025 annual general meeting of shareholders and until her successor is duly elected and qualified, subject to her earlier resignation or removal;DIRECTOR ELECTIONSISSUER1276837.0000000FOR1276837.000000FORS000002088Zai Lab Limited98887Q104US98887Q104006/18/2024An ordinary resolution to re-elect William Lis to serve as a director until the 2025 annual general meeting of shareholders and until his successor is duly elected and qualified, subject to his earlier resignation or removal;DIRECTOR ELECTIONSISSUER1276837.0000000FOR1276837.000000FORS000002088Zai Lab Limited98887Q104US98887Q104006/18/2024An ordinary resolution to re-elect Scott Morrison to serve as a director until the 2025 annual general meeting of shareholders and until his successor is duly elected and qualified, subject to his earlier resignation or removal;DIRECTOR ELECTIONSISSUER1276837.0000000FOR1276837.000000FORS000002088Zai Lab Limited98887Q104US98887Q104006/18/2024An ordinary resolution to re-elect Leon O. Moulder Jr. to serve as a director until the 2025 annual general meeting of shareholders and until his successor is duly elected and qualified, subject to his earlier resignation or removal;DIRECTOR ELECTIONSISSUER1276837.0000000FOR1276837.000000FORS000002088Zai Lab Limited98887Q104US98887Q104006/18/2024An ordinary resolution to re-elect Michel Vounatsos to serve as a director until the 2025 annual general meeting of shareholders and until his successor is duly elected and qualified, subject to his earlier resignation or removal;DIRECTOR ELECTIONSISSUER1276837.0000000FOR1276837.000000FORS000002088Zai Lab Limited98887Q104US98887Q104006/18/2024An ordinary resolution to re-elect Peter Wirth to serve as a director until the 2025 annual general meeting of shareholders and until his successor is duly elected and qualified, subject to his earlier resignation or removal;DIRECTOR ELECTIONSISSUER1276837.0000000FOR1276837.000000FORS000002088Zai Lab Limited98887Q104US98887Q104006/18/2024THAT, the appointment of KPMG LLP and KPMG as the Company's independent registered public accounting firms and auditors to audit the Company's consolidated financial statements to be filed with the U.S. Securities and Exchange Commission and The Stock Exchange of Hong Kong Limited for the year ending December 31, 2024, respectively, is hereby approved.AUDIT-RELATEDISSUER1276837.0000000FOR1276837.000000FORS000002088Zai Lab Limited98887Q104US98887Q104006/18/2024THAT, the authority of the Board of Directors to fix the auditor compensation for 2024, is hereby approved.AUDIT-RELATEDISSUER1276837.0000000FOR1276837.000000FORS000002088Zai Lab Limited98887Q104US98887Q104006/18/2024THAT, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the proxy statement, is hereby approved.SECTION 14A SAY-ON-PAY VOTESISSUER1276837.0000000AGAINST1276837.000000AGAINSTS000002088Zai Lab Limited98887Q104US98887Q104006/18/2024THAT, a general mandate to the Board of Directors to allot and issue ordinary shares and/or ADSs and/or resell treasury shares of up to 20% of the total number of issued ordinary shares of the Company (excluding treasury shares) as of the date of the Annual Meeting until the 2025 annual general meeting of shareholders is hereby approved.CAPITAL STRUCTUREISSUER1276837.0000000AGAINST1276837.000000AGAINSTS000002088Zai Lab Limited98887Q104US98887Q104006/18/2024THAT, if Ordinary Resolution 14 is not approved, a general mandate to the Board of Directors to allot and issue ordinary shares and/or ADSs and/or resell treasury shares of up to 10% of the total number of issued ordinary shares of the Company (excluding treasury shares) as of the date of the Annual Meeting until the 2025 annual general meeting of shareholders, is hereby approved.CAPITAL STRUCTUREISSUER1276837.0000000AGAINST1276837.000000AGAINSTS000002088Zai Lab Limited98887Q104US98887Q104006/18/2024THAT, a general mandate to repurchase ordinary shares and/or ADSs of up to 10% of the total number of issued ordinary shares of the Company (excluding treasury shares) as of the date of the Annual Meeting until the 2025 annual general meeting of shareholders, is hereby approved.CAPITAL STRUCTUREISSUER1276837.0000000FOR1276837.000000FORS000002088Zai Lab Limited98887Q104US98887Q104006/18/2024THAT, an ordinary resolution to approve the Zai Lab Limited 2024 Equity Incentive Plan is hereby approved.COMPENSATIONISSUER1276837.0000000FOR1276837.000000FORS000002088Agios Pharmaceuticals, Inc.00847X104US00847X104606/20/2024To elect each of the four Class II director nominees set forth in the Proxy Statement, each to serve for a three-year term expiring at the 2027 annual meeting of stockholders and until his or her respective successor is duly elected and qualified: Kaye FosterDIRECTOR ELECTIONSISSUER711369.0000000WITHHOLD711369.000000AGAINSTS000002088Agios Pharmaceuticals, Inc.00847X104US00847X104606/20/2024To elect each of the four Class II director nominees set forth in the Proxy Statement, each to serve for a three-year term expiring at the 2027 annual meeting of stockholders and until his or her respective successor is duly elected and qualified: Maykin Ho, Ph.D.DIRECTOR ELECTIONSISSUER711369.0000000WITHHOLD711369.000000AGAINSTS000002088Agios Pharmaceuticals, Inc.00847X104US00847X104606/20/2024To elect each of the four Class II director nominees set forth in the Proxy Statement, each to serve for a three-year term expiring at the 2027 annual meeting of stockholders and until his or her respective successor is duly elected and qualified: Jeffrey CapelloDIRECTOR ELECTIONSISSUER711369.0000000WITHHOLD711369.000000AGAINSTS000002088Agios Pharmaceuticals, Inc.00847X104US00847X104606/20/2024To elect each of the four Class II director nominees set forth in the Proxy Statement, each to serve for a three-year term expiring at the 2027 annual meeting of stockholders and until his or her respective successor is duly elected and qualified: Catherine OwenDIRECTOR ELECTIONSISSUER711369.0000000WITHHOLD711369.000000AGAINSTS000002088Agios Pharmaceuticals, Inc.00847X104US00847X104606/20/2024To vote, on an advisory basis, to approve the compensation paid to our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER711369.0000000FOR711369.000000FORS000002088Agios Pharmaceuticals, Inc.00847X104US00847X104606/20/2024To ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024.AUDIT-RELATEDISSUER711369.0000000FOR711369.000000FORS000002088Aura Biosciences, Inc.05153U107US05153U107906/20/2024To elect two Class III directors to our Board of Directors, to serve until the 2027 annual meeting of stockholders and until their successor has been duly elected and qualified, or until their earlier death, resignation or removal: Antony MattessichDIRECTOR ELECTIONSISSUER411515.0000000FOR411515.000000FORS000002088Aura Biosciences, Inc.05153U107US05153U107906/20/2024To elect two Class III directors to our Board of Directors, to serve until the 2027 annual meeting of stockholders and until their successor has been duly elected and qualified, or until their earlier death, resignation or removal: Sapna Srivastava, Ph.D.DIRECTOR ELECTIONSISSUER411515.0000000FOR411515.000000FORS000002088Aura Biosciences, Inc.05153U107US05153U107906/20/2024To approve an amendment to our Tenth Amended and Restated Certificate of Incorporation to reflect Delaware General Corporation Law provisions regarding exculpation of officers.CORPORATE GOVERNANCEISSUER411515.0000000FOR411515.000000FORS000002088Aura Biosciences, Inc.05153U107US05153U107906/20/2024To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024.AUDIT-RELATEDISSUER411515.0000000FOR411515.000000FORS000002088Biogen Inc.09062X103US09062X103706/20/2024Election of Directors. To elect the 9 nominees identified in the accompanying Proxy Statement to our Board of Directors to serve for a one-year term extending until our 2025 annual meeting of stockholders and their successors are duly elected and qualified: Caroline D. DorsaDIRECTOR ELECTIONSISSUER350256.0000000AGAINST350256.000000AGAINSTS000002088Biogen Inc.09062X103US09062X103706/20/2024Election of Directors. To elect the 9 nominees identified in the accompanying Proxy Statement to our Board of Directors to serve for a one-year term extending until our 2025 annual meeting of stockholders and their successors are duly elected and qualified: Maria C. FreireDIRECTOR ELECTIONSISSUER350256.0000000FOR350256.000000FORS000002088Biogen Inc.09062X103US09062X103706/20/2024Election of Directors. To elect the 9 nominees identified in the accompanying Proxy Statement to our Board of Directors to serve for a one-year term extending until our 2025 annual meeting of stockholders and their successors are duly elected and qualified: William A. HawkinsDIRECTOR ELECTIONSISSUER350256.0000000FOR350256.000000FORS000002088Biogen Inc.09062X103US09062X103706/20/2024Election of Directors. To elect the 9 nominees identified in the accompanying Proxy Statement to our Board of Directors to serve for a one-year term extending until our 2025 annual meeting of stockholders and their successors are duly elected and qualified: Susan K. LangerDIRECTOR ELECTIONSISSUER350256.0000000AGAINST350256.000000AGAINSTS000002088Biogen Inc.09062X103US09062X103706/20/2024Election of Directors. To elect the 9 nominees identified in the accompanying Proxy Statement to our Board of Directors to serve for a one-year term extending until our 2025 annual meeting of stockholders and their successors are duly elected and qualified: Jesus B. MantasDIRECTOR ELECTIONSISSUER350256.0000000AGAINST350256.000000AGAINSTS000002088Biogen Inc.09062X103US09062X103706/20/2024Election of Directors. To elect the 9 nominees identified in the accompanying Proxy Statement to our Board of Directors to serve for a one-year term extending until our 2025 annual meeting of stockholders and their successors are duly elected and qualified: Monish PatolawalaDIRECTOR ELECTIONSISSUER350256.0000000FOR350256.000000FORS000002088Biogen Inc.09062X103US09062X103706/20/2024Election of Directors. To elect the 9 nominees identified in the accompanying Proxy Statement to our Board of Directors to serve for a one-year term extending until our 2025 annual meeting of stockholders and their successors are duly elected and qualified: Eric K. RowinskyDIRECTOR ELECTIONSISSUER350256.0000000AGAINST350256.000000AGAINSTS000002088Biogen Inc.09062X103US09062X103706/20/2024Election of Directors. To elect the 9 nominees identified in the accompanying Proxy Statement to our Board of Directors to serve for a one-year term extending until our 2025 annual meeting of stockholders and their successors are duly elected and qualified: Stephen A. SherwinDIRECTOR ELECTIONSISSUER350256.0000000FOR350256.000000FORS000002088Biogen Inc.09062X103US09062X103706/20/2024Election of Directors. To elect the 9 nominees identified in the accompanying Proxy Statement to our Board of Directors to serve for a one-year term extending until our 2025 annual meeting of stockholders and their successors are duly elected and qualified: Christopher A. ViehbacherDIRECTOR ELECTIONSISSUER350256.0000000FOR350256.000000FORS000002088Biogen Inc.09062X103US09062X103706/20/2024To ratify the selection of PricewaterhouseCoopers LLP as our independent registered public accounting firm for fiscal year ending December 31, 2024.AUDIT-RELATEDISSUER350256.0000000FOR350256.000000FORS000002088Biogen Inc.09062X103US09062X103706/20/2024Say on Pay - To hold an advisory vote on executive compensation.SECTION 14A SAY-ON-PAY VOTESISSUER350256.0000000FOR350256.000000FORS000002088Biogen Inc.09062X103US09062X103706/20/2024To approve an amendment to Biogen's Amended and Restated Certificate of Incorporation, as amended, to add an officer exculpation provision.CORPORATE GOVERNANCEISSUER350256.0000000FOR350256.000000FORS000002088Biogen Inc.09062X103US09062X103706/20/2024To approve the Biogen Inc. 2024 Omnibus Plan.COMPENSATIONISSUER350256.0000000FOR350256.000000FORS000002088Biogen Inc.09062X103US09062X103706/20/2024To approve the Biogen Inc. 2024 Employee Stock Purchase Plan.COMPENSATIONISSUER350256.0000000FOR350256.000000FORS000002088C4 Therapeutics, Inc.12529R107US12529R107706/20/2024To elect three Class I directors to our Board of Directors, each to serve until the 2027 Annual Meeting of Stockholders and until his/her successor has been duly elected and qualified, or until his/her earlier resignation or removal: Kenneth Anderson, M.D.DIRECTOR ELECTIONSISSUER261979.0000000WITHHOLD261979.000000AGAINSTS000002088C4 Therapeutics, Inc.12529R107US12529R107706/20/2024To elect three Class I directors to our Board of Directors, each to serve until the 2027 Annual Meeting of Stockholders and until his/her successor has been duly elected and qualified, or until his/her earlier resignation or removal: Laura Bessen, M.D.DIRECTOR ELECTIONSISSUER261979.0000000WITHHOLD261979.000000AGAINSTS000002088C4 Therapeutics, Inc.12529R107US12529R107706/20/2024To elect three Class I directors to our Board of Directors, each to serve until the 2027 Annual Meeting of Stockholders and until his/her successor has been duly elected and qualified, or until his/her earlier resignation or removal: Owen HughesDIRECTOR ELECTIONSISSUER261979.0000000WITHHOLD261979.000000AGAINSTS000002088C4 Therapeutics, Inc.12529R107US12529R107706/20/2024To cast a non-binding, advisory vote to approve the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER261979.0000000AGAINST261979.000000AGAINSTS000002088C4 Therapeutics, Inc.12529R107US12529R107706/20/2024To ratify the engagement of KPMG LLP as our independent registered public accounting firm for the year ending December 31, 2024.AUDIT-RELATEDISSUER261979.0000000FOR261979.000000FORS000002088EyePoint Pharmaceuticals, Inc.30233G209US30233G209306/20/2024Election of Directors: Goran Ando, M.D.DIRECTOR ELECTIONSISSUER714802.0000000FOR714802.000000FORS000002088EyePoint Pharmaceuticals, Inc.30233G209US30233G209306/20/2024Election of Directors: Jay S. Duker, M.D.DIRECTOR ELECTIONSISSUER714802.0000000FOR714802.000000FORS000002088EyePoint Pharmaceuticals, Inc.30233G209US30233G209306/20/2024Election of Directors: Nancy LurkerDIRECTOR ELECTIONSISSUER714802.0000000FOR714802.000000FORS000002088EyePoint Pharmaceuticals, Inc.30233G209US30233G209306/20/2024Election of Directors: John B. Landis, Ph.D.DIRECTOR ELECTIONSISSUER714802.0000000FOR714802.000000FORS000002088EyePoint Pharmaceuticals, Inc.30233G209US30233G209306/20/2024Election of Directors: David Guyer, M.D.DIRECTOR ELECTIONSISSUER714802.0000000FOR714802.000000FORS000002088EyePoint Pharmaceuticals, Inc.30233G209US30233G209306/20/2024Election of Directors: Wendy DiCiccoDIRECTOR ELECTIONSISSUER714802.0000000FOR714802.000000FORS000002088EyePoint Pharmaceuticals, Inc.30233G209US30233G209306/20/2024Election of Directors: Anthony P. Adamis, M.D.DIRECTOR ELECTIONSISSUER714802.0000000FOR714802.000000FORS000002088EyePoint Pharmaceuticals, Inc.30233G209US30233G209306/20/2024Election of Directors: Karen ZaderejDIRECTOR ELECTIONSISSUER714802.0000000FOR714802.000000FORS000002088EyePoint Pharmaceuticals, Inc.30233G209US30233G209306/20/2024Election of Directors: Stuart DutyDIRECTOR ELECTIONSISSUER714802.0000000FOR714802.000000FORS000002088EyePoint Pharmaceuticals, Inc.30233G209US30233G209306/20/2024To approve an amendment to the EyePoint Pharmaceuticals, Inc. 2023 Long-Term Incentive Plan to (i) increase the number of shares of common stock authorized for issuance thereunder by 4,000,000 shares and (ii) increase the individual non-employee director compensation limit contained therein to $850,000 for ongoing directors in any calendar year and $1,100,000 for new directors in any calendar year.COMPENSATIONISSUER714802.0000000AGAINST714802.000000AGAINSTS000002088EyePoint Pharmaceuticals, Inc.30233G209US30233G209306/20/2024To approve an amendment to the EyePoint Pharmaceuticals, Inc. 2019 Employee Stock Purchase Plan to increase the number of shares of common stock authorized for issuance thereunder by 250,000 shares.COMPENSATIONISSUER714802.0000000FOR714802.000000FORS000002088EyePoint Pharmaceuticals, Inc.30233G209US30233G209306/20/2024To approve, on an advisory basis, the compensation paid to the Company's named executive officers as disclosed in the accompanying proxy statement.SECTION 14A SAY-ON-PAY VOTESISSUER714802.0000000FOR714802.000000FORS000002088EyePoint Pharmaceuticals, Inc.30233G209US30233G209306/20/2024To ratify the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024.AUDIT-RELATEDISSUER714802.0000000FOR714802.000000FORS000002088GeneDx Holdings Corp.81663L200US81663L200706/20/2024Election of Directors: Emily Leproust , Ph.D.DIRECTOR ELECTIONSISSUER30145.0000000WITHHOLD30145.000000AGAINSTS000002088GeneDx Holdings Corp.81663L200US81663L200706/20/2024Election of Directors: Keith MeisterDIRECTOR ELECTIONSISSUER30145.0000000WITHHOLD30145.000000AGAINSTS000002088GeneDx Holdings Corp.81663L200US81663L200706/20/2024Election of Directors: Richard C. Pfenniger, Jr.DIRECTOR ELECTIONSISSUER30145.0000000WITHHOLD30145.000000AGAINSTS000002088GeneDx Holdings Corp.81663L200US81663L200706/20/2024Ratification of the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024.AUDIT-RELATEDISSUER30145.0000000FOR30145.000000FORS000002088Immatics N.V.N44445109NL001528594106/20/2024Adopt Financial Statements and Statutory ReportsCORPORATE GOVERNANCEISSUER1577309.0000000FOR1577309.000000FORS000002088Immatics N.V.N44445109NL001528594106/20/2024Approve Discharge of DirectorsCORPORATE GOVERNANCEISSUER1577309.0000000FOR1577309.000000FORS000002088Immatics N.V.N44445109NL001528594106/20/2024Reelect M.G. Atieh as Non-Executive Director Class IDIRECTOR ELECTIONSISSUER1577309.0000000FOR1577309.000000FORS000002088Immatics N.V.N44445109NL001528594106/20/2024Reelect P.R. Carter as Non-Executive Director Class IDIRECTOR ELECTIONSISSUER1577309.0000000FOR1577309.000000FORS000002088Immatics N.V.N44445109NL001528594106/20/2024Elect E.R. Forster as Non-Executive Director Class IDIRECTOR ELECTIONSISSUER1577309.0000000AGAINST1577309.000000AGAINSTS000002088Immatics N.V.N44445109NL001528594106/20/2024Grant Board Authority to Issue Shares or to Grant Rights to Subscribe for Ordinary SharesCAPITAL STRUCTUREISSUER1577309.0000000AGAINST1577309.000000AGAINSTS000002088Immatics N.V.N44445109NL001528594106/20/2024Authorize Board to Exclude Preemptive Rights from Share IssuancesCAPITAL STRUCTUREISSUER1577309.0000000AGAINST1577309.000000AGAINSTS000002088Immatics N.V.N44445109NL001528594106/20/2024Authorize Repurchase of Ordinary Shares or Depositary ReceiptsCAPITAL STRUCTUREISSUER1577309.0000000FOR1577309.000000FORS000002088Immatics N.V.N44445109NL001528594106/20/2024Approve 2024 Stock Option and Incentive PlanCOMPENSATIONISSUER1577309.0000000AGAINST1577309.000000AGAINSTS000002088Immatics N.V.N44445109NL001528594106/20/2024Ratify PricewaterhouseCoopers Accountants N.V. as AuditorsAUDIT-RELATEDISSUER1577309.0000000FOR1577309.000000FORS000002088Orchestra Biomed Holdings, Inc.68572M106US68572M106206/20/2024Election of Class I Directors: Eric A. Rose, M.D.DIRECTOR ELECTIONSISSUER398209.0000000WITHHOLD398209.000000AGAINSTS000002088Orchestra Biomed Holdings, Inc.68572M106US68572M106206/20/2024Election of Class I Directors: Jason AryehDIRECTOR ELECTIONSISSUER398209.0000000FOR398209.000000FORS000002088Orchestra Biomed Holdings, Inc.68572M106US68572M106206/20/2024Ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2024.AUDIT-RELATEDISSUER398209.0000000FOR398209.000000FORS000002088Protagonist Therapeutics, Inc.74366E102US74366E102906/20/2024To elect the Class II director nominees named below to hold office until the 2027 Annual Meeting of Stockholders and until their successors are duly elected and qualified: Sarah A. O'DowdDIRECTOR ELECTIONSISSUER581698.0000000FOR581698.000000FORS000002088Protagonist Therapeutics, Inc.74366E102US74366E102906/20/2024To elect the Class II director nominees named below to hold office until the 2027 Annual Meeting of Stockholders and until their successors are duly elected and qualified: William D. WaddillDIRECTOR ELECTIONSISSUER581698.0000000FOR581698.000000FORS000002088Protagonist Therapeutics, Inc.74366E102US74366E102906/20/2024To elect the Class II director nominees named below to hold office until the 2027 Annual Meeting of Stockholders and until their successors are duly elected and qualified: Lewis T. "Rusty" Williams, M.D., Ph.D.DIRECTOR ELECTIONSISSUER581698.0000000FOR581698.000000FORS000002088Protagonist Therapeutics, Inc.74366E102US74366E102906/20/2024To approve, on an advisory basis, the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER581698.0000000FOR581698.000000FORS000002088Protagonist Therapeutics, Inc.74366E102US74366E102906/20/2024To ratify the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024.AUDIT-RELATEDISSUER581698.0000000FOR581698.000000FORS000002088Protagonist Therapeutics, Inc.74366E102US74366E102906/20/2024To approve an amendment to our Certificate of Incorporation to increase the number of authorized shares of our common stock from 90,000,000 to 180,000,000.CAPITAL STRUCTUREISSUER581698.0000000FOR581698.000000FORS000002088Revolution Medicines, Inc.76155X100US76155X100006/20/2024To elect three Class I directors to hold office until the 2027 Annual Meeting of Stockholders or until his or her successor is elected: Elizabeth McKee AndersonDIRECTOR ELECTIONSISSUER1529739.0000000WITHHOLD1529739.000000AGAINSTS000002088Revolution Medicines, Inc.76155X100US76155X100006/20/2024To elect three Class I directors to hold office until the 2027 Annual Meeting of Stockholders or until his or her successor is elected: Flavia Borellini, Ph.D.DIRECTOR ELECTIONSISSUER1529739.0000000WITHHOLD1529739.000000AGAINSTS000002088Revolution Medicines, Inc.76155X100US76155X100006/20/2024To elect three Class I directors to hold office until the 2027 Annual Meeting of Stockholders or until his or her successor is elected: Lorence Kim, M.D.DIRECTOR ELECTIONSISSUER1529739.0000000WITHHOLD1529739.000000AGAINSTS000002088Revolution Medicines, Inc.76155X100US76155X100006/20/2024To ratify the appointment, by the Audit Committee of the Company's Board of Directors, of PricewaterhouseCoopers LLP, as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2024; andAUDIT-RELATEDISSUER1529739.0000000FOR1529739.000000FORS000002088Revolution Medicines, Inc.76155X100US76155X100006/20/2024To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement pursuant to the compensation disclosure rules of the Securities and Exchange Commission ("Say-on-Pay").SECTION 14A SAY-ON-PAY VOTESISSUER1529739.0000000FOR1529739.000000FORS000002088Zentalis Pharmaceuticals, Inc.98943L107US98943L107006/21/2024Election of Class I Directors to serve until the 2027 Annual Meeting of Stockholders, and until their respective successors shall have been duly elected and qualified, subject to their earlier death, resignation or removal: Kimberly Blackwell, M.D.DIRECTOR ELECTIONSISSUER1235251.0000000FOR1235251.000000FORS000002088Zentalis Pharmaceuticals, Inc.98943L107US98943L107006/21/2024Election of Class I Directors to serve until the 2027 Annual Meeting of Stockholders, and until their respective successors shall have been duly elected and qualified, subject to their earlier death, resignation or removal: Enoch Kariuki, Pharm.D.DIRECTOR ELECTIONSISSUER1235251.0000000FOR1235251.000000FORS000002088Zentalis Pharmaceuticals, Inc.98943L107US98943L107006/21/2024To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024.AUDIT-RELATEDISSUER1235251.0000000FOR1235251.000000FORS000002088Zentalis Pharmaceuticals, Inc.98943L107US98943L107006/21/2024To approve, on an advisory (non-binding) basis, the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER1235251.0000000AGAINST1235251.000000AGAINSTS000002088Centessa Pharmaceuticals Plc152309100US152309100706/25/2024To re-appoint as a director, Francesco De Rubertis, Ph.D., who retires by rotation in accordance with the Company's articles of associationDIRECTOR ELECTIONSISSUER1781535.0000000FOR1781535.000000FORS000002088Centessa Pharmaceuticals Plc152309100US152309100706/25/2024To re-appoint as a director, Saurabh Saha, M.D., Ph.D., who retires by rotation in accordance with the Company's articles of associationDIRECTOR ELECTIONSISSUER1781535.0000000FOR1781535.000000FORS000002088Centessa Pharmaceuticals Plc152309100US152309100706/25/2024To re-appoint as a director, Mary Lynne Hedley, Ph.D., who retires by rotation in accordance with the Company's articles of associationDIRECTOR ELECTIONSISSUER1781535.0000000FOR1781535.000000FORS000002088Centessa Pharmaceuticals Plc152309100US152309100706/25/2024To re-appoint KPMG LLP, a United Kingdom entity, as U.K. statutory auditors of the Company, to hold office until the conclusion of the next meeting at which the Company's annual accounts and reports are laid before the CompanyAUDIT-RELATEDISSUER1781535.0000000FOR1781535.000000FORS000002088Centessa Pharmaceuticals Plc152309100US152309100706/25/2024To ratify the re-appointment of KPMG LLP, a Delaware limited liability partnership, as the Company's independent registered public accounting firm, for the financial year ending December 31, 2024AUDIT-RELATEDISSUER1781535.0000000FOR1781535.000000FORS000002088Centessa Pharmaceuticals Plc152309100US152309100706/25/2024To authorize the Audit Committee to determine the Company's auditors' remuneration for the financial year ending December 31, 2024AUDIT-RELATEDISSUER1781535.0000000FOR1781535.000000FORS000002088Centessa Pharmaceuticals Plc152309100US152309100706/25/2024To receive and adopt our U.K. statutory annual accounts and reports for the financial year ended December 31, 2023 and to note that the Company's directors do not recommend the payment of any dividend for the financial year ended December 31, 2023CORPORATE GOVERNANCEISSUER1781535.0000000FOR1781535.000000FORS000002088Centessa Pharmaceuticals Plc152309100US152309100706/25/2024To receive and approve on an advisory basis the Company's U.K. statutory directors' remuneration report for the financial year ended December 31, 2023, which is set forth as Annex A to the attached proxy statementCOMPENSATIONISSUER1781535.0000000FOR1781535.000000FORS000002088Centessa Pharmaceuticals Plc152309100US152309100706/25/2024To authorize the directors of the Company, generally and unconditionally for the purpose of section 551 of the U.K. Companies Act 2006 (the "Act"), to allot shares in the Company or to grant rights to subscribe for or to convert any security into shares in the Company up to a maximum aggregate nominal amount of pounds100,740.CAPITAL STRUCTUREISSUER1781535.0000000FOR1781535.000000FORS000002088Centessa Pharmaceuticals Plc152309100US152309100706/25/2024Subject to the passing of Resolution 9, to empower the Board of Directors to allot equity securities for cash, under section 570 of the Act as if section 561(1) of the Act did not apply to such allotment up to a maximum aggregate nominal amount of pounds100,740.CAPITAL STRUCTUREISSUER1781535.0000000AGAINST1781535.000000AGAINSTS000002088Madrigal Pharmaceuticals, Inc.558868105US558868105706/25/2024Re-election of Class II directors: Bill SiboldDIRECTOR ELECTIONSISSUER337769.0000000FOR337769.000000FORS000002088Madrigal Pharmaceuticals, Inc.558868105US558868105706/25/2024Re-election of Class II directors: Rebecca Taub, M.D.DIRECTOR ELECTIONSISSUER337769.0000000FOR337769.000000FORS000002088Madrigal Pharmaceuticals, Inc.558868105US558868105706/25/2024Re-election of Class II directors: Fred B. Craves, Ph.D.DIRECTOR ELECTIONSISSUER337769.0000000FOR337769.000000FORS000002088Madrigal Pharmaceuticals, Inc.558868105US558868105706/25/2024To ratify the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024.AUDIT-RELATEDISSUER337769.0000000FOR337769.000000FORS000002088Madrigal Pharmaceuticals, Inc.558868105US558868105706/25/2024Advisory vote to approve executive compensation.SECTION 14A SAY-ON-PAY VOTESISSUER337769.0000000FOR337769.000000FORS000002088Madrigal Pharmaceuticals, Inc.558868105US558868105706/25/2024To approve an amendment to the Madrigal Pharmaceuticals, Inc. 2015 Amended Stock Plan to increase the total number of shares of our common stock available for issuance by 750,000 shares and extend its duration by 10 years until April 23, 2035.COMPENSATIONISSUER337769.0000000FOR337769.000000FORS000002088Structure Therapeutics Inc.86366E106US86366E106406/25/2024Election of the nominee for Class I director named below to serve until the 2027 annual general meeting of shareholders and until her successor is duly elected and qualified, or until her earlier death, resignation or removal: Sharon TetlowDIRECTOR ELECTIONSISSUER731060.0000000FOR731060.000000FORS000002088Structure Therapeutics Inc.86366E106US86366E106406/25/2024To ratify the appointment by the Audit Committee of the Board of Directors of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024.AUDIT-RELATEDISSUER731060.0000000FOR731060.000000FORS000002088Janux Therapeutics, Inc.47103J105US47103J105106/26/2024To elect the three nominees for Class III director named in the proxy statement to serve for three-year terms until the 2027 Annual Meeting of Stockholders: Vickie CappsDIRECTOR ELECTIONSISSUER92049.0000000FOR92049.000000FORS000002088Janux Therapeutics, Inc.47103J105US47103J105106/26/2024To elect the three nominees for Class III director named in the proxy statement to serve for three-year terms until the 2027 Annual Meeting of Stockholders: Jay LichterDIRECTOR ELECTIONSISSUER92049.0000000FOR92049.000000FORS000002088Janux Therapeutics, Inc.47103J105US47103J105106/26/2024To elect the three nominees for Class III director named in the proxy statement to serve for three-year terms until the 2027 Annual Meeting of Stockholders: Jake SimsonDIRECTOR ELECTIONSISSUER92049.0000000FOR92049.000000FORS000002088Janux Therapeutics, Inc.47103J105US47103J105106/26/2024To ratify the selection by the Audit Committee of the Board of Directors of Ernst & Young LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2024.AUDIT-RELATEDISSUER92049.0000000FOR92049.000000FORS000002088Scholar Rock Holding Corporation80706P103US80706P103006/27/2024To elect three Class III directors to our Board of Directors, each to serve until the 2027 Annual Meeting of stockholders and until his successor has been duly elected and qualified, or until his earlier death, resignation, or removal: Richard BrudnickDIRECTOR ELECTIONSISSUER1833080.0000000FOR1833080.000000FORS000002088Scholar Rock Holding Corporation80706P103US80706P103006/27/2024To elect three Class III directors to our Board of Directors, each to serve until the 2027 Annual Meeting of stockholders and until his successor has been duly elected and qualified, or until his earlier death, resignation, or removal: Jeffrey S. FlierDIRECTOR ELECTIONSISSUER1833080.0000000FOR1833080.000000FORS000002088Scholar Rock Holding Corporation80706P103US80706P103006/27/2024To elect three Class III directors to our Board of Directors, each to serve until the 2027 Annual Meeting of stockholders and until his successor has been duly elected and qualified, or until his earlier death, resignation, or removal: Akshay VaishnawDIRECTOR ELECTIONSISSUER1833080.0000000FOR1833080.000000FORS000002088Scholar Rock Holding Corporation80706P103US80706P103006/27/2024To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024.AUDIT-RELATEDISSUER1833080.0000000FOR1833080.000000FORS000002088Scholar Rock Holding Corporation80706P103US80706P103006/27/2024To approve an amendment to the Company's Amended and Restated Certificate of Incorporation, as amended to date, to increase the number of authorized shares of common stock from 150,000,000 to 300,000,000.CAPITAL STRUCTUREISSUER1833080.0000000FOR1833080.000000FORS000002088Scholar Rock Holding Corporation80706P103US80706P103006/27/2024To approve an amendment to the Company's Amended and Restated Certificate of Incorporation, as amended to date, to limit the liability of certain officers of the Company as permitted by recent amendments to Delaware law.CORPORATE GOVERNANCEISSUER1833080.0000000FOR1833080.000000FORS000002088Scholar Rock Holding Corporation80706P103US80706P103006/27/2024To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER1833080.0000000FOR1833080.000000FORS000002088Scholar Rock Holding Corporation80706P103US80706P103006/27/2024To approve, on a non-binding, advisory basis, the preferred frequency of future advisory votes on compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER1833080.0000000ONE YEAR1833080.000000FORS000002088Autolus Therapeutics Plc05280R100US05280R100506/28/2024Accept Financial Statements and Statutory ReportsCORPORATE GOVERNANCEISSUER1372941.0000000FOR1372941.000000FORS000002088Autolus Therapeutics Plc05280R100US05280R100506/28/2024Approve Remuneration ReportCOMPENSATIONISSUER1372941.0000000AGAINST1372941.000000AGAINSTS000002088Autolus Therapeutics Plc05280R100US05280R100506/28/2024Reappoint Ernst & Young LLP as Auditors and Authorise Their RemunerationAUDIT-RELATEDISSUER1372941.0000000FOR1372941.000000FORS000002088Autolus Therapeutics Plc05280R100US05280R100506/28/2024Elect Director Linda BainDIRECTOR ELECTIONSISSUER1372941.0000000FOR1372941.000000FORS000002088Autolus Therapeutics Plc05280R100US05280R100506/28/2024Elect Director Cynthia ButittaDIRECTOR ELECTIONSISSUER1372941.0000000FOR1372941.000000FORS000002088Autolus Therapeutics Plc05280R100US05280R100506/28/2024Elect Director Christian ItinDIRECTOR ELECTIONSISSUER1372941.0000000FOR1372941.000000FORS000002088Autolus Therapeutics Plc05280R100US05280R100506/28/2024Elect Director William YoungDIRECTOR ELECTIONSISSUER1372941.0000000FOR1372941.000000FORS000002088Autolus Therapeutics Plc05280R100US05280R100506/28/2024Authorise Issue of EquityCAPITAL STRUCTUREISSUER1372941.0000000FOR1372941.000000FORS000002088Autolus Therapeutics Plc05280R100US05280R100506/28/2024Authorise Issue of Equity without Pre-emptive RightsCAPITAL STRUCTUREISSUER1372941.0000000AGAINST1372941.000000AGAINSTS000002088Pharvaris NVN69605108NL00150005Y406/28/2024Adopt Financial Statements and Statutory ReportsCORPORATE GOVERNANCEISSUER474746.0000000FOR474746.000000FORS000002088Pharvaris NVN69605108NL00150005Y406/28/2024Ratify PricewaterhouseCoopers Accountants N.V. as AuditorsAUDIT-RELATEDISSUER474746.0000000FOR474746.000000FORS000002088Pharvaris NVN69605108NL00150005Y406/28/2024Approve Discharge of DirectorsCORPORATE GOVERNANCEISSUER474746.0000000FOR474746.000000FORS000002088Pharvaris NVN69605108NL00150005Y406/28/2024Authorize Repurchase of SharesCAPITAL STRUCTUREISSUER474746.0000000FOR474746.000000FORS000002088Pharvaris NVN69605108NL00150005Y406/28/2024Reelect Modig as Executive DirectorDIRECTOR ELECTIONSISSUER474746.0000000FOR474746.000000FORS000002088Pharvaris NVN69605108NL00150005Y406/28/2024Reelect Schikan as Non-Executive DirectorDIRECTOR ELECTIONSISSUER474746.0000000FOR474746.000000FORS000002088Pharvaris NVN69605108NL00150005Y406/28/2024Grant Board Authority to Issue SharesCAPITAL STRUCTUREISSUER474746.0000000AGAINST474746.000000AGAINSTS000002088Pharvaris NVN69605108NL00150005Y406/28/2024Authorize Board to Exclude Preemptive Rights from Share IssuancesCAPITAL STRUCTUREISSUER474746.0000000AGAINST474746.000000AGAINSTS000002088